Small molecule inhibitor of ubiquitin specific protease 1 (USP1) and application thereof
By developing compounds or pharmaceutical compositions with specific structures to regulate or inhibit USP1, the treatment problems of USP1-related diseases, especially drug-resistant cancers in the prior art have been solved, and effective treatment of USP1-related diseases have been achieved.
Patent Information
- Application Number
- CN202280087378.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-08
- Filing Date
- 2022-11-11
- Publication Date
- 2024-11-29
AI Technical Summary
Existing methods for the treatment of ubiquitin-specific protease 1 (USP1)-related diseases have not been widely developed, especially in cancer treatment with drug resistance and challenges of defective DNA damage repair pathways.
A compound or pharmaceutical composition has been developed, a compound or salt or solvate thereof having a specific structure, for regulating, inhibiting or reducing the activity of USP1, thereby treating diseases or conditions associated with USP1, including cancers such as lung cancer, ovarian cancer and breast cancer.
By administering these compounds or pharmaceutical compositions to a subject, it is possible to effectively regulate USP1 and inhibit its DNA repair activity, thereby providing new therapeutic means of treatment of USP1-related diseases, especially against drug-resistant cancers.
Smart Images

Figure BDA0004923811190000011 
Figure BDA0004923811190000041 
Figure BDA0004923811190000051
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This patent application claims the benefit of International Application No. PCT / CN2021 / 130290 filed on November 12, 2021, and International Application No. PCT / CN2022 / 123827 filed on October 8, 2022, each of which is incorporated herein by reference in its entirety. Background Art
[0003] Ubiquitin-specific protease 1 (USP1) is a gene that plays a role in DNA damage repair. Compounds and pharmaceutical compositions targeting USP1, as well as methods for treating USP1-related diseases and conditions (such as certain cancers), have not been widely developed. Therefore, there remains a need to provide methods for treating USP1-related diseases. Summary of the Invention
[0004] The present disclosure addresses the above-mentioned needs and provides additional advantages as well.
[0005] In one aspect, described herein is a compound having the structure of Formula (IVa) or a salt or solvate thereof,
[0006]
[0007]
[0008] in,
[0009] Y 1 N or CR Y1 ;
[0010] Y 2 N or CR Y2 ;
[0011] Y 3 N or CR Y3 ;
[0012] Y 4 N or CR Y4 ;
[0013] R 1 is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 heterocycloalkyl;
[0014] R 4and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0015] R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0016] R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0017] R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl;
[0018] Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl or a bicyclic heterocycloalkyl;
[0019] R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12)(R 11 );
[0020] R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 alkylene-heteroaryl;
[0021] R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0022] R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl;
[0023] R Y1 、R Y2 、R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, and optionally substituted bicyclic heteroaryl; or
[0024] R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl; or
[0025] R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl;
[0026] m is 0, 1, 2, 3 or 4; and
[0027] p is 0 or 1.
[0028] In some embodiments, the compound has the structure of Formula (IVa-1),
[0029]
[0030] In some embodiments, the compound has the structure of Formula (IVa-2),
[0031]
[0032] In one aspect, described herein is a compound having the structure of Formula (VI) or a salt or solvate thereof,
[0033]
[0034] in,
[0035] Ring C is an optionally substituted 5-membered heteroaryl;
[0036] Ring D is an aromatic, saturated or partially saturated 6-membered carbocyclic or heterocyclic ring, wherein each of the carbocyclic or heterocyclic ring is optionally substituted;
[0037] R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 together to form an oxo group; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl;
[0038] Ring A is phenyl, naphthyl, monocyclic heteroaryl, bicyclic heteroaryl, cycloalkyl or heterocycloalkyl;
[0039] R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 );
[0040] R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 alkylene-heteroaryl;
[0041] R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, and C 3-6 Carbocyclic ring, 3-membered to 6-membered heterocyclic ring, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0042] R B is hydrogen, halogen, -CN, -NO2, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl;
[0043] m is 1, 2, 3 or 4; and
[0044] p is 0 or 1.
[0045] In one aspect, described herein is a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.
[0046] In one aspect, described herein is a method of modulating ubiquitin-specific protease 1 (USP1) in a subject, comprising administering to the subject a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of a compound described herein.
[0047] In one aspect, described herein is a method of inhibiting ubiquitin-specific protease 1 (USP1) in a subject, comprising administering to the subject a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of a compound described herein.
[0048] In one aspect, described herein is a method of inhibiting or reducing DNA repair activity regulated by ubiquitin-specific protease 1 (USP1) in a subject, comprising administering to a subject in need thereof an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of a compound described herein.
[0049] In one aspect, described herein is a method of treating a disease or condition associated with ubiquitin-specific protease 1 (USP1) in a subject, comprising administering to the subject a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of a compound described herein.
[0050] In one aspect, described herein is a method of treating a disease or condition associated with modulation of ubiquitin-specific protease 1 (USP1) in a subject, comprising administering to the subject a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of a compound described herein. In some embodiments, the disease or condition is cancer.
[0051] In one aspect, described herein is a method of treating cancer in a subject, comprising administering to a subject in need thereof an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of a compound described herein. In some embodiments, the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, osteosarcoma, ovarian cancer, skin cancer, and breast cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is ovarian cancer or breast cancer.
[0052] In some embodiments, the cancer comprises cancer cells with elevated levels of RAD 18. In some embodiments, the cancer is a cancer deficient in a DNA damage repair pathway. In some embodiments, the cancer is a cancer resistant or recalcitrant to PARP inhibitors. In some embodiments, the cancer is a BRCA1 mutant cancer and / or a BRCA2 mutant cancer. In some embodiments, the cancer is a BRAC1 deficient cancer.
[0053] Incorporated by Reference
[0054] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent such incorporated by reference publications, patents, or patent applications conflict with the disclosure contained in this specification, this specification is intended to supersede and / or take precedence over any such conflicting material. DETAILED DESCRIPTION
[0055] Although various embodiments have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Many variations, changes, and substitutions may occur to those skilled in the art without departing from the present disclosure. It will be appreciated that a variety of alternatives to the embodiments of the present disclosure described herein may be used.
[0056] A. Definition
[0057] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications mentioned herein are incorporated by reference.
[0058] "Alkyl" refers to an optionally substituted straight chain or optionally substituted branched chain saturated monovalent hydrocarbon group, and preferably has one to fifteen carbon atoms (i.e., C1-C 15 In certain embodiments, the alkyl group contains from one to thirteen carbon atoms (i.e., C1-C 13In certain embodiments, the alkyl group comprises one to eight carbon atoms (i.e., C1-C8 alkyl). In other embodiments, the alkyl group comprises one to five carbon atoms (i.e., C1-C5 alkyl). In other embodiments, the alkyl group comprises one to four carbon atoms (i.e., C1-C4 alkyl). In other embodiments, the alkyl group comprises one to three carbon atoms (i.e., C1-C3 alkyl). In other embodiments, the alkyl group comprises one to two carbon atoms (i.e., C1-C2 alkyl). Whenever a numerical range such as "C1-C3 alkyl" appears herein, it means that the alkyl group consists of 1 carbon atom, 2 carbon atoms, or 3 carbon atoms. In other embodiments, the alkyl group comprises one carbon atom (i.e., C1 alkyl). In other embodiments, the alkyl group comprises five to fifteen carbon atoms (i.e., C5-C 15 In some embodiments, the alkyl group is selected from the group consisting of methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), and 1-pentyl (n-pentyl). In other embodiments, examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl, as well as longer alkyl groups such as heptyl, octyl, etc. The alkyl group is attached to the rest of the molecule by a single bond. Unless otherwise specifically stated in this specification, alkyl is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkyl is optionally substituted by oxo, halogen, -CN, -CF , -OH, -OMe, -NH , -NO , or -C≡CH. In some embodiments, alkyl is optionally substituted by oxo, halogen, -CN, -CF , -OH, or -OMe. In some embodiments, alkyl is optionally substituted by halogen, such as F.
[0059] As used herein, C1-Cx (or C 1-x) includes C1-C2, C1-C3 ... C1-Cx. By way of example only, a group designated as "C1-C4" indicates the presence of one to four carbon atoms in the moiety, i.e., a group containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms, or 4 carbon atoms. Thus, by way of example only, "C1-C4 alkyl" indicates the presence of one to four carbon atoms in the alkyl group, i.e., the alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. Furthermore, by way of example, C0-C2 alkylene includes direct bonds, -CH2-, and -CH2CH2- linkages.
[0060] "Alkoxy" refers to a group having the formula -O-alkyl bonded via an oxygen atom, wherein alkyl is an alkyl chain as defined above. Unless otherwise specifically stated in this specification, alkoxy may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkoxy is optionally substituted by oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, alkoxy is optionally substituted by oxo, halogen, -CN, -CF3, -OH or -OMe. In some embodiments, alkoxy is optionally substituted by halogen.
[0061] "Alkenyl" refers to an optionally substituted straight or branched hydrocarbon chain radical containing at least one carbon-carbon double bond and preferably having two to twelve carbon atoms (i.e., C2-C 12In some embodiments, the alkenyl group comprises two to eight carbon atoms (i.e., C2-C8 alkenyl). In some embodiments, the alkenyl group comprises two to six carbon atoms (i.e., C2-C6 alkenyl). In other embodiments, the alkenyl group comprises two to four carbon atoms (i.e., C2-C4 alkenyl). The group may be in a cis or trans configuration around the double bond and is understood to include two isomers. Examples include, but are not limited to, vinyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl, etc. Whenever it appears in this article, a numerical range such as "C2-C6 alkenyl" means that the alkenyl group may be composed of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms. Unless specifically stated otherwise in this specification, alkenyl is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl etc. In some embodiments, alkenyl is optionally substituted by oxo, halogen, -CN, -CF , -OH, -OMe, -NH or -NO . In some embodiments, alkenyl is optionally substituted by oxo, halogen, -CN, -CF , -OH or -OMe. In some embodiments, alkenyl is optionally substituted by halogen. Alkenyl utilizes a single bond to be connected to the remainder of the molecule, such as vinyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, penta-1-enyl, penta-1,4-dienyl etc. Unless otherwise specifically stated in this specification, alkenyl is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl etc. In some embodiments, alkenyl is optionally substituted by oxo, halogen, -CN, -CF , -OH, -OMe, -NH or -NO . In some embodiments, alkenyl is optionally substituted by oxo, halogen, -CN, -CF , -OH or -OMe. In some embodiments, alkenyl is optionally substituted by halogen.
[0062] "Alkynyl" refers to an optionally substituted straight or branched hydrocarbon chain radical containing at least one carbon-carbon triple bond and preferably having from two to twelve carbon atoms (i.e., C2-C 12In some embodiments, the alkynyl group comprises two to eight carbon atoms (i.e., C2-C8 alkynyl). In other embodiments, the alkynyl group comprises two to six carbon atoms (i.e., C2-C6 alkynyl). In other embodiments, the alkynyl group comprises two to four carbon atoms (i.e., C2-C4 alkynyl). Whenever it appears in this article, the numerical range of "C2-C6 alkynyl" means that the alkynyl group can be composed of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms. The alkynyl group is connected to the rest of the molecule by a single bond, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, etc. Unless otherwise specifically stated in this specification, the alkynyl group is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkynyl is optionally substituted with oxo, halogen, -CN, -CF , -OH, -OMe, -NH , or -NO . In some embodiments, alkynyl is optionally substituted with oxo, halogen, -CN, -CF , -OH, or -OMe. In some embodiments, alkynyl is optionally substituted with halogen.
[0063] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain containing one to twelve carbon atoms, such as methylene, ethylene, propylene, n-butylene, etc., that is connected to the rest of the molecule via a single bond and is connected to the group via a single bond. The alkylene chain and the rest of the molecule and the point of attachment to the group can be realized via any two carbons in the chain. In certain embodiments, the alkylene group comprises one to ten carbon atoms (i.e., C1-C8 alkylene). In certain embodiments, the alkylene group comprises one to eight carbon atoms (i.e., C1-C8 alkylene). In other embodiments, the alkylene group comprises one to five carbon atoms (i.e., C1-C5 alkylene). In other embodiments, the alkylene group comprises one to four carbon atoms (i.e., C1-C4 alkylene). In other embodiments, the alkylene group comprises one to three carbon atoms (i.e., C1-C3 alkylene). In other embodiments, the alkylene group comprises one to two carbon atoms (i.e., C1-C2 alkylene). In other embodiments, the alkylene group comprises one carbon atom (i.e., C1 alkylene). In other embodiments, the alkylene group comprises five to eight carbon atoms (i.e., C5-C8 alkylene). In other embodiments, the alkylene group comprises two to five carbon atoms (i.e., C2-C5 alkylene). In other embodiments, the alkylene group comprises three to five carbon atoms (i.e., C3-C5 alkylene). Unless otherwise specifically stated in this specification, the alkylene group may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkylene group is optionally substituted by oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, the alkylene group is optionally substituted by oxo, halogen, -CN, -CF3, -OH or -OMe. In some embodiments, the alkylene group is optionally substituted by halogen. In some embodiments, alkylene is -CH2-, -CH2CH2-, or -CH2CH2CH2-. In some embodiments, alkylene is -CH2-. In some embodiments, alkylene is -CH2CH2-. In some embodiments, alkylene is -CH2CH2-. In some embodiments, alkylene is -CH2CH2CH2-.
[0064] "Aryl" refers to a group derived from a hydrocarbon ring system containing at least one aromatic ring. In some embodiments, the aryl group comprises hydrogen and 6 to 30 carbon atoms. The aryl group may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused (when fused to a cycloalkyl or heterocycloalkyl ring, the aryl group is bonded via an aromatic ring atom) or a bridged ring system. In some embodiments, the aryl group is a 6- to 10-membered aryl group. In some embodiments, the aryl group is a 6-membered aryl group. Aryl groups include, but are not limited to, aryl groups derived from the following hydrocarbon ring systems: anthracene, naphthylene, phenanthrenyl, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, indane, indene, naphthalene, phenanthene, phenanthren, pyrene, and triphenylene. In some embodiments, the aryl group is phenyl. Unless otherwise specifically stated in the specification, aryl groups can be optionally substituted, for example, with halogen, amino, alkylamino, aminoalkyl, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, -S(O)2NH-C1-C6alkyl, etc. In some embodiments, aryl groups are optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, -NO2, -S(O)2NH2, -S(O)2NHCH3, -S(O)2NHCH2CH3, -S(O)2NHCH ( In some embodiments, aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, aryl is optionally substituted with halogen. In some embodiments, aryl is optionally substituted with alkyl, alkenyl, alkynyl, haloalkyl, or heteroalkyl, wherein each alkyl, alkenyl, alkynyl, haloalkyl, or heteroalkyl is independently unsubstituted or substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2.
[0065] "Aralkyl" refers to a group of the formula -R c -aryl groups, where R c is an alkylene chain as defined above, for example methylene, ethylene, and the like.
[0066] "Aralkenyl" refers to a group of the formula -R d -aryl groups, where R d is an alkenylene chain as defined above. "Aralkynyl" refers to an alkylene group of the formula -R e -aryl groups, where R e is an alkynylene chain as defined above.
[0067] "Carbocycle" refers to a saturated, unsaturated or aromatic ring, wherein each atom of the ring is carbon. Carbocycle can include 3 to 10-membered monocycles and 6 to 12-membered bicyclic rings (e.g., spiro, fused or bridged rings). Each ring of a bicyclic carbocycle can be selected from saturated, unsaturated and aromatic rings. Aromatic rings, such as phenyl, can be fused with a saturated or unsaturated ring (e.g., cyclohexane, cyclopentane or cyclohexene). Any combination of saturated, unsaturated and aromatic bicyclic rings is included in the definition of carbocycle when the valence number permits. In an exemplary embodiment, an aromatic ring (e.g., phenyl) can be fused to a saturated or unsaturated ring, such as cyclohexane, cyclopentane or cyclohexene. When the valence number permits, bicyclic carbocycle includes any combination of saturated bicyclic, unsaturated bicyclic and aromatic bicyclic rings. Bicyclic carbocycles include any combination of ring sizes, such as a 4-5 fused ring system, a 5-5 fused ring system, a 5-6 fused ring system, a 6-6 fused ring system, a 5-7 fused ring system, a 6-5 fused ring system, a 6-7 fused ring system, a 5-8 fused ring system, and a 6-8 fused ring system. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl. The term "unsaturated carbocycle" refers to a carbocycle having at least one degree of unsaturation and excludes aromatic carbocycles. Examples of unsaturated carbocycles include cyclohexadiene, cyclohexene, and cyclopentene. As used herein, the term "saturated cycloalkyl" refers to a saturated carbocycle. Exemplary carbocycles include cyclopropyl, cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, norbornane, and naphthyl. The carbocycle may optionally be substituted with one or more substituents, such as those described herein.
[0068] "Cycloalkyl" refers to a stable, partially or fully saturated monocyclic or polycyclic carbocyclic ring that may include fused (when fused to an aryl or heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom), bridged, or spirocyclic ring systems. Representative cycloalkyl groups include, but are not limited to, groups having three to fifteen carbon atoms (C3-C 15 cycloalkyl), three to ten carbon atoms (C3-C 10In some embodiments, the cycloalkyl group is a 3- to 6-membered cycloalkyl group. In some embodiments, the cycloalkyl group is a 5- to 6-membered cycloalkyl group. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl or carbocyclic ring include, for example, adamantyl, norbornyl, decahydronaphthalene, bicyclo [3.3.0] octane, bicyclo [4.3.0] nonane, cis-decahydronaphthalene, trans-decahydronaphthalene, bicyclo [2.1.1] hexane, bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, bicyclo [3.2.2] nonane and bicyclo [3.3.2] decane and 7,7-dimethyl-bicyclo [2.2.1] heptyl. Partially saturated cycloalkyl includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. Unless otherwise specifically stated in the specification, cycloalkyl is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF , -OH, -OMe, -NH , or -NO . In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF , -OH, or -OMe. In some embodiments, cycloalkyl is optionally substituted with halogen.
[0069] "Cycloalkylalkyl" refers to a group of the formula -R c -cycloalkyl group, where R c is an alkylene chain as described above.
[0070] "Cycloalkylalkoxy" refers to a cycloalkylalkoxy group having the formula -OR c -cycloalkyl group bonded via an oxygen atom, wherein R c is an alkylene chain as described above.
[0071] "Halo" or "halogen" refers to a halogen substituent such as bromo, chloro, fluoro, and iodo substituents.
[0072] As used herein, the term "haloalkyl" or "haloalkane" refers to an alkyl group as defined above that is substituted with one or more halogen groups, for example, trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the fluoroalkyl group is optionally further substituted. Examples of alkanes substituted with halogens ("haloalkanes") include halogenated methanes (e.g., chloromethane, bromomethane, fluoromethane, iodomethane), dihalogenated methanes and trihalogenated methanes (e.g., chloroform, bromomethane, trifluoromethane, iodomethane), 1-haloethane, 2-haloethane, 1,2-dihaloethane, 1-halopropane, 2-halopropane, 3-halopropane, 1,2-dihalopropane, 1,3-dihalopropane, 2,3-dihalopropane, 1,2,3-trihalopropane, and any other suitable combination of an alkane (or substituted alkane) and a halogen (e.g., Cl, Br, F, I, etc.). When an alkyl group is substituted with more than one halogen group, each halogen can be selected independently, for example, 1-chloro, 2-fluoroethane.
[0073] "Fluoroalkyl" refers to an alkyl group as defined above substituted with one or more fluoro groups, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
[0074] "Hydroxyalkyl" refers to an alkyl group as defined above that is substituted with one or more hydroxyl groups. In some embodiments, the alkyl group is substituted with one hydroxyl group. In some embodiments, the alkyl group is substituted with one, two, or three hydroxyl groups. Hydroxyalkyl groups include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl group is hydroxymethyl.
[0075] "Aminoalkyl" refers to an alkyl group as defined above that is substituted with one or more amines. In some embodiments, the alkyl group is substituted with one amine. In some embodiments, the alkyl group is substituted with one, two, or three amines. Aminoalkyl groups include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl group is aminomethyl.
[0076] The term "heteroalkyl" refers to an alkyl group having one or more backbone atoms selected from the group consisting of atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N (alkyl)-), sulphur or a combination thereof. Heteroalkyl is connected to the remainder of the molecule at the carbon atom of the heteroalkyl group. In one aspect, heteroalkyl is a C1-C6 heteroalkyl group, wherein the heteroalkyl group is composed of 1 to 6 carbon atoms and one or more atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N (alkyl)-), sulphur or a combination thereof, wherein the heteroalkyl group is connected to the remainder of the molecule at the carbon atom of the heteroalkyl group. Examples of such heteroalkyl groups include, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3 or -CH(CH3)OCH3. Unless otherwise specifically stated in this specification, heteroalkyl is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl etc. In some embodiments, heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF , -OH, -OMe, -NH , or -NO . In some embodiments, heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF , -OH, or -OMe. In some embodiments, heteroalkyl is optionally substituted with halogen.
[0077] "Heterocycloalkyl" refers to a stable 3- to 24-membered partially or fully saturated cyclic radical containing 2 to 23 carbon atoms and at least one ring heteroatom. In some embodiments, the heterocycloalkyl contains 1 to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur. Unless otherwise specifically stated in this specification, the heterocycloalkyl may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused (when fused to an aryl or heteroaryl ring, the heterocycloalkyl is bonded via a non-aromatic ring atom) or bridged ring system; and the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl may be optionally oxidized; the nitrogen atom may be optionally quaternized.
[0078] Representative heterocycloalkyl groups include, but are not limited to, groups having two to fifteen carbon atoms (C2-C 15 Heterocycloalkyl), two to ten carbon atoms (C2-C 10In some embodiments, the heterocycloalkyl group is a 3- to 6-membered heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a 5- to 6-membered heterocycloalkyl group. Examples of such heterocycloalkyl groups include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, , quinuclidine, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl -2-oxo-1,3-dioxol-4-yl and 2-oxo-1,3-dioxol-4-yl. The term heterocycloalkyl also includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. It should be understood that when referring to the number of carbon atoms in heterocycloalkyl, the number of carbon atoms in heterocycloalkyl is not the same as the total number (including heteroatoms) of the atoms constituting the heterocycloalkyl (i.e., the backbone atoms of the heterocycloalkyl ring). Unless otherwise specifically stated in this specification, heterocycloalkyl is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heterocycloalkyl is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF , -OH, -OMe, -NH or -NO . In some embodiments, heterocycloalkyl is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF , -OH or -OMe. In some embodiments, heterocycloalkyl is optionally substituted by halogen.
[0079] "Heterocycle" or "heterocyclyl" refers to a saturated, unsaturated or aromatic ring containing one or more ring heteroatoms. Exemplary heteroatoms include N, O, Si, P, B and S atoms. Heterocycles include, for example, 3- to 10-membered monocycles and 6- to 12-membered bicyclic rings (e.g., spiro, fused or bridged rings). Unless otherwise specifically stated in this specification, heterocyclyl is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which optionally includes a fused, bridged or spiro ring system. The heteroatoms in the heterocyclyl are optionally oxidized. If one or more nitrogen atoms are present, they are optionally quaternized. The heterocyclyl may be partially or fully saturated. The heteroaryl is attached to the rest of the molecule via any atom of the ring. Examples of such heterocyclic groups include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thimorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless otherwise specifically stated in the specification, the term "heterocyclic group" is intended to include optionally substituted heterocyclic groups as defined above. For example, the heterocyclyl group may be optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -CN, -R b -OR e -C(O)N(R a)2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2), where each R a R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R e is a straight or branched alkylene or alkenylene chain, and unless otherwise specified, wherein each of the above substituents is unsubstituted.
[0080] "Heteroaryl" or "aromatic heterocycle" refers to a ring system radical comprising carbon atoms and one or more ring heteroatoms (e.g., selected from the group consisting of nitrogen, oxygen, phosphorus, silicon, and sulfur) and at least one aromatic ring. In some embodiments, the heteroaryl group is a 5- to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur. The heteroaryl group may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused (when fused to a cycloalkyl or heterocycloalkyl ring, the heteroaryl group is bonded via an aromatic ring atom) or a bridged ring system; and the nitrogen, carbon, or sulfur atoms in the heteroaryl group may be optionally oxidized; the nitrogen atom may be optionally quaternized. In some embodiments, the heteroaryl group is a 5- to 10-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5- to 6-membered heteroaryl group. Examples include, but are not limited to, azaquinazole, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxazole, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranone, benzothienyl / benzothiophenyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanone, isothiazolyl, imidazolyl, oxazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolyl, isoquinolinyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxopyridinyl, 1-oxopyrimidinyl, 1-oxopyrazinyl, 1-oxopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless otherwise specifically stated in this specification, heteroaryl is optionally substituted, for example, by halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl etc. In some embodiments, heteroaryl is optionally substituted by halogen, methyl, ethyl, -CN, -CF , -OH, -OMe, -NH or -NO . In some embodiments, heteroaryl is optionally substituted by halogen, methyl, ethyl, -CN, -CF , -OH or -OMe. In some embodiments, heteroaryl is optionally substituted by halogen.
[0081] The term "substituted" refers to a portion of a substituent having one or more carbon atoms of a replacement structure or a substituent having a hydrogen atom (e.g., NH) on a substituent group. It should be understood that "substituted" or "substituted" includes implicit restrictions: such substitutions are consistent with the permitted valences of the substituted atom and the substituent group, and the substitution produces a stable compound, i.e., a compound that does not spontaneously undergo a transformation such as by rearrangement, cyclization, elimination, etc. In certain embodiments, substituted refers to a portion of a substituent having a substituent group that replaces two hydrogen atoms on the same carbon atom, such as replacing two hydrogen atoms on a single carbon with an oxo group, an imino group, or a thio group. As used herein, the term "substituted" is intended to include all permissible substituents of an organic compound. In a broad aspect, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. For appropriate organic compounds, permissible substituents may be one or more and the same or different. For the purposes of this disclosure, for example, a heteroatom of nitrogen may have a hydrogen substituent and / or any permissible substituent of an organic compound described herein that satisfies the heteroatom valence.
[0082] In some embodiments, the substituents may include any of the substituents described herein, for example, halogen, hydroxy, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O)t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (wherein t is 1 or 2); and alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl and heterocycle, any of which may be optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), SF5, -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a(where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); where each R a is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl and heterocycle, wherein each R a It may be optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); and where each R b are independently selected from a direct bond or a straight or branched alkylene, alkenylene or alkynylene chain, and each Rc is a straight or branched alkylene, alkenylene or alkynylene chain.
[0083] As used in this specification and the claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0084] The term "salt" or "pharmaceutically acceptable salt" refers to salts derived from a variety of organic and inorganic counterions well known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, basic ion exchange resins, and the like, particularly isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, pharmaceutically acceptable base addition salts are selected from ammonium, potassium, sodium, calcium, and magnesium salts.
[0085] As used herein, the phrases "parenteral administration" and "administered parenterally" mean modes of administration other than enteral and topical administration, usually injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.
[0086] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0087] As used herein, the phrase "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, and teff oil. oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer solution; and (21) other nontoxic compatible substances used in pharmaceutical preparations.
[0088] In certain embodiments, the terms "prevent" or "preventing" as used in connection with a disease or condition may refer to a compound that reduces the occurrence of the condition or disorder in a treated sample relative to an untreated control sample, or delays the onset of or reduces the severity of one or more symptoms of the condition or disorder relative to an untreated control sample in a statistical sample.
[0089] As used herein, the terms "treat," "treating," and "treatment" can include alleviating, alleviating, or ameliorating symptoms of a disease or disorder; preventing additional symptoms; ameliorating or preventing the underlying cause of symptoms; inhibiting the disease or disorder, such as arresting the development of the disease or disorder, relieving the disease or disorder, causing regression of the disease or disorder, alleviating a symptom caused by the disease or disorder, or preventing and / or therapeutically arresting the symptoms of the disease or disorder.
[0090] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a compound disclosed herein that is administered that is sufficient to alleviate to some extent one or more of the symptoms of the disease or disorder being treated (e.g., cancer or inflammatory disease). In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein that is necessary to produce a clinically significant reduction in the symptoms of the disease. In some embodiments, techniques such as dose escalation studies are used to determine the appropriate "effective" amount in any individual case.
[0091] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "optionally substituted alkyl" means "alkyl" or "substituted alkyl" as defined above. In addition, an optionally substituted group may be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at any level between fully substituted and monosubstituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, -CFHCHF2, etc.).
[0092] As used herein, the term "subject" can be a vertebrate, such as a mammal, fish, bird, reptile, or amphibian. Thus, the subject of the methods disclosed herein can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent. The term does not indicate a specific age or sex. Thus, adult and newborn subjects, as well as fetuses, regardless of male or female, are intended to be encompassed. In one aspect, the subject is a mammal.
[0093] The scope provided herein should be understood as a shorthand for all values within the scope. For example, range 1 to 50 should be understood to include any number, number combination or subrange selected from the group consisting of: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50, and all intermediate decimal values between the aforementioned integers, such as 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 and 1.9. With respect to subranges, "nested subranges" extending from either end of a scope are particularly encompassed. For example, nested sub-ranges of the exemplary range 1 to 50 may include 1 to 10, 1 to 20, 1 to 30, and 1 to 40 in one direction, or 50 to 40, 50 to 30, 50 to 20, and 50 to 10 in the other direction.
[0094] B. Compounds of the Disclosure
[0095] In one aspect, the present disclosure provides a compound represented by formula (IVa) or a pharmaceutically acceptable salt or solvate thereof:
[0096]
[0097] in,
[0098] Y 1 N or CR Y1 ;
[0099] Y 2 N or CR Y2 ;
[0100] Y 3 N or CR Y3 ;
[0101] Y 4 N or CR Y4 ;
[0102] R 1 Each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 heterocycloalkyl;
[0103] R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0104] R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0105] R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0106] R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl;
[0107] Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl or a bicyclic heterocycloalkyl;
[0108] R A are each independently selected from halogen, -NO2, oxo, CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 );
[0109] R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 alkylene-heteroaryl;
[0110] R 12 Each independently selected from hydrogen, halogen, -OH, -NO2, CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0111] R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl;
[0112] R Y1 、R Y2 、R Y3 and RY4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, and optionally substituted bicyclic heteroaryl; or
[0113] R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl; or
[0114] R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl;
[0115] m is 0, 1, 2, 3 or 4; and
[0116] p is 0 or 1.
[0117] In some embodiments of Formula (IVa), R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl. In some embodiments, R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl. In some embodiments, R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R 6 and R 6 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl.
[0118] In some embodiments, the compounds of formula (IVa), (IVa-1) and (IVa-2),
[0119] Y 1 N or CR Y1 ;
[0120] Y 2 N or CR Y2 ;
[0121] Y 3 N or CR Y3 ;
[0122] Y 4 N or CR Y4 ;
[0123] R 1 Each is hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 heterocycloalkyl;
[0124] wherein the alkyl, heteroalkyl, alkenyl or alkynyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, oxo, -OH, -NO2, -CN and C 1-3 alkoxy;
[0125] R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 4 and R 4 ' combine to form an oxo group, or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0126] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0127] R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 5 and R 5 ' combine to form an oxo group, or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0128] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0129] R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 6 and R 6 ' combine to form an oxo group, or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0130] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0131] R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, or R 8 and R 9 together with the carbon to which it is attached, form an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl,
[0132] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0133] Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl or a bicyclic heterocycloalkyl;
[0134] R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ),
[0135] wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, oxo, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0136] R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl,
[0137] wherein the alkyl, alkenyl, alkynyl, heteroalkyl, alkylene, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 alkyl halide;
[0138] R 12 Each independently selected from hydrogen, halogen, -OH, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0139] R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl or optionally substituted bicyclic heteroaryl,
[0140] wherein the cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0141] R Y1 、R Y2 、R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl and optionally substituted bicyclic heteroaryl,
[0142] wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 haloalkyl; or
[0143] R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl,
[0144] wherein the cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 haloalkyl; or
[0145] R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl,
[0146] wherein the cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 alkyl halide;
[0147] m is 0, 1, 2, 3 or 4; and
[0148] p is 0 or 1.
[0149] In some embodiments of Formula (IVa), R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 4 and R 4 ' combine to form an oxo group, or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0150] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
[0151] In some embodiments of Formula (IVa), R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7Heterocycloalkyl, or R 5 and R 5 ' combine to form an oxo group, or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0152] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
[0153] In some embodiments of Formula (IVa), R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 6 and R 6 ' combine to form an oxo group, or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0154] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
[0155] In some embodiments, the compounds of formula (IVa), (IVa-1) and (IVa-2),
[0156] Y 1 N or CR Y1 ;
[0157] Y 2 N or CR Y2 ;
[0158] Y 3N or CR Y3 ;
[0159] Y 4 N or CR Y4 ;
[0160] R 1 Each is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 heterocycloalkyl;
[0161] wherein the alkyl, heteroalkyl, alkenyl or alkynyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, oxo, -OH, -NO2, -CN and C 1-3 alkoxy;
[0162] R 4 and R 4 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 4 and R 4 ' combine to form an oxo group, or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0163] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0164] R 5 and R 5 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C2-7 Heterocycloalkyl, or R 5 and R 5 ' combine to form an oxo group, or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0165] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0166] R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 6 and R 6 ' combine to form an oxo group, or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl,
[0167] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0168] R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, or R 8 and R 9together with the carbon to which it is attached, form an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl,
[0169] wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0170] Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl or a bicyclic heterocycloalkyl;
[0171] R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ),
[0172] wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, oxo, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0173] R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl,
[0174] wherein the alkyl, alkenyl, alkynyl, heteroalkyl, alkylene, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 alkyl halide;
[0175] R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0176] R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl or optionally substituted bicyclic heteroaryl,
[0177] wherein the cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0178] R Y1 、R Y2 、R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl and optionally substituted bicyclic heteroaryl,
[0179] wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 haloalkyl; or
[0180] R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl,
[0181] wherein the cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 haloalkyl; or
[0182] R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl,
[0183] wherein the cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 alkyl halide;
[0184] m is 0, 1, 2, 3 or 4; and
[0185] p is 0 or 1.
[0186] In one aspect, the present disclosure provides a compound represented by formula (IVa) or a pharmaceutically acceptable salt or solvate thereof:
[0187]
[0188] in,
[0189] Y 1 N or CR Y1 ;
[0190] Y 2 N or CR Y2 ;
[0191] Y 3 N or CR Y3 ;
[0192] Y 4 N or CR Y4 ;
[0193] R 1 is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 heterocycloalkyl;
[0194] R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0195] R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0196] R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl group or a 3-6 membered heterocycloalkyl group;
[0197] R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl;
[0198] Ring A is aryl, monocyclic heteroaryl, bicyclic heteroaryl, monocyclic heterocycloalkyl or bicyclic heterocycloalkyl;
[0199] R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 );
[0200] R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 alkylene-heteroaryl;
[0201] R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0202] R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl;
[0203] R Y1 、R Y2 、R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, and optionally substituted bicyclic heteroaryl; or
[0204] R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl; or
[0205] R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl;
[0206] m is 0, 1, 2, 3 or 4; and
[0207] p is 0 or 1.
[0208] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Ring A is aryl, monocyclic heteroaryl, bicyclic heteroaryl, monocyclic heterocycloalkyl, or bicyclic heterocycloalkyl, wherein when Ring A is aryl, for
[0209] Y 1 、Y 2 、Y 3 and Y 4 At least one of is N; and
[0210] R B1 is an optionally substituted monocyclic heteroaryl group or an optionally substituted bicyclic heteroaryl group.
[0211] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Ring A is aryl. In some embodiments, Ring A is phenyl.
[0212] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), for In some embodiments, for In some embodiments of formula (IVa), (IVa-1) and (IVa-2), Ring A is unsubstituted aryl (e.g., phenyl). In some embodiments of formula (IVa), (IVa-1) and (IVa-2), Ring A is optionally substituted with 1 to 5 R A In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Ring A is substituted with 1 R A In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Ring A is substituted with 2 R A In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Ring A is substituted with 3 R A In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Ring A is substituted with 4 R A In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Ring A is substituted with 5 R A Substituted aryl (eg, phenyl).
[0213] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Y 1 、Y 2 、Y 3 and Y 4 At least one of is N. In some embodiments, Y 1 、Y 2 、Y 3 and Y 4 One of is N. In some embodiments, Y 1 、Y 2 、Y 3 and Y 4 In some embodiments, both of Y 1 、Y 2 、Y 3 and Y 4 In some embodiments of formula (IVa), (IVa-1) and (IVa-2), R B1 is an optionally substituted monocyclic heteroaryl or an optionally substituted bicyclic heteroaryl. B1 is an optionally substituted monocyclic heteroaryl (eg, a 5-membered heteroaryl). B1 is a substituted monocyclic heteroaryl group.
[0214] In some embodiments of Formulas (IVa), (IVa-1), and (IVa-2), each R A independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ). In some embodiments, R A Not for C 1-6 In some embodiments, R A is not Cl. In some embodiments, R A Not halogen.
[0215] In some embodiments, the compound of formula (IVa) is represented by formula (IVa-1), or a pharmaceutically acceptable salt or solvate thereof:
[0216]
[0217] In some embodiments, the compound of formula (IVa) is represented by formula (IVa-2), or a pharmaceutically acceptable salt or solvate thereof:
[0218]
[0219]
[0220] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), R 1 Each is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 Heterocycloalkyl.
[0221] In some embodiments of Formula (IVa) and (IVa-1), R 4 and R 4 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl.
[0222] In some embodiments of Formula (IVa) and (IVa-1), R 5 and R 5 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl.
[0223] In some embodiments of Formula (IVa) and (IVa-1), R 6 and R 6 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R 6 and R 6 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl.
[0224] In some embodiments of Formula (IVa), R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl.
[0225] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), R 12 Each independently selected from hydrogen, -NO2, CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl.
[0226] In some embodiments of Formula (IVa), (IVa-1) and (IVa-2), Ring A is a 3-6 membered monocyclic heterocycloalkyl containing 1-4 heteroatoms selected from O, S, N, P and Si. In some embodiments, Ring A is a fused, spiro or bridged bicyclic heterocycloalkyl containing 1-4 heteroatoms selected from O, S, N, P and Si. In some embodiments, Ring A is a 5 membered monocyclic heteroaryl. In some embodiments, Ring A is a 6 membered monocyclic heteroaryl. In some embodiments, Ring A is a 6 membered monocyclic heteroaryl containing 1-3 heteroatoms. In some embodiments, Ring A is pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, oxazole, isoxazole or thiophene. In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for
[0227] In some embodiments, Ring A is a bicyclic heteroaryl. In some embodiments, Ring A is a fused 5-6, 6-6, or 6-5 bicyclic heteroaryl.
[0228] In some embodiments of Formulas (IVa), (IVa-1), and (IVa-2), each R A independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 In some embodiments of Formula (IVa), Formula (IVa-1), and Formula (IVa-2), each R A Independently selected from halogen, OH, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl and C 3-6 In some embodiments, each R A independently selected from halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 3-6 In some embodiments, each R A Independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Haloalkyl and C 3-6 In some embodiments, each R A independently selected from halogen, C 1-6 Alkyl, C 1-6Alkoxy and C 3-6 Cycloalkyl, wherein the alkyl, alkoxy and cycloalkyl are optionally substituted with one or more halogens (e.g., 1-3 fluorines). In some embodiments, each R A is independently selected from methyl, ethyl, propyl, butyl, -O-methyl, -O-ethyl, -O-propyl, -O-butyl, cyclopropyl, CN, OH, -O-CHF2, -O-CH2F, CHF2, CH2F and CF3. In some embodiments, R A In some embodiments, R A In some embodiments, R A In some embodiments, R A In some embodiments, R A is optionally substituted C 1-6 In some embodiments, R A In some embodiments, R A In some embodiments, R A In some embodiments, R A is optionally substituted C 1-6 In some embodiments, R A In some embodiments, R A is optionally substituted C 3-8 In some embodiments, R A In some embodiments, R A is optionally substituted C 2-7 In some embodiments, R A In some embodiments, R A For-OR 11 In some embodiments, R A For-SR 11 In some embodiments, R A -N(R 12 )(R 11 ). In some embodiments, R A -C(O)R 12 In some embodiments, R A -C(O)OR 12 In some embodiments, R A -OC(O)R 12 In some embodiments, R A -OC(O)N(R 12 )(R 11 ). In some embodiments, RA -C(O)N(R 12 )(R 11 ). In some embodiments, R A -N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 In some embodiments, R A -N(R 12 )C(O)N(R 12 )(R 11 ). In some embodiments, R A -N(R 12 )2S(O)2(R 12 ). In some embodiments, R A -S(O)R 12 In some embodiments, R A is -S(O)2R 12 In some embodiments, R A -S(O)2N(R 12 )(R 11 ).
[0229] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), R A is independently substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl.
[0230] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), Selected from:
[0231]
[0232] In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for
[0233] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), p is 1. In some embodiments, p is 0.
[0234] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 In some embodiments, R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl.
[0235] In some embodiments of Formula (IVa), (IVa-1), and (IVa-2), R B1 is optionally substituted C 3-8 In some embodiments, R B1 is optionally substituted C 2-9In some embodiments, R B1 is optionally substituted C 3-8 In some embodiments, R B1 In some embodiments, R B1 In some embodiments, R B1 In some embodiments, R B1 is an optionally substituted phenyl. B1 is optionally substituted C 2-9 In some embodiments, R B1 In some embodiments, R B1 In some embodiments, R B1 In some embodiments, R B1 is an optionally substituted monocyclic heteroaryl. B1 is an optionally substituted bicyclic heteroaryl. B1 is imidazole, pyrazole, triazole or tetrazole, each of which is optionally substituted. B1 In some embodiments, R B1 In some embodiments, R B1 In some embodiments, R B1 In some embodiments, R B1 is an optionally substituted fused 5-6, 6-6, or 6-5 heteroaryl. B1 Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12)(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 In some embodiments, R B1 Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 , -NO2, oxo, -CN, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 aminoalkyl, optionally substituted C 1-6 Hydroxyalkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 In some embodiments, R B1 Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-NO2、oxo、-CN、C 1-3 Halogenated alkyl, C 1-3 Alkyl, C 1-3 aminoalkyl, C 1-3 Hydroxyalkyl, optionally substituted C 1-4 Heteroalkyl (eg, -CH2C(=O)N(CH3)2), optionally substituted C 3-6 Cycloalkyl and optionally substituted C 2-5 In some embodiments, R B1 Optionally substituted with one or more substituents independently selected from the group consisting of halogen, oxo, -CN, C 1-3 Halogenated alkyl, C 1-3 Alkyl, C1-3 Aminoalkyl, C 1-3 Hydroxyalkyl, C 3-6 Cycloalkyl, and C 2-5 heterocycloalkyl. In some embodiments, R B1 is optionally independently substituted with one or more substituents (e.g., 1, 2, or 3) selected from C 1-3 haloalkyl and C 1-3 alkyl. In some embodiments, R B1 is substituted with halogen. In some embodiments, R B1 is substituted with -OR 11 . In some embodiments, R B1 is substituted with -NO2. In some embodiments, R B1 is substituted with an oxo group. In some embodiments, R B1 is substituted with -CN. In some embodiments, R B1 is substituted with optionally substituted C 1-6 haloalkyl. In some embodiments, R B1 is substituted with optionally substituted C 1-6 alkyl. In some embodiments, R B1 is substituted with optionally substituted C 1-6 aminoalkyl.
[0236] In some embodiments of formulae (IVa), (IVa-1), and (IVa-2), R B1 is
[0237] [[ID=is N. In some embodiments, Y 1 CR Y1 In some embodiments, Y 2 is N. In some embodiments, Y 2 CR Y2 In some embodiments, Y 3 is N. In some embodiments, Y 3 CR Y3 In some embodiments, Y 4 is N. In some embodiments, Y 4 CR Y4 .
[0239] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R 1 is hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 ) 2. optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 In some embodiments of the compounds of Formula (IVa), (IVa-1), and (IVa-2), R 1 is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 For-OR 11 In some embodiments, R 1 For-SR 11 In some embodiments, R 1 -N(R 12 )2. In some embodiments, R 1 is optionally substituted C 1-6 In some embodiments, R 1 C 1-3 In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R1 In some embodiments, R 1 is optionally substituted C 1-6 In some embodiments, R 1 C 1-3 In some embodiments, R 1 is optionally substituted C 2-6 In some embodiments, R 1 C 2-3 In some embodiments, R 1 is optionally substituted C 2-6 Alkynyl.
[0240] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R 1 is hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 In some embodiments of the compounds of Formula (IVa), (IVa-1), and (IVa-2), R 1 is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 For-OR 11 In some embodiments, R 1 For-SR 11 In some embodiments, R 1 -N(R 12 )(R 11 ). In some embodiments, R 1is optionally substituted C 1-6 In some embodiments, R 1 is optionally substituted C 1-6 In some embodiments, R 1 is optionally substituted C 2-6 In some embodiments, R 1 is optionally substituted C 2-6 In some embodiments, R 1 is optionally substituted C 3-8 In some embodiments, R 1 is optionally substituted C 2-7 Heterocycloalkyl.
[0241] In some embodiments of the compound of Formula (IVa) or (IVa-1), R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl. In some embodiments of the compound of formula (IVa) or (IVa-1), R 4 and R 4 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl. In some embodiments, R 4 In some embodiments, R4 In some embodiments, R 4 In some embodiments, R 4 For-OR 11 In some embodiments, R 4 For-SR 11 In some embodiments, R 4 -N(R 12 )(R 11 ). In some embodiments, R 4 is optionally substituted C 1-6 In some embodiments, R 4 is optionally substituted C 1-6 In some embodiments, R 4 is optionally substituted C 2-6 In some embodiments, R 4 is optionally substituted C 1-6 In some embodiments, R 4 is optionally substituted C 2-6 In some embodiments, R 4 is optionally substituted C 3-8 In some embodiments, R 4 is optionally substituted C 2-7 In some embodiments, R 4 ' is hydrogen. In some embodiments, R 4 ' is halogen. In some embodiments, R 4 ' is -CN. In some embodiments, R 4 'for-OR 11 In some embodiments, R 4 'for-SR 11 In some embodiments, R 4 ' is -N(R 12 )(R 11 ). In some embodiments, R 4 ' is optionally substituted C 1-6 In some embodiments, R 4 ' is optionally substituted C 1-6 In some embodiments, R 4 ' is optionally substituted C 1-6 In some embodiments, R 4 ' is optionally substituted C 2-6 In some embodiments, R 4 ' is optionally substituted C 2-6In some embodiments, R 4 ' is optionally substituted C 3-8 In some embodiments, R 4 ' is optionally substituted C 2-7 In some embodiments, R 4 and R 4 ' together to form an oxo group. In some embodiments, R 4 and R 4 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl.
[0242] In some embodiments of the compound of Formula (IVa) or (IVa-1), R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 In some embodiments of the compound of Formula (IVa) or (IVa-1), R 5 and R 5 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 In some embodiments, R 5 In some embodiments, R 5 In some embodiments, R 5 In some embodiments, R 5 For-OR 11 In some embodiments, R 5 For-SR 11 In some embodiments, R 5 -N(R 12 )(R 11 ). In some embodiments, R 5 is optionally substituted C 1-6 In some embodiments, R 5is optionally substituted C 1-6 In some embodiments, R 5 is optionally substituted C 1-6 In some embodiments, R 5 is optionally substituted C 2-6 In some embodiments, R 5 is optionally substituted C 2-6 In some embodiments, R 5 is optionally substituted C 3-8 In some embodiments, R 5 is optionally substituted C 2-7 In some embodiments, R 5 ' is hydrogen. In some embodiments, R 5 ' is halogen. In some embodiments, R 5 ' is -CN. In some embodiments, R 5 'for-OR 11 In some embodiments, R 5 'for-SR 11 In some embodiments, R 5 ' is -N(R 12 )(R 11 ). In some embodiments, R 5 ' is optionally substituted C 1-6 In some embodiments, R 5 ' is optionally substituted C 1-6 In some embodiments, R 5 ' is optionally substituted C 1-6 In some embodiments, R 5 ' is optionally substituted C 2-6 In some embodiments, R 5 ' is optionally substituted C 2-6 In some embodiments, R 5 ' is optionally substituted C 3-8 In some embodiments, R 5 ' is optionally substituted C 2-7 In some embodiments, R 5 and R 5 ' together to form an oxo group. In some embodiments, R 5 and R 5 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl.
[0243] In some embodiments of the compound of Formula (IVa) or (IVa-1), R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 In some embodiments of the compound of Formula (IVa) or (IVa-1), R 6 and R 6 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 In some embodiments, R 6 In some embodiments, R 6 In some embodiments, R 6 In some embodiments, R 6 For-OR 11 In some embodiments, R 6 For-SR 11 In some embodiments, R 6 -N(R 12 )(R 11 ). In some embodiments, R 6 is optionally substituted C 1-6 In some embodiments, R 6 is optionally substituted C 1-6 In some embodiments, R 6 is optionally substituted C 1-6 In some embodiments, R 6 is optionally substituted C 2-6 In some embodiments, R 6 is optionally substituted C 2-6 In some embodiments, R 6 is optionally substituted C 3-8 In some embodiments, R 6is optionally substituted C 2-7 In some embodiments, R 6 ' is hydrogen. In some embodiments, R 6 ' is halogen. In some embodiments, R 6 ' is -CN. In some embodiments, R 6 'for-OR 11 In some embodiments, R 6 'for-SR 11 In some embodiments, R 6 ' is -N(R 12 )(R 11 ). In some embodiments, R 6 ' is optionally substituted C 1-6 In some embodiments, R 6 ' is optionally substituted C 1-6 In some embodiments, R 6 ' is optionally substituted C 1-6 In some embodiments, R 6 ' is optionally substituted C 2-6 In some embodiments, R 6 ' is optionally substituted C 2-6 In some embodiments, R 6 ' is optionally substituted C 3-8 In some embodiments, R 6 ' is optionally substituted C 2-7 In some embodiments, R 6 and R 6 ' together to form an oxo group. In some embodiments, R 6 and R 6 ' together with the carbon to which it is attached form a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl.
[0244] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 In some embodiments of the compounds of Formula (IVa), (IVa-1), and (IVa-2), R 8 and R 9are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 In some embodiments, R 8 In some embodiments, R 8 In some embodiments, R 8 In some embodiments, R 8 is optionally substituted C 1-6 In some embodiments, R 8 is optionally substituted C 1-6 In some embodiments, R 8 is optionally substituted C 2-6 In some embodiments, R 8 is optionally substituted C 2-6 In some embodiments, R 9 In some embodiments, R 9 In some embodiments, R 9 In some embodiments, R 9 is optionally substituted C 1-6 In some embodiments, R 9 is optionally substituted C 1-6 In some embodiments, R 9 is optionally substituted C 2-6 In some embodiments, R 9 is optionally substituted C 2-6 In some embodiments, R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl.
[0245] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl, or a bicyclic heterocycloalkyl. In some embodiments, Ring A is a monocyclic heteroaryl. In some embodiments, Ring A is a bicyclic heteroaryl. In some embodiments, Ring A is a monocyclic heterocycloalkyl. In some embodiments, Ring A is a bicyclic heterocycloalkyl.
[0246] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R A are each independently selected from halogen, -NO2, oxo, CN, optionally substituted C1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ). In some embodiments, R A In some embodiments, R A In some embodiments, R A In some embodiments, R A In some embodiments, R A is optionally substituted C 1-6 In some embodiments, R A is optionally substituted C 1-3 In some embodiments, R A is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CF3, -CH2CF3 or -CH2CH2F. In some embodiments, R A is optionally substituted C 2-6 In some embodiments, R A is optionally substituted C 2-6 In some embodiments, R Ais optionally substituted C 1-6 In some embodiments, R A is optionally substituted C 3-8 In some embodiments, R A is optionally substituted C 3-6 In some embodiments, R A for In some embodiments, R A is optionally substituted C 2-7 In some embodiments, R A is optionally substituted C 2-5 In some embodiments, R A For-OR 11 In some embodiments, R A For-OC 1-3 In some embodiments, R A In some embodiments, R A In some embodiments, R A for In some embodiments, R A For-SR 11 In some embodiments, R A -N(R 12 )(R 11 ). In some embodiments, R A -C(O)R 12 In some embodiments, R A C(O)OR 12 In some embodiments, R A -OC(O)R 12 In some embodiments, R A -OC(O)N(R 12 )(R 11 ). In some embodiments, R A -C(O)N(R 12 )(R 11 ). In some embodiments, R A -N(R 12 )C(O)R 12 In some embodiments, R A -N(R 12 )C(O)OR 12 In some embodiments, RA -N(R 12 )C(O)N(R 12 )(R 11 ). In some embodiments, R A -N(R 12 )2S(O)2(R 12 ). In some embodiments, R A -S(O)R 12 In some embodiments, R A is -S(O)2R 12 In some embodiments, R A -S(O)2N(R 12 )(R 11 ).
[0247] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 In some embodiments, R 11 In some embodiments, R 11 is optionally substituted C 1-6 In some embodiments, R 11 is optionally substituted C 1-3 In some embodiments, R 11 is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CF3, -CH2CF3 or -CH2CH2F. In some embodiments, R 11 is optionally substituted C 2-6 In some embodiments, R 11 is optionally substituted C 2-6 In some embodiments, R 11is optionally substituted C 1-6 In some embodiments, R 11 is optionally substituted C 3-8 In some embodiments, R 11 is optionally substituted C 2-7 In some embodiments, R 11 is an optionally substituted phenyl. 11 is an optionally substituted heteroaryl. In some embodiments, R 11 is optionally substituted -C 1-4 Alkylene-C 3-8 In some embodiments, R 11 is optionally substituted -C 1-4 Alkylene-C 2-7 In some embodiments, R 11 is optionally substituted -C 1-4 In some embodiments, R 11 is optionally substituted -C 1-4 Alkylene-heteroaryl.
[0248] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R 12 Each independently selected from hydrogen, halogen, -OH, -NO2, CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 In some embodiments of the compounds of Formula (IVa), (IVa-1), and (IVa-2), R 12 Each independently selected from hydrogen, -NO2, CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 In some embodiments, R 12 In some embodiments, R 12 In some embodiments, R 12 In some embodiments, R 12 In some embodiments, R 12 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 3-6 In some embodiments, R 12 is a 3- to 6-membered heterocyclic ring, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 In some embodiments, one or more substituents are halogen. In some embodiments, one or more substituents are -OH. In some embodiments, one or more substituents are oxo. In some embodiments, one or more substituents are amino. In some embodiments, one or more substituents are -NO2. In some embodiments, one or more substituents are CN. In some embodiments, one or more substituents are C 1-6 In some embodiments, one or more substituents are C 1-6 In some embodiments, one or more substituents are C 1-6 Halogenated alkyl.
[0249] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R B1 is optionally substituted C 3-8Cycloalkyl, optionally substituted C 2-9 In some embodiments, R B1 is optionally substituted C 3-8 In some embodiments, R B1 is optionally substituted C 2-9 In some embodiments, R B1 is an optionally substituted 5-6 membered heterocycloalkyl. B1 In some embodiments, R B1 is an optionally substituted phenyl. B1 is an optionally substituted monocyclic heteroaryl. B1 is an optionally substituted bicyclic heteroaryl group.
[0250] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R Y1 Hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 In some embodiments, R Y1 In some embodiments, R Y1 In some embodiments, R Y1 In some embodiments, R Y1 In some embodiments, R Y1 For-OR 11 In some embodiments, R Y1 For-SR 11 In some embodiments, R Y1 -N(R 12 )(R 11 ). In some embodiments, R Y1 is optionally substituted C 1-6 In some embodiments, R Y1 is optionally substituted C 1-6 In some embodiments, R Y1 is optionally substituted C 2-6 In some embodiments, R Y1 is optionally substituted C 2-6 In some embodiments, R Y1 For-OR 11 In some embodiments, R Y1 For-SR 11 In some embodiments, R Y1 -N(R 12 )(R 11 ). In some embodiments, R Y1 -C(O)R 12 In some embodiments, R Y1 -C(O)OR 12 In some embodiments, R Y1 -OC(O)R 12 In some embodiments, R Y1 -OC(O)N(R 12 )(R 11 ). In some embodiments, R Y1 -C(O)N(R 12 )(R11 ). In some embodiments, R Y1 -N(R 12 )C(O)R 12 In some embodiments, R Y1 -N(R 12 )C(O)OR 12 In some embodiments, R Y1 -N(R 12 )C(O)N(R 12 )(R 11 ). In some embodiments, R Y1 -N(R 12 )S(O)2(R 12 ). In some embodiments, R Y1 -S(O)R 12 In some embodiments, R Y1 is -S(O)2R 12 In some embodiments, R Y1 -S(O)2N(R 12 )(R 11 ). In some embodiments, R Y1 is optionally substituted C 3-8 In some embodiments, R Y1 is optionally substituted C 2-9 In some embodiments, R Y1 In some embodiments, R Y1 is an optionally substituted phenyl. Y1 In some embodiments, R Y1 is an optionally substituted bicyclic heteroaryl group.
[0251] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R Y2 Hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 In some embodiments, R Y2 In some embodiments, R Y2 In some embodiments, R Y2 In some embodiments, R Y2 In some embodiments, R Y2 For-OR 11 In some embodiments, R Y2 For-SR 11 In some embodiments, R Y2 -N(R 12 )(R 11 ). In some embodiments, R Y2 is optionally substituted C 1-6 In some embodiments, R Y2 is optionally substituted C 1-6 In some embodiments, R Y2 is optionally substituted C 2-6 In some embodiments, R Y2 is optionally substituted C 2-6 In some embodiments, R Y2 For-OR 11 In some embodiments, R Y2For-SR 11 In some embodiments, R Y2 -N(R 12 )(R 11 ). In some embodiments, R Y2 -C(O)R 12 In some embodiments, R Y2 -C(O)OR 12 In some embodiments, R Y2 -OC(O)R 12 In some embodiments, R Y2 -OC(O)N(R 12 )(R 11 ). In some embodiments, R Y2 -C(O)N(R 12 )(R 11 ). In some embodiments, R Y2 -N(R 12 )C(O)R 12 In some embodiments, R Y2 -N(R 12 )C(O)OR 12 In some embodiments, R Y2 -N(R 12 )C(O)N(R 12 )(R 11 ). In some embodiments, R Y2 -N(R 12 )S(O)2(R 12 ). In some embodiments, R Y2 -S(O)R 12 In some embodiments, R Y2 is -S(O)2R 12 In some embodiments, R Y2 -S(O)2N(R 12 )(R 11 ). In some embodiments, R Y2 is optionally substituted C 3-8 In some embodiments, R Y2 is optionally substituted C 2-9 In some embodiments, R Y2 In some embodiments, R Y2 is an optionally substituted phenyl. Y2 In some embodiments, R Y2 is an optionally substituted bicyclic heteroaryl group.
[0252] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R Y3 Hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 In some embodiments, R Y3 In some embodiments, R Y3 In some embodiments, R Y3 In some embodiments, R Y3 In some embodiments, R Y3 For-OR 11 In some embodiments, R Y3 For-SR11 In some embodiments, R Y3 -N(R 12 )(R 11 ). In some embodiments, R Y3 is optionally substituted C 1-6 In some embodiments, R Y3 is optionally substituted C 1-6 In some embodiments, R Y3 is optionally substituted C 2-6 In some embodiments, R Y3 is optionally substituted C 2-6 In some embodiments, R Y3 For-OR 11 In some embodiments, R Y3 For-SR 11 In some embodiments, R Y3 -N(R 12 )(R 11 ). In some embodiments, R Y3 -C(O)R 12 In some embodiments, R Y3 -C(O)OR 12 In some embodiments, R Y3 -OC(O)R 12 In some embodiments, R Y3 -OC(O)N(R 12 )(R 11 ). In some embodiments, R Y3 -C(O)N(R 12 )(R 11 ). In some embodiments, R Y3 -N(R 12 )C(O)R 12 In some embodiments, R Y3 -N(R 12 )C(O)OR 12 In some embodiments, R Y3 -N(R 12 )C(O)N(R 12 )(R 11 ). In some embodiments, R Y3 -N(R 12 )S(O)2(R 12 ). In some embodiments, R Y3 -S(O)R 12 In some embodiments, R Y3is -S(O)2R 12 In some embodiments, R Y3 -S(O)2N(R 12 )(R 11 ). In some embodiments, R Y3 is optionally substituted C 3-8 In some embodiments, R Y3 is optionally substituted C 2-9 In some embodiments, R Y3 In some embodiments, R Y3 is an optionally substituted phenyl. Y3 In some embodiments, R Y3 is an optionally substituted bicyclic heteroaryl group.
[0253] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R Y4 Hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 In some embodiments, R Y4 In some embodiments, R Y4 In some embodiments, R Y4 In some embodiments, R Y4 In some embodiments, R Y4 For-OR 11 In some embodiments, R Y4 For-SR 11 In some embodiments, R Y4 -N(R 12 )(R 11 ). In some embodiments, R Y4 is optionally substituted C 1-6 In some embodiments, R Y4 is optionally substituted C 1-6 In some embodiments, R Y4 is optionally substituted C 2-6 In some embodiments, R Y4 is optionally substituted C 2-6 In some embodiments, R Y4 For-OR 11 In some embodiments, R Y4 For-SR 11 In some embodiments, R Y4 -N(R 12 )(R 11 ). In some embodiments, R Y4 -C(O)R 12 In some embodiments, R Y4 -C(O)OR 12 In some embodiments, R Y4 -OC(O)R 12 In some embodiments, R Y4 -OC(O)N(R 12 )(R 11 ). In some embodiments, R Y4 -C(O)N(R 12 )(R 11 ). In some embodiments, RY4 -N(R 12 )C(O)R 12 In some embodiments, R Y4 -N(R 12 )C(O)OR 12 In some embodiments, R Y4 -N(R 12 )C(O)N(R 12 )(R 11 ). In some embodiments, R Y4 -N(R 12 )S(O)2(R 12 ). In some embodiments, R Y4 -S(O)R 12 In some embodiments, R Y4 is -S(O)2R 12 In some embodiments, R Y4 -S(O)2N(R 12 )(R 11 ). In some embodiments, R Y4 is optionally substituted C 3-8 In some embodiments, R Y4 is optionally substituted C 2-9 In some embodiments, R Y4 In some embodiments, R Y4 is an optionally substituted phenyl. Y4 In some embodiments, R Y4 is an optionally substituted bicyclic heteroaryl group.
[0254] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 In some embodiments of the compounds of Formula (IVa), (IVa-1), and (IVa-2), R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl.
[0255] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), m is 1, 2, 3, or 4. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.
[0256] In some embodiments of compounds of Formula (IVa), (IVa-1), and (IVa-2), p is 0 or 1. In some embodiments, p is 0. In some embodiments, p is 1.
[0257] In some embodiments of the compound of Formula (IVa-2), Y 1 N or CR Y1 ; Y 2 N or CR Y2 ; Y 3 CR Y3 ; Y 4 CR Y4 ; R Y1 、R Y2 、R Y3 and R Y4 Each is independently hydrogen or C1-C6 alkyl; R1 is hydrogen or C1-C6 alkyl; p is 0; for And each R A are independently OH, C 1-6 Alkoxy (e.g. -OCH3), C 1-6 Alkyl, C 1-6 haloalkyl or C3-C6 cycloalkyl (eg cyclopropyl); and R B1 is optionally one or more selected from C 1-3 Haloalkyl and C 1-3 5-membered heteroaryl substituted with an alkyl substituent (e.g. ). In some embodiments, R B1 1 or 2 selected from C 1-3 Haloalkyl and C 1-3 In some embodiments, each R A are independently OH, C 1-3 Alkyl, C 1-3 Alkoxy (e.g. -OCH3), C 1-3 In some embodiments, each R A Independently C 1-3 In some embodiments, each R A are independently -OCH3, C 1-3Alkyl, C 1-3 In some embodiments, each R A are independently C1-C3 alkoxy, C 1-3 Alkyl, C 1-3 In some embodiments, -OCH3 is -OCD3.
[0258] In one aspect, described herein is a compound having the structure of Formula (VI) or a salt or solvate thereof:
[0259]
[0260] in,
[0261] Ring C is phenyl or 5-membered heteroaryl, wherein said phenyl or heteroaryl are each optionally substituted;
[0262] Ring D is an aromatic, saturated or partially saturated 6-membered carbocyclic or heterocyclic ring, wherein each of the carbocyclic or heterocyclic ring is optionally substituted;
[0263] R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 together to form an oxo group; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl;
[0264] Ring A is phenyl, naphthyl, monocyclic heteroaryl, bicyclic heteroaryl, cycloalkyl or heterocycloalkyl;
[0265] R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 );
[0266] R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 alkylene-heteroaryl;
[0267] R 12 Each independently selected from hydrogen, halogen, -OH, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, and C 3-6 Carbocyclic ring, 3-membered to 6-membered heterocyclic ring, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C1-6 Alkoxy and C 1-6 alkyl halide;
[0268] R B is hydrogen, halogen, -CN, -NO2, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl; or
[0269] m is 0, 1, 2, 3 or 4; and
[0270] p is 0 or 1
[0271] In some embodiments of Formula (VI), R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, and C 3-6 Carbocyclic ring, 3-membered to 6-membered heterocyclic ring, wherein the C3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl.
[0272] In some embodiments of Formula (VI), Ring C is phenyl or a 5-membered heteroaryl, wherein
[0273] The phenyl or heteroaryl groups are each optionally substituted with 1, 2, 3 or 4 R 1C Replace, and each R 1C are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d 、-SH、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 aminoalkyl, C 1-6 Heteroalkyl, C 2-6 Alkenyl, C2-C6 alkynyl, C 3-8 Cycloalkyl, C 2-7 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally and independently replaced by one or more R 1Ca replace;
[0274] Ring D is an aromatic, saturated or partially saturated 6-membered carbocyclic or heterocyclic ring, wherein each of the carbocyclic or heterocyclic rings is optionally substituted by 1, 2, 3, 4, 5 or 6 R 1D Replace, and
[0275] Each R 1D are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d 、-SH、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 aminoalkyl, C 1-6 Heteroalkyl, C 2-6 Alkenyl, C2-C6 alkynyl, C 3-8 Cycloalkyl, C 2-7 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally and independently replaced by one or more R 1Da replace;
[0276] R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, or R 8and R 9 together to form an oxo group, or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0277] R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, oxo, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0278] R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl, wherein the alkyl, alkenyl, alkynyl, heteroalkyl, alkylene, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 alkyl halide;
[0279] R 12 Each independently selected from hydrogen, halogen, -OH, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, and C 3-6 Carbocyclic ring, 3-membered to 6-membered heterocyclic ring, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 alkyl halide;
[0280] R Bis hydrogen, halogen, -CN, -NO2, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl or optionally substituted bicyclic heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 alkyl halide;
[0281] Each R aC1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-C6 alkylene-cycloalkyl, -C1-C6 alkylene-heterocycloalkyl, -C1-C6 alkylene-aryl or -C1-C6 alkylene-heteroaryl; wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more of the following groups: oxo, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S(= -C(=O)NH, -S(=O)NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(=O)OC1-C6 alkyl, -C(=O)C1-C6 alkyl, -C(=O)OH, -C(=O)OC1-C6 alkyl, -C(=O)NH2, -C(=O)N(C1-C6 alkyl)2, -C(=O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl;
[0282] Each R b is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-C6 alkylene-cycloalkyl, -C1-C6 alkylene-heterocycloalkyl, -C1-C6 alkylene-aryl or -C1-C6 alkylene-heteroaryl; wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more of the following groups: oxo, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S( -C(=O)NH, -S(=O)NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(=O)OC1-C6 alkyl, -C(=O)C1-C6 alkyl, -C(=O)OH, -C(=O)OC1-C6 alkyl, -C(=O)NH2, -C(=O)N(C1-C6 alkyl)2, -C(=O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl;
[0283] Each Rc and R d is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-C6 alkylene-cycloalkyl, -C1-C6 alkylene-heterocycloalkyl, -C1-C6 alkylene-aryl or -C1-C6 alkylene-heteroaryl; wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more of the following groups: oxo, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S( -C(=O)NH, -S(=O)NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(=O)OC1-C6 alkyl, -C(=O)C1-C6 alkyl, -C(=O)OH, -C(=O)OC1-C6 alkyl, -C(=O)NH2, -C(=O)N(C1-C6 alkyl)2, -C(=O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl;
[0284] or R c and R d and the atoms to which they are attached form a heterocycloalkyl group optionally substituted by one or more of the following groups: oxo, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S(=O)2C1-C6 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C -C6 alkyl)2, -NHC(═O)OC1-C6 alkyl, -C(═O)C1-C6 alkyl, -C(═O)C1-C6 alkyl, -C(═O)OH, -C(═O)OC1-C6 alkyl, -C(═O)NH2, -C(═O)N(C1-C6 alkyl)2, -C(═O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl;
[0285] Each R 1Ca and R 1Da are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b、-OC(=O)NR c R d 、-SH、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
[0286] m is 0, 1, 2, 3 or 4; and
[0287] p is 0 or 1.
[0288] In some embodiments of Formula (VI), Ring C is a 5-membered heteroaryl and Ring D is a 6-membered heteroaryl. In some embodiments, Ring C is a 5-membered heteroaryl and Ring D is a 6-membered heterocycloalkyl.
[0289] In some embodiments of Formula (VI), Ring C and Ring D are each independently optionally substituted with one or more substituents selected from the group consisting of halo, -CN, -OR a 、-SH、-SR a 、-NR c R d , optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, and wherein the alkyl, heteroalkyl, alkenyl or alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, oxo, -OH, -NO2, -CN and C 1-3 Alkoxy.
[0290] In some embodiments of Formula (VI), for
[0291] In some embodiments of Formula (VI), Ring A is phenyl. In some embodiments, Ring A is naphthyl. In some embodiments, Ring A is a 5- or 6-membered monocyclic heteroaryl. In some embodiments, Ring A is a 6-membered monocyclic heteroaryl containing 1-3 heteroatoms.
[0292] In some embodiments of Formula (VI), Ring A is pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, oxazole, isoxazole, or thiophene. In some embodiments, for
[0293] In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for
[0294] In some embodiments of Formula (VI), Ring A is aryl. In some embodiments, Ring A is phenyl. In some embodiments of Formula (VI), for In some embodiments, for In some embodiments of Formula (VI), Ring A is unsubstituted aryl (eg, phenyl). In some embodiments of Formula (VI), Ring A is optionally substituted with 1 to 5 R A In some embodiments of Formula (VI), Ring A is substituted with 1 R A In some embodiments of Formula (VI), Ring A is substituted with 2 R A In some embodiments of Formula (VI), Ring A is substituted with 3 R A In some embodiments of Formula (VI), Ring A is substituted with 4 R A In some embodiments of Formula (VI), Ring A is substituted with 5 R A Substituted aryl (eg, phenyl).
[0295] In some embodiments of Formula (VI), Ring A is a bicyclic heteroaryl. In some embodiments, Ring A is a fused 5-6, 6-6, or 6-5 bicyclic heteroaryl.
[0296] In some embodiments of Formula (VI), R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R12 and -S(O)2N(R 12 )(R 11 ). In some embodiments, each R A is independently substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl.
[0297] In some embodiments of Formula (VI), Selected from: In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for
[0298] In some embodiments of Formula (VI), p is 0. In some embodiments, p is 1.
[0299] In some embodiments of Formula (VI), R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6In some embodiments of Formula (VI), R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl.
[0300] In some embodiments of Formula (VI), R 8 and R 9 Combined together to form an oxo group.
[0301] In some embodiments of Formula (VI), R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl.
[0302] In some embodiments of Formula (VI), R B is halogen, -CN, -NO2, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C2-9 In some embodiments, R B is an optionally substituted 5-membered monocyclic heteroaryl group having 1 to 4 heteroatoms selected from N, O, S and P. In some embodiments, R B is imidazole, pyrazole, triazole or tetrazole, each of which is optionally substituted. B is an optionally substituted fused 5-6, 6-6 or 6-5 heteroaryl.
[0303] In some embodiments of Formula (VI), R B Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 In some embodiments, RB Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 , -NO2, oxo, -CN, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 aminoalkyl, optionally substituted C 1-6 Hydroxyalkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 In some embodiments, R B Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-NO2、oxo、-CN、C 1-3 Halogenated alkyl, C 1-3 Alkyl, C 1-3 aminoalkyl, C 1-3 Hydroxyalkyl, optionally substituted C 1-4 Heteroalkyl (eg, -CH2C(=O)N(CH3)2), optionally substituted C 3-6 Cycloalkyl and optionally substituted C 2-5 In some embodiments, R B is optionally substituted C 3-8 In some embodiments, R B In some embodiments, R B In some embodiments, R B In some embodiments, R B is an optionally substituted phenyl. B is optionally substituted C 2-9 In some embodiments, R B In some embodiments, R B In some embodiments, R B In some embodiments, R B is an optionally substituted 5-6 membered heterocycloalkyl or heteroaryl. B is an optionally substituted monocyclic heteroaryl. B is an optionally substituted bicyclic heteroaryl. B is imidazole, pyrazole, triazole or tetrazole, each of which is optionally substituted. BIn some embodiments, R B In some embodiments, R B In some embodiments, R B For tetrazole.
[0304] In some embodiments of Formula (VI), R B Selected from:
[0305] In some embodiments of Formula (VI), R B for In some embodiments, R B for In some embodiments, R B for In some embodiments, R B for In some embodiments, R B for In some embodiments, R B for In some embodiments, R B for
[0306] In some embodiments of Formula (VI), Ring C is a 5-membered heteroaryl, wherein the heteroaryl is optionally substituted. In some embodiments, Ring C is an optionally substituted 5-membered heteroaryl.
[0307] In some embodiments of Formula (VI), Ring D is an aromatic, saturated or partially saturated 6-membered carbocyclic or heterocyclic ring, wherein each of the carbocyclic or heterocyclic ring is optionally substituted. In some embodiments, Ring D is an optionally substituted aromatic 6-membered carbocyclic ring. In some embodiments, Ring D is an optionally substituted aromatic 6-membered heterocyclic ring. In some embodiments, Ring D is an optionally substituted saturated 6-membered carbocyclic ring. In some embodiments, Ring D is an optionally substituted saturated 6-membered heterocyclic ring. In some embodiments, Ring D is an optionally substituted partially saturated 6-membered carbocyclic ring. In some embodiments, Ring D is an optionally substituted partially saturated 6-membered heterocyclic ring.
[0308] In some embodiments of Formula (VI), R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6In some embodiments of Formula (VI), R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 In some embodiments, R 8 In some embodiments, R 8 In some embodiments, R 8 In some embodiments, R 8 is optionally substituted C 1-6 In some embodiments, R 8 is optionally substituted C 1-6 In some embodiments, R 8 is optionally substituted C 2-6 In some embodiments, R 8 is optionally substituted C 2-6 In some embodiments, R 9 In some embodiments, R 9 In some embodiments, R 9 In some embodiments, R 9 is optionally substituted C 1-6 In some embodiments, R 9 is optionally substituted C 1-6 In some embodiments, R 9 is optionally substituted C 2-6 In some embodiments, R 9 is optionally substituted C 2-6 In some embodiments, R 8 and R 9 In some embodiments, R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl.
[0309] In some embodiments of Formula (VI), Ring A is phenyl, naphthyl, monocyclic heteroaryl, or bicyclic heteroaryl. In some embodiments, Ring A is phenyl. In some embodiments, Ring A is naphthyl. In some embodiments, Ring A is monocyclic heteroaryl. In some embodiments, Ring A is bicyclic heteroaryl.
[0310] In some embodiments of Formula (VI), R Aindependently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ). In some embodiments, R A In some embodiments, R A In some embodiments, R A In some embodiments, R A In some embodiments, R A is optionally substituted C 1-6 In some embodiments, R A is optionally substituted C 1-3 In some embodiments, R A is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CF3, -CH2CF3 or -CH2CH2F. In some embodiments, R A is optionally substituted C 2-6 In some embodiments, R A is optionally substituted C2-6 In some embodiments, R A is optionally substituted C 1-6 In some embodiments, R A is optionally substituted C 3-8 In some embodiments, R A is optionally substituted C 3-6 In some embodiments, R A for In some embodiments, R A is optionally substituted C 2-7 In some embodiments, R A is optionally substituted C 2-5 In some embodiments, R A For-OR 11 In some embodiments, R A For-OC 1-3 In some embodiments, R A In some embodiments, R A In some embodiments, R A for In some embodiments, R A For-SR 11 In some embodiments, R A -N(R 12 )(R 11 ). In some embodiments, R A -C(O)R 12 In some embodiments, R A -C(O)OR 12 In some embodiments, R A -OC(O)R 12 In some embodiments, R A -OC(O)N(R 12 )(R 11 ). In some embodiments, R A -C(O)N(R 12 )(R 11 ). In some embodiments, R A -N(R 12 )C(O)R 12 In some embodiments, R A -N(R12 )C(O)OR 12 In some embodiments, R A -N(R 12 )C(O)N(R 12 )(R 11 ). In some embodiments, R A -N(R 12 )2S(O)2(R 12 ). In some embodiments, R A -S(O)R 12 In some embodiments, R A is -S(O)2R 12 In some embodiments, R A -S(O)2N(R 12 )(R 11 ). In some embodiments, -OCH3 is -OCD3.
[0311] In some embodiments of Formula (VI), R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 In some embodiments, R 11 In some embodiments, R 11 is optionally substituted C 1-6 In some embodiments, R 11 is optionally substituted C 1-3 In some embodiments, R A is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CF3, -CH2CF3 or -CH2CH2F. In some embodiments, R 11 is optionally substituted C 2-6 In some embodiments, R 11is optionally substituted C 2-6 In some embodiments, R 11 is optionally substituted C 1-6 In some embodiments, R 11 is optionally substituted C 3-8 In some embodiments, R 11 is optionally substituted C 2-7 In some embodiments, R 11 is an optionally substituted phenyl. 11 is an optionally substituted heteroaryl. In some embodiments, R 11 is optionally substituted -C 1-4 Alkylene-C 3-8 In some embodiments, R 11 is optionally substituted -C 1-4 Alkylene-C 2-7 In some embodiments, R 11 is optionally substituted -C 1-4 In some embodiments, R 11 is optionally substituted -C 1-4 Alkylene-heteroaryl.
[0312] In some embodiments of Formula (VI), R 12 Each independently selected from hydrogen, halogen, -OH, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, and C 3-6 Carbocyclic ring, 3-membered to 6-membered heterocyclic ring, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 In some embodiments of Formula (VI), R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, and C 3-6 Carbocyclic ring, 3-membered to 6-membered heterocyclic ring, wherein the C 3-6The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 In some embodiments, R 12 In some embodiments, R 12 In some embodiments, R 12 In some embodiments, R 12 In some embodiments, R 12 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 1-6 In some embodiments, R 12 C 3-6 In some embodiments, R 12 is a 3- to 6-membered heterocyclic ring, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 In some embodiments, one or more substituents are halogen. In some embodiments, one or more substituents are -OH. In some embodiments, one or more substituents are oxo. In some embodiments, one or more substituents are amino. In some embodiments, one or more substituents are -NO2. In some embodiments, one or more substituents are -CN. In some embodiments, one or more substituents are C 1-6 In some embodiments, one or more substituents are C 1-6 In some embodiments, one or more substituents are C 1-6 Halogenated alkyl.
[0313] In some embodiments of Formula (VI), R B is hydrogen, halogen, -CN, -NO2, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6Alkynyl, optionally substituted C 1-6 Heteroalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 ),-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 In some embodiments, R B In some embodiments, R B In some embodiments, R B In some embodiments, R B In some embodiments, R B is optionally substituted C 1-6 In some embodiments, R B is optionally substituted C 2-6 In some embodiments, R B is optionally substituted C 2-6 In some embodiments, R B is optionally substituted C 1-6 In some embodiments, R B For-OR 11 In some embodiments, R B For-SR 11 In some embodiments, R B -N(R12 )(R 11 ). In some embodiments, R B -C(O)R 12 In some embodiments, R B -C(O)OR 12 In some embodiments, R B -OC(O)R 12 In some embodiments, R B -OC(O)N(R 12 )(R 11 ). In some embodiments, R B -C(O)N(R 12 )(R 11 ). In some embodiments, R B -N(R 12 )C(O)R 12 In some embodiments, R B -N(R 12 )C(O)OR 12 In some embodiments, R B -N(R 12 )C(O)N(R 12 )(R 11 ). In some embodiments, R B -N(R 12 )S(O)2(R 12 ). In some embodiments, R B -S(O)R 12 In some embodiments, R B is -S(O)2R 12 In some embodiments, R B -S(O)2N(R 12 )(R 11 ). In some embodiments, R B is optionally substituted C 3-8 In some embodiments, R B is optionally substituted C 2-9 In some embodiments, R B In some embodiments, R B is an optionally substituted phenyl. B is an optionally substituted monocyclic heteroaryl. B is an optionally substituted bicyclic heteroaryl group.
[0314] In some embodiments of Formula (VI), m is 1, 2, 3, or 4. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.
[0315] In some embodiments of Formula (VI), p is 0 or 1. In some embodiments, p is 0. In some embodiments, p is 1.
[0316] Non-limiting examples of compounds described herein are the compounds presented in Table 1 and pharmaceutically acceptable salts or solvates thereof.
[0317] Table 1. Exemplary compounds of the present disclosure
[0318]
[0319]
[0320]
[0321]
[0322]
[0323] Table 2 presents the corresponding biological data of USP1 IC50 (nM) and MDA-MB-436 IC50 (nM) of the compounds presented in Table 1.
[0324] Table 2:
[0325]
[0326]
[0327] IC 50 (nM): 0 <A≤50;50<B≤1,000;1,000<C≤10,000
[0328] The present disclosure includes salts of the compounds described herein, particularly pharmaceutically acceptable salts. Compounds of the present disclosure having sufficient acidity, sufficient basicity, or both functional groups can react with a variety of inorganic bases and any of inorganic and organic acids to form salts. Alternatively, intrinsically charged compounds, such as those having quaternary nitrogen, can form salts with appropriate counterions, such as halides such as bromide, chloride, or fluoride, particularly bromide.
[0329] Chemical entities with carbon-carbon double bonds or carbon-nitrogen double bonds can exist in Z- or E-form (or cis- or trans-form). In addition, some chemical entities can exist in various tautomeric forms. Unless otherwise indicated, the compounds described herein are also intended to include all Z-, E- and tautomeric forms.
[0330] As used herein, "phenyl isostere" refers to a portion or functional group that exhibits physical, biological, and / or chemical properties similar to phenyl. Exemplary phenyl isosteres include, but are not limited to, cubanes, bicyclo[1.1.1]pentane (BCP), bicyclo[2.2.1]heptane, bicyclo[2.1.1]hexane, bicyclo[2.2.2]octane, adamantane, norbornene, closed-1,2-carborane, closed-1,7-carborane, closed-1,12-carborane, and ethynyl. In some embodiments, the phenyl isostere is cubanes. In some embodiments, the phenyl isostere is ethynyl.
[0331] "Tautomers" refer to molecules in which a proton may shift from one atom of a molecule to another atom of the same molecule. In certain embodiments, the compounds presented herein exist as tautomers. Where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include:
[0332]
[0333] In some embodiments, the compounds disclosed herein are used in different isotopically enriched forms, such as 2 H. 3 H. 11 C. 13 C and / or 14 In one embodiment, the compound is deuterated at at least one position. Such deuterated forms can be prepared by the procedures described in U.S. Patents 5,846,514 and 6,334,997. As described in U.S. Patents 5,846,514 and 6,334,997, deuteration can improve metabolic stability and / or efficacy, thereby increasing the duration of drug action.
[0334] Unless otherwise stated, the compounds described herein may exhibit their natural isotopic abundance, or one or more atoms may be artificially enriched in a particular isotope having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. All isotopic variants of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure. For example, the compounds described herein may be artificially enriched in one or more specific isotopes. In some embodiments, the compounds described herein may be artificially enriched in one or more isotopes that are not found in large quantities in nature. In some embodiments, the compounds described herein may be artificially enriched in one or more isotopes selected from deuterium ( 2 H), tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 In some embodiments, the compounds described herein are artificially enriched in one or more isotopes selected from: 2 H. 11 C. 13 C. 14 C. 15 C. 12 N. 13 N. 15 N. 16 N. 16 O. 17 O. 14 F. 15 F. 16 F. 17 F. 18 F. 33 S. 34 S. 35 S. 36 S. 35 Cl, 37 Cl, 79 Br, 81 Br, 131 I and 125 I. In some embodiments, the abundance of the enriched isotopes is independently at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% on a molar basis.
[0335] In some embodiments of the compounds disclosed herein, R 1 、R 4 、R 4 '、R 5 、R 5 '、R 6 、R 6 '、R8 、R 9 、R Y1 、R Y2 、R Y3 、R Y4 、R 11 、R 12 、R A 、R B 、R B1 、R 1Ca 、R 1Da 、R a 、R b 、R c and / or R d One or more of the groups comprises a percentage of deuterium that is higher than the natural abundance of deuterium.
[0336] In some embodiments of the compounds disclosed herein, one or more 1 H is replaced by one or more deuteriums selected from one or more of the following groups: R 1 、R 4 、R 4 '、R 5 、R 5 '、R 6 、R 6 '、R 8 、R 9 、R Y1 、R Y2 、R Y3 、R Y4 、R 11 、R 12 、R A 、R B 、R B1 、R 1Ca 、R 1Da 、R a 、R b 、R c and / or R d .
[0337] In some embodiments of the compounds disclosed herein, R 1 、R 4 、R 4 '、R 5 、R 5 '、R 6 、R 6 '、R 8 、R 9 、R Y1 、R Y2 、R Y3 、R Y4 、R 11 、R 12、R A 、R B 、R B1 、R 1Ca 、R 1Da 、R a 、R b 、R c and / or R d The abundance of deuterium in each is independently at least 1 mol%, at least 10 mol%, at least 20 mol%, at least 30 mol%, at least 40 mol%, at least 50 mol%, at least 60 mol%, at least 70 mol%, at least 80 mol%, at least 90 mol%, or 100 mol%.
[0338] In some embodiments of the compounds disclosed herein, one or more of Ring A, Ring C, and / or Ring D 1 H is replaced by one or more deuteriums.
[0339] In certain embodiments, some or all of the compounds disclosed herein 1 H atoms are 2 H atom replacement. Methods for synthesizing deuterium-containing compounds are known in the art and include, by way of non-limiting example only, the following synthetic methods. Deuterium-substituted compounds can be synthesized using various methods described, for example, in Dean, Dennis C.; ed. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [Curr., Pharm. Des., 2000; 6(10)] 2000, p. 110; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.
[0340] Deuterated starting materials are readily available and are subjected to the synthetic methods described herein to provide the synthesis of deuterium-containing compounds. A large number of deuterium-containing reagents and building blocks are commercially available from chemical suppliers, such as Aldrich Chemical Co.
[0341] The compounds of the present disclosure also include crystalline and amorphous forms of those compounds, pharmaceutically acceptable salts, and active metabolites of these compounds having the same type of activity, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates), conformational polymorphs, and amorphous forms of the compounds, and mixtures thereof.
[0342] In some cases, the compounds described herein can exist as diastereomers, enantiomers or other stereoisomeric forms. When absolute stereochemistry is not specified, the compounds presented herein include all diastereomers, enantiomers and epimeric forms and appropriate mixtures thereof. The separation of stereoisomers can be carried out by chromatography or by forming diastereomers and by recrystallization or chromatography separation or any combination thereof. (Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981, incorporated herein by reference for this disclosure). Stereoisomers can also be obtained by stereoselective synthesis.
[0343] The methods and compositions described herein include the use of amorphous forms as well as crystalline forms (also referred to as polymorphs). The compounds described herein may be in the form of pharmaceutically acceptable salts. In some embodiments, active metabolites of these compounds having the same type of activity are also included within the scope of this disclosure. In addition, the compounds described herein may exist in unsolvated form as well as in solvated form with pharmaceutically acceptable solvents such as water, ethanol, etc. The solvated forms of the compounds presented herein are also considered to be disclosed herein.
[0344] In certain embodiments, the compound or salt of the compound may be a prodrug, for example, where a hydroxyl group in the parent compound is present as an ester or carbonate, or a carboxylic acid present in the parent compound is present as an ester. The term "prodrug" is intended to encompass compounds that are converted to pharmaceutical agents of the present disclosure under physiological conditions. One method of preparing a prodrug is to include one or more selected moieties that are hydrolyzed under physiological conditions to produce the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of a host animal, such as a specific target cell in the host animal. For example, esters or carbonates (e.g., esters of alcohols or carboxylic acids or carbonates and phosphonates) are preferred prodrugs of the present disclosure.
[0345] Prodrug forms of the compounds described herein, wherein the prodrug is metabolized in vivo to produce the compound as described herein, are included within the scope of the claims. In some cases, some of the compounds described herein may be a prodrug of another derivative or active compound.
[0346] Prodrugs are generally useful because they can be more easily administered than the parent drug in some cases. They can be, for example, bioavailable by oral administration, whereas the parent drug is not. Prodrugs can help enhance the cell permeability of compounds relative to the parent drug. Prodrugs can also have improved solubility in pharmaceutical compositions that is superior to the parent drug. Prodrugs can be designed as reversible drug derivatives, useful as modulators that promote drug transport to site-specific tissues or increase drug retention within cells.
[0347] In some embodiments, the design of the prodrug increases the lipophilicity of the pharmaceutical agent. In some embodiments, the design of the prodrug increases the effective water solubility. See, e.g., Fedorak et al., Am. J. Physiol., 269:G210-218 (1995); McLoed et al., Gastroenterol, 106:405-413 (1994); Hochhaus et al., Biomed. Chrom., 6:283-286 (1992); J. Larsen and H. Bundgaard, Int. J. Pharmaceutics, 37, 87 (1987); J. Larsen et al., Int. J. Pharmaceutics, 47, 103 (1988); Sinkula et al., J. Pharm. Sci., 64:181-210 (1975); T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, ACS Symposium Series Vol. 14; and Edward B. Roche, Bioreversible Carriers in Drug Delivery Systems. Design, American Pharmaceutical Association and Pergamon Press, 1987, the disclosure of which is incorporated herein in its entirety). According to another embodiment, the present disclosure provides methods for producing the compounds defined above. The compounds can be synthesized using conventional techniques. Advantageously, these compounds are preferably synthesized from readily available starting materials.
[0348] Synthetic chemistry transformations and methods for synthesizing the compounds described herein are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations (1989); T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 2nd ed. (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis (1995).
[0349] C. Pharmaceutical Compositions
[0350] In certain embodiments, provided herein are compositions (also referred to herein as "pharmaceutical agents") comprising a therapeutically effective amount of any compound or salt of any of Formula (IVa), (IVa-1), (IVa-2), and (VI).
[0351] Pharmaceutical compositions can be formulated using one or more physiologically acceptable carriers, including excipients and adjuvants that aid in processing the pharmaceutical agent into a pharmaceutically useful preparation. Appropriate formulations depend on the chosen route of administration. Overviews of pharmaceutical compositions are found, for example, in Remington: The Science and Practice of Pharmacy, 19th ed. (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed. (Lippincott Williams & Wilkins 1999).
[0352] The compositions and methods of the present disclosure can be used to treat individuals in need. In certain embodiments, the individual is a mammal, such as a human, or a non-human mammal. When administering a composition or pharmaceutical agent to an animal such as a human, it is preferably administered in the form of a pharmaceutical composition comprising, for example, a pharmaceutical agent and a pharmaceutically acceptable carrier or excipient. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions, such as water or physiologically buffered saline, or other solvents or vehicles, such as glycols, glycerol, oils (such as olive oil) or injectable organic esters. In a preferred embodiment, when such pharmaceutical compositions are used for human administration, particularly for invasive routes of administration, such as avoiding routes of transmission or diffusion through an epithelial barrier, such as injection or implantation, the aqueous solution is pyrogen-free, or substantially pyrogen-free. Excipients can be selected, for example, to achieve delayed release of a medicament or selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in unit dosage form, such as tablets, capsules, granules, lyophilized materials for reconstitution, powders, solutions, syrups, suppositories, injections, etc. The composition can also be present in a transdermal delivery system (such as a skin patch). The composition may also be presented in a solution suitable for topical administration (eg, eye drops).
[0353] Pharmaceutically acceptable excipients may contain physiologically acceptable agents, the effects of which are, for example, to stabilize, increase solubility or increase absorption of compounds such as pharmaceutical agents. Such physiologically acceptable agents include, for example, carbohydrates such as glucose, sucrose or polydextrose; antioxidants such as ascorbic acid or glutathione; chelating agents, low molecular weight proteins or other stabilizers or excipients. The selection of pharmaceutically acceptable excipients including physiologically acceptable agents depends on, for example, the route of administration of the composition. The formulation or pharmaceutical composition may be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical composition (formulation) may also be a liposome or other polymer matrix, into which, for example, a compound of the present disclosure may be incorporated. Liposomes (e.g., comprising phospholipids or other lipids) are physiologically acceptable and metabolizable non-toxic carriers that are relatively simple to prepare and administer.
[0354] The pharmaceutical composition (formulation) can be administered to a subject by any of a variety of routes of administration, including, for example, oral, such as bolus solutions in the form of aqueous or non-aqueous solutions or suspensions, tablets, capsules including dispersible capsules and gelatin capsules, boluses, powders, granules, pastes applied to the tongue; absorption via the oral mucosa, such as sublingually; anal, rectal or vaginal, such as in the form of pessaries, creams or foams; parenteral, including intramuscular, intravenous, subcutaneous or intrathecal, such as in the form of sterile solutions or suspensions; nasal; intraperitoneal; subcutaneous; transdermal, such as in the form of patches applied to the skin; and topical, such as in the form of creams, ointments or sprays applied to the skin, or in the form of eye drops. The compound can also be formulated for inhalation. In certain embodiments, the compound can simply be dissolved or suspended in sterile water.
[0355] The pharmaceutical composition can be a sterile aqueous or non-aqueous solution, a suspension or an emulsion, such as a microemulsion. The excipients described herein are examples and are not intended to be limiting. An effective amount or therapeutically effective amount refers to an amount of one or more pharmaceutical agents administered to a subject in a single dose or as part of a series of doses that is effective to produce the desired therapeutic effect.
[0356] The subject can usually monitor the effectiveness of treatment using an assay and method suitable for the illness being treated, which assay will be familiar to those of ordinary skill in the art and is described herein. The pharmacokinetics of a pharmaceutical agent or one or more metabolites thereof administered to a subject can be monitored by measuring the level of the pharmaceutical agent or metabolite in a biological fluid (e.g., blood, blood separator (e.g., serum) and / or urine) and / or other biological samples or biological tissues from the subject. Any method implemented in the art and described herein for detecting a pharmaceutical agent can be used to measure the level of a pharmaceutical agent or metabolite during the course of treatment.
[0357] The dosage of the pharmaceutical agents described herein for treating a disease or condition may depend on the subject's condition, i.e., the stage of the disease, the severity of the symptoms caused by the disease, overall health, and age, sex, and weight, as well as other factors apparent to those skilled in the medical field. The pharmaceutical composition may be administered in a manner determined by those skilled in the medical field to be suitable for the disease being treated. In addition to the factors described herein and above regarding the use of pharmaceutical agents for treating a disease or condition, the suitable duration and frequency of administration of the pharmaceutical agent may also be determined or adjusted by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. Experimental models and / or clinical trials can generally be used to determine the optimal dosage of the pharmaceutical agent. The optimal dosage may depend on the subject's body mass, weight, or blood volume. It is generally preferred to use the minimum dosage sufficient to provide effective therapy. The design and execution of preclinical and clinical studies of the pharmaceutical agents described herein, including when administered for prophylactic benefit, are entirely within the skill of those skilled in the relevant art. When two or more pharmaceutical agents are administered to treat a disease or condition, the optimal dosage of each pharmaceutical agent may be different, for example, less than the dosage when either pharmaceutical agent is administered alone as a single-dose therapy. In some specific embodiments, two kinds of pharmaceutical agents are combined and can be worked synergistically or additively, and any medicament can be used in less amount than when being used alone.The amount of the pharmaceutical agent that can be used every day can be for example between about 0.01mg / kg and 100mg / kg, for example, between about 0.1 to 1mg / kg, between about 1 to 10mg / kg, between about 10 to 50mg / kg, between about 50 to 100mg / kg body weight.In other embodiments, the amount of the pharmaceutical agent that can be used every day is between about 0.01mg / kg and 1000mg / kg, between about 100 to 500mg / kg or between about 500 to 1000mg / kg body weight.For the disease or illness treated, the optimum dose every day or each treatment process can be different and also can change with route of administration and treatment regimen.
[0358] Pharmaceutical compositions comprising pharmaceutical agents can be formulated in a manner suitable for the delivery method using techniques commonly practiced in the art. The compositions can be in the form of solids (e.g., tablets, capsules), semisolids (e.g., gels), liquids, or gases (e.g., aerosols). In other embodiments, the pharmaceutical compositions are administered as bolus infusions.
[0359] Pharmaceutically acceptable excipients are well known in the pharmaceutical field and are described, for example, in Rowe et al., Handbook of Pharmaceutical Excipients: A Comprehensive Guide to Uses, Properties, and Safety, 5th ed., 2006, and Remington: The Science and Practice of Pharmacy (Gennaro, 21st ed., Mack Pub. Co., Easton, PA (2005)). Exemplary pharmaceutically acceptable excipients include sterile saline and phosphate-buffered saline at physiological pH. Preservatives, stabilizers, dyes, buffers, and the like may be provided in the pharmaceutical composition. In addition, antioxidants and suspending agents may also be used. Generally, the type of excipient is selected based on the mode of administration and the chemical composition of the active ingredient. Alternatively, the compositions described herein may be formulated as a lyophilizate. The compositions described herein may be lyophilized or otherwise formulated as a lyophilized product using one or more appropriate excipient solutions to dissolve and / or dilute the pharmaceutical agent of the composition after administration. In other embodiments, the pharmaceutical agent may be encapsulated within liposomes using techniques known and practiced in the art. In certain embodiments, the pharmaceutical agent is not formulated within a liposome for use in vascular stents, which are used to treat highly but not completely blocked arteries.The pharmaceutical composition can be formulated for any suitable mode of administration as described herein and in the art.
[0360] For example, pharmaceutical compositions for oral administration or for injection, infusion, subcutaneous delivery, intramuscular delivery, intraperitoneal delivery or other methods may be in liquid form. Liquid pharmaceutical compositions may include, for example, one or more of the following: sterile diluents, such as water, saline solutions, preferably physiological saline, Ringer's solution, isotonic sodium chloride; fixed oils, polyethylene glycol, glycerol, propylene glycol or other solvents that can serve as solvents or suspension media; antibacterial agents; antioxidants; chelating agents; buffers and agents for regulating osmotic properties, such as sodium chloride or dextrose. Parenteral compositions may be packaged in ampoules, disposable syringes or multidose vials made of glass or plastic. Physiological saline is preferably used, and injectable pharmaceutical compositions are preferably sterile. In another embodiment, in order to treat ophthalmic disorders or diseases, liquid pharmaceutical compositions may be applied to the eye in the form of eye drops. Liquid pharmaceutical compositions may be delivered orally.
[0361] For oral formulations, at least one of the pharmaceutical agents described herein can be used alone or in combination with appropriate additives to prepare tablets, powders, granules or capsules, and, when necessary, in combination with diluents, buffers, wetting agents, preservatives, colorants and flavorings. The pharmaceutical agent can be formulated with a buffer to provide protection for the compound to resist the low pH of the gastric environment and / or an enteric coating. The pharmaceutical agent included in the pharmaceutical composition can be formulated for oral delivery, for example, in the form of a liquid, solid or semisolid formulation, and / or formulated with an enteric coating, together with a flavoring.
[0362] Pharmaceutical compositions comprising any of the pharmaceutical agents described herein can be formulated for sustained or slow release, also referred to as timed release or controlled release. Such compositions can typically be prepared using well-known techniques and administered, for example, orally, rectally, intradermally or subcutaneously, or by implantation at a desired target site. Sustained-release formulations may contain compounds dispersed in a carrier matrix and / or contained within a reservoir surrounded by a rate-controlling membrane. The excipients used in such formulations are biocompatible and may also be biodegradable; the formulations preferably provide a relatively constant level of active ingredient release. The amount of pharmaceutical agent contained in a sustained-release formulation depends on the site of implantation, the rate of release, and the expected duration, and the nature of the disorder, disease, or condition to be treated or prevented.
[0363] In certain embodiments, the pharmaceutical composition comprising the pharmaceutical agent is formulated for transdermal, intradermal or topical administration. The composition can be administered in the form of a powder / talcum or other solid, liquid, spray, aerosol, ointment, foam, cream, gel, or paste using a syringe, bandage, transdermal patch, insert, or syringe-type applicator. This is preferably in the form of a controlled release formulation or sustained release formulation, administered topically or directly injected into the skin near the area to be treated or within the area to be treated, such as intradermally or subcutaneously. The active composition can also be delivered via iontophoresis. Preservatives can be used to prevent the growth of fungi and other microorganisms. Suitable preservatives include, but are not limited to, benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate, sodium propionate, benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, thimerosal, and combinations thereof.
[0364] Pharmaceutical compositions containing pharmaceutical agents can be formulated as emulsions for topical application. Emulsions contain one liquid distributed in a second liquid body. Emulsions can be oil-in-water emulsions or water-in-oil emulsions. Either or both the oil phase and the aqueous phase can contain one or more surfactants, emulsifiers, emulsion stabilizers, buffers, and other excipients. The oil phase can contain other oily, pharmaceutically approved excipients. Suitable surfactants include, but are not limited to, anionic surfactants, nonionic surfactants, cationic surfactants, and amphoteric surfactants. Compositions for topical application can also include at least one suitable suspending agent, antioxidant, chelating agent, emollient, or moisturizer.
[0365] Ointments and creams can be prepared, for example, with aqueous or oily bases that add suitable thickeners and / or gelling agents. Lotions can be prepared with aqueous or oily bases and should usually also contain one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners or colorants. Liquid sprays can be delivered from pressurized packaging, for example, via a specially shaped closure. Oil-in-water emulsions can also be used in compositions, patches, bandages and products. These systems are semisolid emulsions, microemulsions or foam emulsion systems.
[0366] In some embodiments, the pharmaceutical agents described herein can be formulated as inhalants. Inhalation can deliver drugs directly to the airways. The pharmaceutical agents can be formulated as aerosols, microparticles, liposomes, or nanoparticles. The pharmaceutical agents can be formulated with solvents, gases, nitrates, or any combination thereof. The compositions described herein are optionally formulated for delivery in the form of liquid aerosols or inhalable dry powders. Liquid aerosol formulations are optionally atomized primarily into particle sizes that can be delivered to the terminal and respiratory bronchioles. Liquid aerosol and inhalable dry powder formulations are preferably delivered within the endobronchial tree to the terminal bronchioles and ultimately to the parenchymal tissue.
[0367] The aerosolized formulations described herein are optionally delivered using an aerosol-forming device, such as an ejector, a vibrating porous plate, or an ultrasonic nebulizer, preferably selected to allow formation of aerosol particles having a mean diameter primarily between 1 and 5 μm in the presence of a mass medium. Furthermore, the formulation preferably has a balanced osmotic concentration, ionic strength, and chloride concentration, and the minimum aerosolizable volume is capable of delivering an effective dose of the pharmaceutical agent. Furthermore, the aerosolized formulation preferably does not adversely impair the function of the airways and does not cause undesirable side effects.
[0368] Aerosolization devices suitable for administering the aerosol formulations described herein include, for example, ejectors, vibrating porous plates, ultrasonic nebulizers, and powered dry powder inhalers, which are capable of atomizing the formulation into aerosol particle sizes primarily in the 1-5 μm size range. Primarily in this application means that at least 70% but preferably more than 90% of all aerosol particles produced are within the 1-5 μm range. Jet nebulizers work by separating liquid solutions into aerosol droplets through air pressure. Vibrating porous plate nebulizers work by using a vacuum of sonic waves generated by rapidly vibrating a porous plate to squeeze solvent droplets through the porous plate. Ultrasonic nebulizers work by shearing a liquid into small aerosol droplets through a piezoelectric transistor. A variety of suitable devices are available, including, for example, AeroNeb™ and AeroDose™ vibrating porous plate nebulizers (AeroGen, Inc., Sunnyvale, California), Nebulizer (Medic-Aid Ltd., West Sussex, England), Pari and Pari LC Jet nebulizer (Pari Respiratory Equipment, Inc., Richmond, Virginia) and Aerosonic™ (DeVilbiss Medizinische Produkte (Deutschland) GmbH, Heiden, Germany) and (Omron Healthcare, Inc., Vernon Hills, Illinois) ultrasonic nebulizer.
[0369] In some embodiments, the pharmaceutical agent can be formulated with an oily base or ointment to form a semi-solid composition having a desired shape. In addition to the pharmaceutical agent, these semi-solid compositions may contain dissolved and / or suspended antiseptics, preservatives, and / or buffer systems. The petrolatum component that may be included may be any paraffin wax with a viscosity ranging from mineral oil to paraffin wax combined with isobutylene, colloidal silica, or stearate. An absorption matrix can be used with the oily system. Additives may include, alone or in combination, cholesterol, wool wax (wool wax derivatives, beeswax, fatty alcohols, wool wax alcohol, emulsifiers with a low hydrophilic-lipophilic balance (HLB), and various ionic and nonionic surfactants.
[0370] Control or sustained release transdermal or topical preparation can be realized by adding timed release additive, and described additive is for example obtainable polymer structure, matrix in this area.For example, composition can be via using hot melt extrusion goods, and for example bioadhesive hot melt extrusion film is used.Preparation can comprise cross-linked polycarboxylic acid polymer preparation.Cross-linking agent can provide enough adhesive force amount to exist, thereby makes system keep being attached to target epithelium or endothelial cell surface and continue to be enough to allow compound to realize the time of required release.
[0371] The insert, transdermal patch, bandage, or article may comprise a mixture or coating of polymers that provides for release of the pharmaceutical agent at a constant rate over an extended period of time. In some embodiments, the article, transdermal patch, or insert comprises a water-soluble pore-forming agent, such as polyethylene glycol (PEG), which may be mixed with a water-insoluble polymer to increase the durability of the insert and prolong the release of the active ingredient.
[0372] Transdermal devices (inserts, patches, bandages) may also contain water-insoluble polymers. Rate-controlling polymers may be suitable for application to sites where pH changes can be used to affect release. These rate-controlling polymers can be applied using a continuous coating film during the spraying and drying process of the active compound. In one embodiment, the coating formulation is used to coat pellets containing the active ingredient, which are compressed to form a solid, biodegradable insert.
[0373] Polymer formulations can also be utilized to provide controlled or sustained release. Bioadhesive polymers described in the art can be used. For example, sustained-release gels and compounds can be incorporated into polymer matrices such as hydrophobic polymer matrices. Examples of polymer matrices include microparticles. Microparticles can be microspheres, and the core can have a material different from the polymer shell. Alternatively, the polymer can be cast as a thin plate or film, a powder produced by grinding or other standard techniques, or a gel such as a hydrogel. The polymer can also be in the form of a coating, or be a part of a bandage, vascular stent, catheter, vascular graft, or other device to promote the delivery of a pharmaceutical agent. The matrix can be formed by solvent evaporation, spray drying, solvent extraction, and other methods known to those skilled in the art.
[0374] Kits are provided having unit doses of one or more of the agents described herein, typically in oral or injectable dosage form. Such kits may include a container containing the unit doses, an informative package insert describing the use of the drug in treating the disease and the attendant benefits, and optionally an implement or device for delivering the composition.
[0375] D. Treatment methods
[0376] Ubiquitin-specific protease 1 (USP1) is a member of the ubiquitin-specific processing protease family. USP1 is a deubiquitinating enzyme ("DUB") and deubiquitinates substrates involved in key oncogenic pathways to regulate their function. Among its actions, USP1 exhibits DNA-mediated activation at replication forks, protecting forks and promoting survival in BRCA1-deficient cells. Because loss of both USP1 and BRCA1 leads to replication fork degradation, inhibition of USP1 can selectively reduce the viability or kill tumor cells with defects in BRCA deficiency without affecting the survival of cells with normal BRCA function.
[0377] In the United States (US), it is estimated that inherited BRCA1 and BRCA2 mutations are present in 5% to 10% of breast cancers and 10% to 15% of ovarian cancers. Breast cancer is the most common cancer in the world and the most common malignancy in women. BRCA1 and BRCA2 can be detected in at least 5% of unselected breast cancer patients and approximately 30% of patients with a family history of breast or ovarian cancer. Currently, treatment options including chemotherapy and immune checkpoint inhibitors are limited for breast cancer patients with germline BRCA mutations, more aggressive progression, and a higher risk of recurrence. Although PARP inhibitors have been approved by the U.S. Food and Drug Administration (FDA) as monotherapy for harmful / suspected harmful germline BRCA mutations, HER2-negative breast cancer, in some cases, resistance to PARP inhibitors can be observed in breast cancer patients to develop rapidly. Ovarian cancer represents a heterogeneous group of solid tumors. On average, one-fifth of ovarian cancers can be associated with germline mutations. Of those ovarian cancers with germline mutations, 65-85% can be associated with germline BRCA mutations. Similar to the breast cancer setting, while PARP inhibitors can be first-line maintenance therapy for patients with BRCA-mutated ovarian cancer, those patients can develop resistance to PARP inhibitors.
[0378] The compounds described herein can be used as inhibitors of USP1. Such compounds can exhibit BRCA1 and / or BRCA2 mutation-selective antiproliferative activity. The compounds described herein can be used to treat BRCA1 and / or BRCA2 mutation- or homologous recombination (HRD)-positive cancers. The compounds described herein can exhibit antiproliferative activity in cancer cells with BRCA1 and / or BRCA2 mutations, particularly MDA-MB-436 cells. The compounds described herein may not exhibit similar antiproliferative activity in cancer cells with wild-type BRCA, particularly SNG-M cells. In some embodiments, the compounds described herein can exhibit selectivity for mutant BRCA1 and / or BRCA2 that is at least 50-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, 450-fold, 500-fold, 550-fold, 600-fold, or more, compared to wild-type BRCA.
[0379] The compounds described herein can be used to prepare a medicament for preventing or treating a disease or disorder. In some embodiments, the compounds described herein are used in a method for regulating USP1 in a subject. In some embodiments, the compounds described herein are used in a method for inhibiting USP1 in a subject. In some embodiments, the compounds described herein are used in a method for inhibiting or reducing DNA repair activity regulated by USP1 in a subject. In some embodiments, the compounds described herein are used in a method for treating a disease or disorder associated with USP1 in a subject. In some embodiments, the compounds described herein are used in a method for treating a disease or disorder associated with the regulation of USP in a subject. In addition, a method for regulating, inhibiting or treating any of the diseases or disorders described herein in a subject in need of such treatment involves administering to the subject a pharmaceutical composition containing at least one compound described herein or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug or pharmaceutically acceptable solvate thereof in a therapeutically effective amount.
[0380] The compositions containing the compounds described herein can be administered for prophylactic and / or therapeutic treatments. In therapeutic applications, the compositions are administered to a patient already suffering from a disease or disorder in an amount sufficient to cure or at least partially arrest the symptoms of the disease or disorder. Amounts effective for this use will depend on the severity and course of the disease or disorder, previous therapy, the patient's health, weight, response to the drugs, and the judgment of the treating physician.
[0381] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of developing a particular disease, condition, or disorder. This amount is defined as a "prophylactically effective amount or dose." In this use, the precise amount will also depend on the patient's health status, weight, etc. When used in a patient, an effective amount for this use will depend on the severity of the disease, condition, or disorder, its course, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.
[0382] In cases where the patient's condition does not improve, the compound may be administered chronically, i.e., for extended periods of time, including the entire duration of the patient's life, to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition, at the physician's discretion.
[0383] Once the patient's condition improves, a maintenance dose is administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced to a level that maintains the improved disease, condition, or illness, depending on the symptoms. However, the patient may require long-term intermittent treatment upon any recurrence of symptoms.
[0384] The amount of a given dose that will correspond to this amount will vary depending on factors such as the specific compound, the disease or disorder and its severity, the identity of the subject or host in need of treatment (e.g., weight), but nonetheless can be determined in a manner recognized in the art based on the specific circumstances surrounding the case, including, for example, the specific dose being administered, the route of administration, the disorder being treated, and the subject or host being treated. However, in general, dosages for adult treatment will typically range from about 0.02 to about 5000 mg per day, and in some embodiments, from about 1 to about 1500 mg per day. The desired dose may be suitably presented in a single dose form or as divided doses administered simultaneously (or over a shorter period of time) or at appropriate intervals, for example, as two, three, four, or more sub-doses per day.
[0385] The pharmaceutical compositions described herein can be in unit dosage form suitable for single administration of precise doses. In a unit dosage form, the formulation is divided into unit doses containing appropriate amounts of one or more compounds. The unit dose can be in a packaged form containing discrete amounts of the formulation. Non-limiting examples are packaged tablets or capsules and powders in vials or ampoules. Aqueous suspension compositions can be packaged in non-reclosable single-dose containers. Alternatively, reclosable multi-dose containers can be used, in which case a preservative is typically included in the composition. By way of example only, formulations for parenteral injection can be presented in unit dosage form, including but not limited to ampoules, or in multi-dose containers with the addition of a preservative.
[0386] Toxicity and therapeutic efficacy of such treatment regimens can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, including but not limited to determining the LD 50 (50% population lethal dose) and ED 50 The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD 50 / ED 50 Compounds that exhibit high therapeutic indices are preferred. Data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans. The dosage of such compounds preferably lies within a range of circulating concentrations that include the ED with minimal toxicity. 50 The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
[0387] In one aspect, the present disclosure provides a method of modulating USP1 in a subject, the method comprising administering to the subject a compound described herein, or a pharmaceutically acceptable salt or solvate thereof.
[0388] In one aspect, the present disclosure provides a method of inhibiting USP1 in a subject, comprising administering to the subject a compound described herein, or a pharmaceutically acceptable salt or solvate thereof.
[0389] In one aspect, the present disclosure provides a method of inhibiting or reducing DNA repair activity regulated by USP1 in a subject in need thereof, comprising administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition described herein.
[0390] In one aspect, the present disclosure provides a method of treating a disease or condition associated with USP1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition described herein. In some embodiments, the disease or condition is cancer.
[0391] In one aspect, the present disclosure provides a method of treating a disease or condition associated with USP1 regulation in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition described herein. In some embodiments, the disease or condition is cancer.
[0392] In one aspect, the present disclosure provides a method of treating cancer in a subject, comprising administering to the subject in need thereof an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition described herein.
[0393] In some embodiments, the administration of the compounds described herein, or their pharmaceutically acceptable salts or solvates, may also include combination with other biologically active ingredients (e.g., a second therapeutic agent). Other biologically active ingredients may include a second and different anti-neoplastic agent or second agent that targets a USP1-independent DNA repair mechanism. In some embodiments, the administration of the compounds described herein, or their pharmaceutically acceptable salts or solvates, may also include combination with non-drug therapies. Non-drug therapies may include surgery, radiation therapy, or any other type of therapy that does not include the administration of a drug. Such combinations of the compounds described herein, or their pharmaceutically acceptable salts or solvates, with other biologically active ingredients or non-drug therapies may enhance the effects of the compounds described herein, or their pharmaceutically acceptable salts or solvates. The compounds described herein may be administered simultaneously or sequentially with other biologically active ingredients, but at least two or more compounds or biologically active ingredients may be administered during a single cycle or course of therapy. In some embodiments, the second therapeutic agent is a poly ADP ribose polymerase (PARP) inhibitor. In some embodiments, the USP1 inhibitors described herein are administered together with two PARP inhibitors. In some embodiments, the PARP inhibitor is olaparib, niraparib, talazoparib, or rucaparib.
[0394] In one aspect, the present disclosure provides a method of treating cancer in a subject, the method comprising administering to a subject in need thereof an amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition described herein. In some embodiments, the cancer is leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), or multiple myeloma (MM).
[0395] In some embodiments, the cancer is a carcinoma, a squamous carcinoma, an adenocarcinoma, a sarcoma, an endometrial cancer, a breast cancer, an ovarian cancer, a cervical cancer, a fallopian tube cancer, a primary peritoneal cancer, a colon cancer, a colorectal cancer, a squamous cell carcinoma of the anogenital region, a melanoma, a renal cell carcinoma, a lung cancer, a non-small cell lung cancer, a squamous cell carcinoma of the lung, a stomach cancer, a bladder cancer, a gallbladder cancer, a liver cancer, a thyroid cancer, a laryngeal cancer, a salivary gland cancer, an esophageal cancer, a head and neck cancer, a glioblastoma, a glioma, a squamous cell carcinoma of the head and neck, a prostate cancer, a pancreatic cancer, a mesothelioma, a sarcoma, a blood cancer, a leukemia, a lymphoma, a neuroma, and a combination thereof. In some embodiments, the cancers treated by the methods of the present disclosure include, for example, carcinomas, squamous carcinomas (e.g., cervical canal, eyelid, conjunctiva, vagina, lung, oral cavity, skin, bladder, tongue, larynx, and esophagus) and adenocarcinomas (e.g., prostate, small intestine, endometrium, cervical canal, large intestine, lung, pancreas, esophagus, rectum, uterus, stomach, breast, and ovary). In some embodiments, the cancers treated by the methods of the present disclosure also include sarcomas (e.g., myogenic sarcomas), leukocytosis, neuromas, melanomas, and lymphomas. In some embodiments, the cancer to be treated by the methods of the present disclosure is breast cancer. In some embodiments, the cancer to be treated by the methods of the present disclosure is triple-negative breast cancer (TNBC). In some embodiments, the cancer to be treated by the methods of the present disclosure is ovarian cancer. In some embodiments, the cancer to be treated by the methods of the present disclosure is colorectal cancer. In some embodiments, the cancer is a homologous recombination-deficient cancer. In some embodiments, the cancer comprises cancer cells having a mutation in a gene encoding p53.
[0396] In some embodiments, the patient or patient colony to be treated by the pharmaceutical composition of the present disclosure suffers from solid tumors.In some embodiments, solid tumors are melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gallbladder cancer, laryngeal cancer, liver cancer, thyroid cancer, gastric cancer, salivary gland cancer, prostate cancer, pancreatic cancer or Merkel cell carcinoma (Merkel cell carcinoma).In some embodiments, the patient or patient colony to be treated by the pharmaceutical composition of the present disclosure suffers from hematological cancer.In some embodiments, the patient suffers from hematological cancer, such as diffuse large B cell lymphoma ("DLBCL"), Hodgkin lymphoma ("HL"), non-Hodgkin lymphoma ("NHL"), follicular lymphoma ("FL"), acute myeloid leukemia ("AML") or multiple myeloma ("MM").In some embodiments, the patient to be treated or patient colony suffers from the cancer selected from the group consisting of ovarian cancer, lung cancer and melanoma.
[0397] Specific examples of cancers that can be prevented and / or treated according to the present disclosure include, but are not limited to, the following: renal cancer, kidney cancer, glioblastoma multiforme, metastatic breast cancer; breast carcinoma; breast sarcoma; neurofibroma; neurofibromatosis; childhood tumors; neuroblastoma; malignant melanoma; epidermal cancer; leukemias, such as, but not limited to, acute leukemias, acute lymphocytic leukemias, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemias and myelodysplastic syndromes, chronic leukemias such as, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia, blood diseases; polycythemia vera; lymphomas, such as, but not limited to, Hodgkin's disease and non-Hodgkin's disease; multiple myeloma, such as, but not limited to, smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone cancer and connective tissue sarcomas, such as, but not limited to, osteosarcoma, myeloma bone disease, multiple myeloma, cholesteatoma-induced osteosarcoma of bone, Paget's disease of bone, osteosarcoma, chondrosarcoma, Ewing's sarcoma, sarcoma), malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft tissue sarcoma, angiosarcoma (angiosarcoma / hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, schwannoma, rhabdomyosarcoma, and synovial sarcoma; brain tumors such as, but not limited to, gliomas, astrocytomas, brain stem gliomas, ependymomas, oligodendrogliomas, non-glial tumors, acoustic neurothema, craniopharyngiomas, medulloblastomas, meningiomas, pineal cell tumors, pineoblastomas, and primary brain lymphoma; breast cancer, including but not limited to adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease (including juvenile Paget's disease), and inflammatory breast cancer; adrenal cancer, such as but not limited to pheochromocytoma and adrenocortical carcinoma; thyroid cancer, such as but not limited to papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; pancreatic cancer, such as but not limited to insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancer, such as but not limited to Cushing's disease, prolactin-secreting tumor, acromegaly, and diabetes insipidus; eye cancer, such as but not limited to ocular melanoma, such as iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma;Vaginal cancer, such as squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, such as squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancer, such as, but not limited to, squamous cell carcinoma and adenocarcinoma; uterine cancer, such as, but not limited to, endometrial cancer and uterine sarcoma; ovarian cancer, such as, but not limited to, epithelial ovarian cancer, borderline tumors, germ cell tumors, and stromal tumors; cervical cancer; esophageal cancer, such as, but not limited to, squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma , verrucous carcinoma and oat cell (small cell) carcinoma; gastric cancer, such as but not limited to adenocarcinoma, mycosis fungoides (polypoid), ulcerative, superficial spreading, diffuse spreading, malignant lymphoma, liposarcoma, fibrosarcoma and carcinosarcoma; colon cancer; colorectal cancer, KRAS mutant colorectal cancer; colon carcinoma; rectal cancer; liver cancer, such as but not limited to hepatocellular carcinoma and hepatoblastoma, gallbladder cancer such as adenocarcinoma; bile duct cancer, such as but not limited to papillary, nodular and diffuse; lung cancer, such as KRAS mutant non-small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma ( epidermoid carcinoma), adenocarcinoma, large cell carcinoma, and small cell lung cancer; lung cancer; testicular cancers such as, but not limited to, germinal tumors, seminoma, anaplastic, classical (typical), spermatogonial, non-seminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk sac tumor); prostate cancers such as, but not limited to, androgen-independent prostate cancer, androgen-dependent prostate cancer, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penile cancer; oral cancers such as, but not limited to, squamous cell carcinoma; basal carcinoma; salivary gland cancers such as, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and Adenoid cystic carcinoma; pharyngeal cancers such as, but not limited to, squamous cell carcinoma and verrucous carcinoma; skin cancers such as, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo-like malignant melanoma, acral lentigo melanoma; kidney cancers such as, but not limited to, renal cell carcinoma, adenocarcinoma, adrenal tumor, fibrosarcoma, transitional cell carcinoma (renal pelvis and / or uterus); renal cancer; Wilms' tumor; bladder cancers such as, but not limited to, transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, carcinosarcoma. In addition, cancers include myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphoendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinoma.
[0398] In one aspect, the present disclosure provides a method for treating cancer in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition described herein. In some embodiments, the cancer may comprise cancer cells with elevated RAD 18 mRNA expression levels. In some embodiments, elevated RAD 18 levels are elevated RAD 18 protein levels. In some embodiments, RAD 18 levels can be detected using quantitative methods such as microarrays, RNA-Seq, or reverse transcriptase polymerase chain reaction (RT-PCR). In some embodiments, RAD 18 levels in cancer cells can be detected before administering the compounds described herein. In some embodiments, RAD 18 levels can be detected in cancer samples obtained from subjects. In some embodiments, if a subject has elevated RAD 18 levels, the subject can be treated with the compounds described herein. In some embodiments, elevated RAD 18 levels in cancer cells indicate that the subject administering the compounds described herein or pharmaceutical compositions has responded to treatment with the compounds described herein or pharmaceutical compositions. In some embodiments, a compound described herein is not administered to a subject with elevated RAD18 levels.
[0399] In some embodiments, the cancer is a cancer with a defect in a DNA damage repair pathway. In some embodiments, the cancer is a BRCA1 or BRCA2 mutant cancer that is resistant or recalcitrant to PARP inhibitors. In some embodiments, the cancer comprises cells with elevated levels of RAD 18, wherein the elevated levels of RAD 18 are at least as high as the levels of RAD 18 mRNA and / or protein in ES2 cells or HEP3B217 cells.
[0400] In some embodiments, the cancer is a BRCA1 mutant cancer and / or a BRCA2 mutant cancer. In some embodiments, the cancer is a BRCA1 or BRCA2 wild-type cancer. In some embodiments, the cancer is a BRCA1 deficient cancer. In some embodiments, the cancer is a BRAC2 deficient cancer. In some embodiments, the cancer comprises cancer cells having mutations in the genes encoding BRCA1 and / or BRCA2. In some embodiments, the cancer is a BRCA1 mutant cancer and a BRCA2 deficient cancer. In some embodiments, the cancer is a BRCA1 deficient cancer and a BRCA2 mutant cancer. In some embodiments, the cancer comprises cells having elevated levels of RAD 18, wherein the elevated levels of RAD 18 are at least as high as the levels of RAD 18 mRNA and / or protein in ES2 cells or HEP3B217 cells.
[0401] Example
[0402] The following examples are provided to illustrate, but not to limit, the claimed disclosure.The following examples further illustrate the present disclosure, but of course should not be construed as limiting its scope in any way.
[0403] The following synthetic schemes are provided for illustrative purposes and are not intended to be limiting. The following examples illustrate various methods for preparing the compounds described herein. It will be appreciated that one skilled in the art will be able to prepare these compounds by similar methods or by combining other methods known to those skilled in the art. It will also be appreciated that one skilled in the art will be able to prepare in a similar manner as described below by using appropriate starting materials and modifying the synthetic pathways as needed. In general, starting materials and reagents can be obtained from commercial suppliers or synthesized from sources known to those skilled in the art or prepared as described herein.
[0404] Compounds and salts of formula (IVa), (IVa-1), (IVa-2) and (VI) can be synthesized according to one or more illustrative schemes herein and / or techniques known in the art. The materials used herein are commercially available or prepared by synthetic methods generally known in the art. These schemes are not limited to the compounds or any specific substituents listed in the examples, which are employed for illustrative purposes. Although various steps are described and depicted in the following synthetic schemes, the steps may, in some cases, be performed in an order different from that shown below. The numbering or R groups in each scheme do not necessarily correspond to those in the claims or other schemes or tables herein.
[0405] Example A - Biological Assay
[0406] Example A1: Enzyme assay
[0407] Human recombinant USP1 / UAF1 (R&D, E-568-050) expressed in baculovirus-infected Sf21 cells was used. Test compounds and / or vehicle were incubated with 2 nM USP1 / UAF1 in modified HEPES buffer (pH 8.0) for 15 minutes at room temperature. The reaction was initiated by adding 500 nM ubiquitin rhodamine 110 (R&D, U-555-050) for kinetic reading. The slope change of fluorescence intensity was read at 485 nm / 535 nm using spectrofluorimetry. The dose response of the test compound or reference compound ML-323 was analyzed by nonlinear regression analysis using GraphPad Prism software. The results of the assay are shown in Table 2.
[0408] Example A2: MDA-MB-436 breast cancer cell culture
[0409] MDA-MB-436 cells were grown in Leibovitz L-15 medium containing 10 μg / ml insulin, 16 μg / ml glutathione, and 10% FBS. Cells were passaged at subconfluence after trypsinization and maintained in an incubator at 37° C. in a humidified atmosphere with 5% CO 2 .
[0410] Example A3: MDAMB-436 breast cancer cell proliferation assay
[0411] use Luminescent cell viability assay (Promega, #G7573) measures cell proliferation. MDA-MB-436 cells were seeded in 384-well plates and allowed to adhere for 24 hours. Compounds were added to 384-well plates via ECHO and incubated at 37°C in a humidified atmosphere with 5% CO2. After 7 days, CellTiter-Glo was added to the 384-well plates, the contents were mixed on a 400g orbital shaker for 2 minutes, and the plates were then centrifuged at 1000 rpm for 2 minutes. After incubation at room temperature for 30 minutes, luminescence was read on Envision. The results of the assay are shown in Table 2.
[0412] Example B_Chemical Synthesis
[0413] Example B1: LCMS method
[0414] The LCMS methods used in the following synthetic procedures are provided in Table 3.
[0415] Table 3: LCMS method codes (flow rate in mL / min; column temperature (T) in °C; run time in minutes).
[0416]
[0417] Example B2: Synthesis of Intermediate A
[0418]
[0419] 4-Cyclopropyl-6-methoxypyrimidine
[0420] To a solution of 4-chloro-6-methoxypyrimidine (150.00 g, 1.04 mol) in dioxane (1500 mL) and H2O (300 mL) was added cyclopropylboronic acid (178.27 g, 2.08 mol), K2CO3 (286.82 g, 2.08 mol) and Pd(dppf)Cl2 (75.92 g, 0.10 mol). The reactant was stirred at 100 ° C for 16 h under an Ar atmosphere. The mixture was diluted with water (500 ml) and extracted with EtOAc (400 mL x 3). The combined organic layer was washed with brine (500 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography eluted with PE / EtOAc=20 / 1 to obtain the desired product (82.10 g, 0.55 mol, 53%) as a yellow oil.
[0421] LCMS: retention time: 1.157 min, (M+H) + =151.1, Method A.
[0422] 5-Bromo-4-cyclopropyl-6-methoxypyrimidine
[0423] To a solution of 4-cyclopropyl-6-methoxypyrimidine (82.00 g, 546.01 mmol) in EtOH (900 mL) was added Br2 (30.85 mL, 600.61 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 16 h. The suspension was filtered and washed with MeOH (200 mL). The solid was dried to give the desired product (99.70 g, 435.22 mmol, 79.7%) as a white solid.
[0424] LCMS: retention time: 1.707 min, (M+H) + =229.1, Method A.
[0425] 4-Cyclopropyl-6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
[0426] To a solution of 5-bromo-4-cyclopropyl-6-methoxypyrimidine (50.00 g, 218.26 mmol) in DMSO (500 mL) was added 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolanane (110.88 g, 436.53 mmol), KOAc (64.26 g, 654.79 mmol) and Pd(dppf)Cl2 (15.97 g, 21.83 mmol). The reactants were stirred at 100 ° C for 16 h under an Ar atmosphere. The mixture was diluted with 600 mL of water and extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (200 mL x 3), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography eluting with PE / EtOAc = 10: 1 to give the desired product (28.00 g, 101.40 mmol, 46%) as a white solid.
[0427] LCMS: retention time: 1.627 min, (M+H) + =277.2, Method A.
[0428] 1 H NMR (400MHz, DMSO-d6): δ = 8.59 (s, 1H), 3.86 (s, 3H), 2.05-2.02 (m, 1H), 1.32 (s, 12H), 1.04-1.00 (m, 4H).
[0429] Example B3: Synthesis of Intermediate B
[0430]
[0431] 2-Isopropylpyridin-3-yl trifluoromethanesulfonate
[0432] To a solution of 2-isopropylpyridin-3-ol (4.50 g, 32.80 mmol) in pyridine (20 mL) was added trifluoromethanesulfonic anhydride (5.44 mL, 32.80 mmol) at 0 ° C. The mixture was stirred at room temperature for 2 h. The mixture was quenched with ice water (30 mL) and basified with saturated NaHCO solution until pH = 7. The mixture was extracted with DCM (20 mL x 3). The combined organic eluents were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE / EtOAc from 50 / 1 to 20 / 1) to obtain the desired product (7.88 g, 29.30 mmol, 89.3%) as a light yellow oil. LCMS confirmed.
[0433] LCMS: retention time: 1.597 min, (M+H) + =270.0, Method A.
[0434] 2-Isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
[0435] A mixture of 2-isopropylpyridin-3-yl trifluoromethanesulfonate (5.88 g, 21.84 mmol), B2pin2 (11.09 g, 43.66 mmol), potassium acetate (4.28 g, 43.66 mmol) and Pd(dppf)Cl2 (1.60 g, 2.18 mmol) in dioxane (50 mL) was stirred at 95 ° C. under Ar for 5 h. The mixture was concentrated and the residue was purified by silica gel column chromatography (eluted with DCM / MeOH from 100 / 1 to 40 / 1) to give the desired product (5.20 g, 21.04 mmol, 96%) as a brown oil.
[0436] LCMS: retention time: 0.360 min, (M+H) + = 166.1 (MS corresponding to boronic acid), method A.
[0437] Example B4: Synthesis of Intermediate C
[0438]
[0439] 2-(4-bromophenyl)-4-(trifluoromethyl)-1H-imidazole
[0440] To a solution of 3,3-dibromo-1,1,1-trifluoropropane-2-one (17.5g, 64.86mmol) in H o (30mL) was added NaOAc (8.87g, 108.10mmol). The mixture was stirred at 100 ° C for 1 hour and then cooled to room temperature. A mixture of 4-bromobenzaldehyde (7.05g, 38.1mmol), NH OH (27.75mL, 216.19mmol) and MeOH (50mL) was added. The resulting mixture was stirred at room temperature for 16h. The reaction mixture was then concentrated under reduced pressure. The precipitate was collected by filtration and washed with ethyl acetate / petroleum ether (1 / 5, 60mL). The solid was collected and dried in vacuo to obtain the desired product (6.00g, 20.6mmol, 54%) as a yellow solid.
[0441] LCMS: retention time: 1.267 min, (M+H) + =290.9, Method B.
[0442] 2-(4-bromophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole
[0443] To a solution of 2-(4-bromophenyl)-4-(trifluoromethyl)-1H-imidazole (6.00 g, 20.61 mmol) in DMF (100 mL) was added NaH (1.65 g, 41.22 mmol, 60% dispersion in mineral oil) at 0 ° C. After stirring at 0 ° C for 0.5 h, CH3I (3.51 g, 24.73 mmol) was added. The mixture was stirred at room temperature for 16 h. The mixture was then diluted with water (80 mL) and extracted with EtOAc (70 mL x 3). The combined organic eluents were washed with brine (80 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE / EtOAc from 100 / 1 to 20 / 1) to obtain the desired product (2.81 g, 9.21 mmol, 45%) as a yellow solid. NMR confirmed.
[0444] H NMR: (400MHz, CDCl3) δ = 7.63-7.60 (m, 2H), 7.53-7.50 (m, 2H), 7.31 (d, J = 0.8Hz, 1H), 3.76 (s, 3H)
[0445] Example B5: Synthesis of Intermediate D
[0446]
[0447] tert-Butyl 3-iodo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0448] To a solution of tert-butyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (50.00 g, 223.93 mmol) in DMF (800 mL) was added I2 (113.67 g, 447.87 mmol) and KOH (50.26 g, 895.74 mmol) at 0 ° C. The resulting mixture was stirred at 60 ° C for 16 h. The reaction mixture was then cooled to room temperature, quenched with Na2SO3 aqueous solution (100 mL) and water (1500 mL), and then extracted with EtOAc (350 mL x 6). The combined organic layer was washed with brine (300 mL x 5), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was recrystallized from Et2O (200 mL) to obtain the desired product (32.50 g, 93.07 mmol, 42%) as a white solid.
[0449] 1H NMR (400MHz, DMSO-d6) δ = 12.98 (s, 1H), 4.11 (s, 2H), 3.58 (t, J = 5.6Hz, 2H), 2.63 (s, 2H), 1.42 (s, 9H)
[0450] tert-Butyl 3-iodo-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0451] To a solution of tert-butyl 3-iodo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (625 mg, 1.79 mmol) in DMF (10 mL) was added CsCO (1750 mg, 5.37 mmol) and CHI (0.17 mL, 2.68 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. The mixture was diluted with water (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layer was washed with brine (10 mL x 3), dried over NaSO, filtered and concentrated in vacuo to give the desired product (630 mg, 1.73 mmol, 97% crude yield) as a yellow oil.
[0452] LCMS: retention time: 1.825 min, (M+H) + =364.1, Method A.
[0453] The two N-methylated isomers were separated by silica gel column chromatography eluting with ethyl acetate (0% to 10%) in petroleum ether to give the pure product (350 mg, 0.96 mmol, 54%). 1 H NMR (400MHz, DMSO-d6) δ = 4.10 (s, 2H), 3.69 (s, 3H), 3.59 (t, J = 5.8Hz, 2H), 2.64 (t, J = 5.6Hz, 2H), 1.42 (s, 9H).
[0454] tert-Butyl 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0455] To a solution of tert-butyl 3-iodo-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (200 mg, 0.55 mmol) in dioxane (5 mL) and H2O (1 mL) was added 4-cyclopropyl-6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (152 mg, 0.55 mmol), Pd(dppf)Cl2 (40 mg, 0.06 mmol) and Na2CO3 (117 mg, 1.10 mmol). The mixture was stirred at 100 ° C for 6 h. The mixture was cooled to room temperature, diluted with water (15 mL) and extracted with EtOAc (15 mL x 3). The combined organic phase was washed with brine (15 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluting with PE / EtOAc 100 / 0 to 5 / 1) to give the desired product (50 mg, 0.13 mmol, 24%) as a white solid.
[0456] LCMS: retention time: 1.667 min, (M+H) + =386.3, Method A.
[0457] 1 H NMR (400MHz, CDCl3) δ = 8.59 (s, 1H), 4.27 (s, 2H), 3.96 (s, 3H), 3.82 (s, 3H), 3.80-3.72 (m, 2H) ,2.74(t,J=5.6Hz,2H),2.16-2.06(m,1H),1.46(s,9H),1.23-1.16(m,2H),0.99-0.92(m,2H).
[0458] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0459] A solution of tert-butyl 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (50 mg, 0.13 mmol) in TFA (5 mL) and DCM (15 mL) was stirred at room temperature for 2 h. The mixture was concentrated and dissolved in MeOH (10 mL). Saturated NaHCO3 aqueous solution (15 mL) was added until pH = 8. The mixture was concentrated and purified by reverse phase column chromatography (HO / CH3CN from 100 / 0 to 4:1) to give the desired product (20 mg, 0.07 mmol, 54%) as a white solid.
[0460] LCMS: retention time: 0.380 min, (M+H) + =286.2, Method A.
[0461] 1 H NMR (400MHz, CDCl3) δ = 10.01 (s, 1H), 8.58 (s, 1H), 4.03 (s, 2H), 3.93 (s, 3H), 3.85 (s, 3H), 3.52 ( t,J=6.0Hz,2H),3.06(t,J=5.8Hz,2H),2.19-2.11(m,1H),1.21-1.13(m,2H),1.00-0.91(m,2H).
[0462] Example B6: Synthesis of Compound 1
[0463]
[0464] tert-Butyl 3-(2-isopropylpyridin-3-yl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0465] To a solution of tert-butyl 3-iodo-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (600 mg, 1.65 mmol) in dioxane (2 mL) and H2O (0.4 mL) was added 2-(propyl-2-yl)-3-(tetramethyl-1,3,2-dioxaborolane-2-yl)pyridine (612 mg, 2.48 mmol), Na2CO3 (70 mg, 0.66 mmol) and Pd(dppf)Cl2 (16 mg, 0.02 mmol). The reaction mixture was stirred at 100 ° C under a nitrogen atmosphere for 4 h. The mixture was cooled to room temperature, quenched with 60 mL of water and extracted with EtOAc (60 mL x 2). The combined organic layer was washed with brine (50 mL x 2), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluted with PE / EtOAc = 3 / 2) to give the desired product (350 mg, 0.98 mmol, 59%) as a yellow solid.
[0466] LCMS: retention time: 1.220 min, (M+H) + =357.2, Method A.
[0467] 3-(2-Isopropylpyridin-3-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0468] To a solution of tert-butyl 3-(2-isopropylpyridin-3-yl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (40 mg, 0.112 mmol) in methanol (5 mL) was slowly added methanolic hydrochloric acid (0.21 mL, 3 M). The mixture was stirred at room temperature for 16 h. The pH value of the reaction mixture was adjusted to 8-9 with NaHCO 3 . The resulting suspension was filtered, and the filtrate was concentrated to give a crude product. The crude product was purified by C18 column chromatography (H 2 O / CH 3 CN, 100 / 1 to 30 / 70) to give the desired product (25 mg, 0.098 mmol, 87%) as a colorless oil.
[0469] LCMS: retention time: 0.267 min, (M+H) + =257.1, Method A.
[0470] 3-(2-Isopropylpyridin-3-yl)-1-methyl-5-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0471] To a mixture of 3-(2-isopropylpyridin-3-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (30 mg, 0.12 mmol), 2-(4-bromophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole (36 mg, 0.12 mmol) and t-BuONa (23 mg, 0.23 mmol) in toluene (10 mL) was added PEPPSI-IPr (2.8 mg, 0.003 mmol). The mixture was stirred at 100 ° C under N2 atmosphere for 16 h and then cooled to room temperature. The mixture was diluted with water (20 mL) and extracted with EtOAc (30 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated to give a crude product. The crude product was purified by preparative TLC (PE / EtOAc=3 / 2) to give the desired product (4.80 mg, 0.01 mmol, 8%).
[0472] LCMS: retention time: 1.157 min, (M+H) + =481.2, Method A.
[0473] 1H NMR: (400MHz, DMSO-d6) δ = 8.57 (dd, J = 4.8Hz, J = 1.6Hz, 1H), 7.84 (s, 1H), 7.64 (dd, J = 7.6Hz, J = 1.6Hz, 1H), 7.53 (d, J = 8.8Hz, 2H), 7.29 (dd, J = 7.6Hz ,J=4.4Hz,1H),7.06(d,J=8.8Hz,2H),4.21(s,2H),3.79-3.77(m,5H),3.7 4(s,3H),3.46-3.42(m,1H),2.88(t,J=5.2Hz,2H),1.17(d,J=6.8Hz,6H).
[0474] Example B7: Synthesis of Compound 2
[0475]
[0476] 5-Bromo-4-isopropylpyrimidine
[0477] To a mixture of 5-bromopyrimidine (5.00 g, 31.45 mmol), isobutyric acid (3.325 g, 37.74 mmol), silver nitrate (2.67 g, 15.72 mmol) and potassium persulfate (10.2 g, 37.74 mmol) was added DCM (50 mL) and water (50 mL) at 0 ° C. The mixture was stirred at room temperature for 18 h. The solvent was evaporated. The residue was diluted with EtOAc (60 mL), washed with brine (60 mL), and dried over anhydrous Na2SO4. The solvent was evaporated, followed by purification on silica gel column chromatography (eluted with PE / EtOAc from 1 / 0 to 80 / 1) to obtain the desired product (1.30 g, 6.47 mmol, 21% yield) as a colorless oil.
[0478] 1 H NMR(400MHz, CDCl3)δ9.03(s,1H),8.71(s,1H),3.50-3.46(m,1H),1.30-1.27(m,6H)
[0479] 4-Isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
[0480] A mixture of 5-bromo-4-isopropylpyrimidine (350 mg, 1.74 mmol), 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (442 mg, 1.74 mmol), Pd(dppf)Cl (127 mg, 0.17 mmol) and KOAc (171 mg, 1.74 mmol) in toluene (2.25 mL) / DME (1.5 mL) / EtOH (1.5 mL) / H O (0.75 mL) was heated at 90 ° C. using microwaves under Ar for 0.5 h. The mixture was used in the next step without further treatment.
[0481] LCMS: retention time: 1.497 min, (M+H) + =249.2, Method B.
[0482] tert-Butyl 3-(4-isopropylpyrimidin-5-yl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0483] By 4-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (120mg, 0.48mmol), 3-iodo-1-methyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (176mg, 0.48mmol), Pd(dppf)Cl2(35mg, 0.05mmol) and Na2CO3(103mg, 0.97mmol) in dioxane (5mL) and H2O (1mL) mixture was heated and stirred at 80°C under Ar using microwave for 1h. The mixture was diluted with water (10mL) and extracted with EtOAc (10mL x 3). The combined organic phase was washed with brine (10mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EtOAc = 5 / 1) to give the desired product (68 mg, 0.19 mmol, 39%) as a yellow oil.
[0484] LCMS: retention time: 1.207 min, (M+H) + =358.2, Method B.
[0485] 3-(4-Isopropylpyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0486] A solution of tert-butyl 3-(4-isopropylpyrimidin-5-yl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (96 mg, 0.27 mmol) in TFA (1 mL) and DCM (2 mL) was stirred at room temperature for 2 h. The pH of the mixture was adjusted to 8.0 with 8N NH / MeOH and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH = 10 / 1) to give the desired product (60 mg, 0.23 mmol, 86.82%) as a white solid.
[0487] LCMS: retention time: 0.607 min, (M+H) + =258.2, Method A.
[0488] 3-(4-Isopropylpyrimidin-5-yl)-1-methyl-5-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0489] A mixture of 3-(4-isopropylpyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (50 mg, 0.19 mmol), 2-(4-bromophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole (89 mg, 0.29 mmol), Pd(dba) (36 mg, 0.04 mmol), t-BuXpHos (17 mg, 0.04 mmol) and sodium tert-butoxide (56 mg, 0.58 mmol) in dioxane (1.5 mL) was stirred at 100 ° C under Ar for 16 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic phase was washed with brine (10 mL), dried over NaSO, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EtOAc = 1 / 1) to give the desired product (1.30 mg, 0.0027 mmol, 1.4%).
[0490] LCMS: retention time: 1.455 min, (M+H) + =482.3, Method B.
[0491] 1H NMR (400MHz, DMSO-d6) δ = 9.14 (s, 1H), 8.64 (s, 1H), 7.83 (s, 1H), 7.52 (d, J = 8.8Hz, 2H), 7.09 (d, J = 9.2 Hz, 2H), 4.29 (s, 2H), 3.78-3.73 (m, 8H), 3.50-3.43 (m, 1H), 2.89 (t, J = 4.8Hz, 2H), 1.20-1.18 (m, 6H).
[0492] Example B8: Synthesis of Compound 3
[0493]
[0494] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-5-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0495] To a solution of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (130 mg, 0.46 mmol) in dioxane (5 mL) was added 2-(4-bromophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole (167 mg, 0.55 mmol), RuPhos Pd G3 (4 mg, 0.01 mmol), t-BuONa (61 mg, 0.64 mmol) and RuPhos (64 mg, 0.14 mmol). The mixture was stirred at 100 ° C for 16 h. The mixture was then cooled to room temperature, diluted with water (15 mL) and extracted with EtOAc (15 mL x 3). The combined organic phases were washed with brine (15 mL) and dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (PE / EtOAc=1 / 3) to give the desired product (30.00 mg, 0.06 mmol, 13%).
[0496] LCMS: retention time: 1.670 min, (M+H) + =510.3, Method A.
[0497] 1H NMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 7.83 (d, J = 1.2Hz, 1H), 7.52 (d, J = 8.8Hz, 2H), 7.08 (d, J = 9.2Hz, 2H), 4.14 (s, 2 H), 3.91 (s, 3H), 3.80-3.70 (m, 8H), 2.85 (t, J = 4.8Hz, 2H), 2.16-2.12 (m, 1H), 1.04-1.03 (m, 2H), 0.93-0.90 (m, 2H).
[0498] Example B9: Synthesis of Compound 4
[0499]
[0500] 2-(4-bromophenyl)-1-isopropyl-4-(trifluoromethyl)-1H-imidazole
[0501] To a mixture of 2-(4-bromophenyl)-4-(trifluoromethyl)-1H-imidazole (7.20 g, 24.74 mmol) in DMF (20 mL) was added CsCO (20.15 g, 61.84 mmol) and 2-iodopropane (8.41 g, 49.47 mmol). The mixture was stirred at 60 ° C for 16 h. The mixture was then diluted with water (100 mL) and extracted with EtOAc (150 mL x 3). The combined organic eluents were washed with brine (100 mL), dried over NaSO, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE / EtOAc 10 / 1 to 6 / 1) to obtain the desired product (5.80 g, 17.41 mmol, 70.37%) as a yellow solid.
[0502] LCMS: retention time: 1.600 min, (M+H) + =333.0, Method B.
[0503] tert-Butyl 3-iodo-1-(methyl-d3)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0504] To a solution of tert-butyl 3-iodo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (3.10 g, 8.88 mmol) in DMF (35 mL) was added CsCO (4.34 g, 13.32 mmol) and CDI (1.93 g, 13.32 mmol). The mixture was stirred at room temperature for 16 h. The mixture was then diluted with water (100 mL) and extracted with EtOAc (80 mL x 3). The combined organic fractions were washed with brine (50 mL), dried over NaSO, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluting with PE / EA from 100 / 1 to 5 / 1) to give the desired product (1.80 g, 4.92 mmol, 55.4%) as a white solid.
[0505] LCMS: retention time: 1.740 min, (M+H)+=367.1, method A.
[0506] tert-Butyl 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0507] To a mixture of tert-butyl 3-iodo-1-(methyl-d3)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (1.50 g, 4.10 mmol), 4-cyclopropyl-6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.24 g, 4.49 mmol) and Na2CO3 (1.30 g, 12.29 mmol) in dioxane (10 mL) and H2O (2 mL) was added Pd(dppf)Cl2 (0.30 g, 0.41 mmol) under N2. The mixture was stirred at 100 ° C for 6 hours and then cooled to room temperature. The mixture was diluted with water (60 mL) and extracted with EtOAc (50 mL x 3). The organic layer was collected, washed with brine (60 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product. The residue was purified by silica gel column chromatography (eluted with PE / EA from 100 / 1 to 3 / 1) to give the desired product (400 mg, 1.03 mmol, 25.12%) as a colorless oil.
[0508] LCMS: retention time: 1.630 min, (M+H) + =389.2, Method A.
[0509] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0510] To a solution of tert-butyl 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (380 mg, 0.98 mmol) in DCM (10 mL) was added TFA (0.73 mL, 9.79 mmol). The mixture was stirred at room temperature for 2 h. NaHCO3 powder was added to adjust the pH to 7-8 and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (eluted with DCM / MeOH from 40 / 1 to 10 / 1) to give the desired product (190 mg, 0.66 mmol, 67%) as a yellow solid.
[0511] LCMS: retention time: 0.517 min, (M+H) + =289.2, Method A.
[0512] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-5-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-1-(methyl-d3)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0513] To a mixture of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (170 mg, 0.59 mmol), 2-(4-bromophenyl)-1-(propan-2-yl)-4-(trifluoromethyl)-1H-imidazole (197 mg, 0.59 mmol), t-BuONa (454 mg, 4.72 mmol) and X-Phos (563 mg, 1.18 mmol) in toluene (5 mL) was added Pd(OAc)2 (13 mg, 0.06 mmol). The mixture was stirred at 100 ° C for 16 h. The mixture was then diluted with water (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic fractions were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EA=1 / 3) to give the desired product (117.08 mg, 0.22 mmol, 97.76% purity, 37.29%).
[0514] LCMS: retention time: 1.800 min, (M+H) + =541.3, Method A.
[0515] 1HNMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 8.07 (s, 1H), 7.36 (d, J = 9.2Hz, 2H), 7.09 (d, J = 9.2Hz, 2H), 4.48-4.44 (m, 1H), 4.14 (s, 2H), 3.9 1(s,3H),3.77(t,J=5.6Hz,2H),2.85(t,J=5.6Hz,2H),2.16-2.14(m,1H),1.39(d,J=6.8Hz,6H),1.05-1.02(m,2H),0.94-0.89(m,2H).
[0516] Example B10: Synthesis of Compound 5
[0517]
[0518] 2-Bromo-5-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine
[0519] A mixture of 3,3-dibromo-1,1,1-trifluoropropane-2-one (7.258 g, 26.88 mmol) and NaOAc (4.41 g, 53.76 mmol) in H o (50 mL) was stirred at 100 ° C for 1 h and then cooled to room temperature. The mixture of 6-bromonicotinealdehyde (5.00 g, 26.88 mmol) and NH OH (13.80 mL, 107.52 mmol) in MeOH (50 mL) was then added to the above mixture. The resulting mixture was stirred at room temperature for 16 h. The mixture was concentrated, diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layer was washed with brine (200 mL), dried over Na sO , filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluted with PE / EA = 10 / 1) to give the desired product (5.30 g, 18.16 mmol, 67.6%) as a white solid.
[0520] LCMS: retention time: 1.647 min, (M+H) + =291.9, Method A.
[0521] 2-Bromo-5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine
[0522] To a solution of 2-bromo-5-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine (5.50 g, 18.83 mmol) in DMF (55 mL) was added NaH (0.90 g, 22.60 mmol, 60% dispersion in mineral oil) at 0 ° C under Ar. After stirring for 30 minutes, CH3I (1.172 mL, 18.83 mmol) was added. The mixture was stirred at room temperature for 16 h. The reaction mixture was then quenched with water (30 mL) at 0 ° C and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated in vacuo to give a crude product. The crude product was purified by flash chromatography on silica gel (eluting with PE / EA=5 / 1) to give the desired product (2.35 g, 7.66 mmol, 40.7%) as a white solid.
[0523] LCMS: retention time: 1.667 min, (M+H) + =306.0, Method A.
[0524] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-5-(5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0525] To a solution of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (70 mg, 0.25 mmol) and 2-bromo-5-(1-methyl-4-(trifluoromethyl)-1H-imidazole-2-yl)pyridine (83 mg, 0.27 mmol) in anhydrous DMSO (2 mL) was added CsCO (160 mg, 0.49 mmol). The mixture was degassed three times with N and stirred at 140 ° C for 2 hours under microwave conditions. The reaction mixture was then cooled to room temperature and water (10 mL) was added. The resulting mixture was extracted with ethyl acetate (10 mL x 3). The combined organic layer was washed with brine (20 mL), dried over NaSO, filtered and concentrated to give a crude product. The crude product was purified by preparative TLC (PE / EA=1 / 1) to give the desired product (20.00 mg, 0.039 mmol, 15.6%).
[0526] LCMS: retention time: 1.727 min, (M+H) + =511.2, Method A.
[0527] 1H NMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 8.41 (d, J = 2.0Hz, 1H), 7.87 (d, J = 1.2Hz, 1H), 7.84 (dd, J = 8.8, 2.4Hz, 1H), 7.03 (d, J = 9.2Hz, 1H), 4.46 (s, 2 H),4.03(t,J=6.0Hz,2H),3.91(s,3H),3.75(s,3H),3.74(s,3H),2.86(t ,J=6.0Hz,2H),2.18-2.15(m,1H),1.05-1.02(m,2H),0.95-0.91(m,2H).
[0528] Example B11: Synthesis of Compound 6
[0529]
[0530] 5-Bromo-2-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine
[0531] A mixture of 3,3-dibromo-1,1,1-trifluoropropane-2-one (9.07g, 33.60mmol) and NaOAc (5.51g, 67.20mmol) in H o (50mL) was stirred at 100°C for 1 hour and then cooled to room temperature. A mixture of 5-bromopyridine-2-carboxaldehyde (5.00g, 26.88mmol) and NH4OH (17.26mL, 134.40mmol) in MeOH (50mL) was added and the resulting mixture was stirred at room temperature for 16h. The mixture was then concentrated under reduced pressure to remove methanol and extracted three times with ethyl acetate (50mL). The combined organic eluents were washed with brine (80mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluting with PE / EA from 10 / 1 to 3 / 1) to obtain the desired product (5.73g, 19.62mmol, 73.00%) as a yellow solid.
[0532] LCMS: retention time: 1.737 min, (M+H) + =291.9, Method A.
[0533] 5-Bromo-2-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine
[0534] To a solution of 5-bromo-2-(4-(trifluoromethyl)-1H-imidazole-2-yl)pyridine (6.00 g, 20.54 mmol) in DMF (70 mL) was added NaH (1.64 g, 41.08 mmol, 60% in mineral oil) at 0 ° C under Ar. After stirring for 30 minutes, iodomethane (1.53 mL, 24.65 mmol) was added to the mixture. The resulting mixture was stirred at room temperature for 16 h. The mixture was diluted with water (100 mL) and extracted three times with ethyl acetate (70 mL). The combined organic eluents were washed with brine (90 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluting with PE / EA from 100 / 1 to 3 / 1) to give the desired product (5.00 g, 16.33 mmol, 79.5%) as a yellow solid.
[0535] LCMS: retention time: 1.877 min, (M+H) + =306.0, Method A.
[0536] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-5-(6-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-3-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0537] To a solution of 3- (4- cyclopropyl -6- methoxypyrimidin -5- bases) -1- methyl -4,5,6,7- tetrahydro -1H- pyrazolo [4,3-c] pyridine (150 mg, 0.53 mmol), 5- bromo -2- (1- methyl -4- (trifluoromethyl) -1H- imidazole -2- bases) pyridine (226 mg, 0.74 mmol), X-Phos (501 mg, 1.05 mmol) and t-BuONa (101 mg, 1.05 mmol) in toluene (5 mL) was added Pd (OAc) (12 mg, 0.05 mmol). The mixture was degassed three times with N2 and stirred at 100 ° C for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was then diluted with water (10 mL) and extracted with ethyl acetate (15 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by preparative TLC (PE / EA=1 / 1) to give the desired product (130 mg, 0.24 mmol, 96.30% purity, 45%).
[0538] LCMS: retention time: 1.567 min, (M+H) + =511.2, Method A.
[0539] 1 H NMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 8.41 (s, 1H), 7.87-7.85 (m, 2H), 7.51 (dd, J = 2.8Hz, 8.8Hz, 1H), 4.21 (s, 2H), 4.02 (s, 3H), 3.92(s,3H),3.83(t,J=5.6Hz,2H),3.75(s,3H),2.87(t,J=5.6Hz,2H),2.16-2.13(m,1H),1.05-1.03(m,2H),0.93-0.90(m,2H).
[0540] Example B12: Synthesis of Compound 7
[0541]
[0542] 2-(4-bromo-3-fluorophenyl)-4-(trifluoromethyl)-1H-imidazole
[0543] By 3,3-dibromo-1,1,1-trifluoropropane-2-one (8.313g, 30.79mmol) and NaOAc (5.05g, 61.57mmol) in H mixture in O (50mL) is stirred at 100 DEG C for 1h and then cooled to room temperature.Add 4-bromo-3-fluorobenzaldehyde (5.00g, 24.63mmol), MeOH (50mL) and NH4OH (15.81mL, 123.15mmol), and stir gained mixture at room temperature 16h.Mixture is diluted with water (100mL) and extracted with EtOAc (80mL x 5).The organic elution portion merged is washed with brine (100mL), through Na2SO4, dried, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluting with PE / EA from 100 / 1 to 15 / 1) to give the desired product (3.60 g, 11.65 mmol, 47%) as a yellow solid.
[0544] LCMS: retention time: 1.827 min, (M+H)+=308.9, Method A.
[0545] 2-(4-Bromo-3-fluorophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole
[0546] To a solution of 2-(4-bromo-3-fluorophenyl)-4-(trifluoromethyl)-1H-imidazole (3.60 g, 11.65 mmol) in DMF (40 mL) was added NaH (0.93 g, 23.30 mmol, 60% dispersion in mineral oil) at 0 ° C. After stirring for 30 minutes, CH 3 I (0.87 mL, 13.98 mmol) was added to the mixture. The mixture was stirred at room temperature for 16 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (60 mL x 5). The combined organic fractions were washed with brine (80 mL x 3), dried over Na 2 SO 4, filtered and concentrated. The residue was purified by silica gel column chromatography (eluting with PE / EA from 100 / 1 to 20 / 1) to obtain the desired product (2.19 g, 6.78 mmol, 58.2%) as a yellow solid.
[0547] LCMS: retention time: 1.117 min, (M+H) + =323.1, Method A.
[0548] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-5-(2-fluoro-4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0549] By 2- (4- bromo -3- fluorophenyl) -1- methyl -4- (trifluoromethyl) -1H- imidazole (181mg, 0.56mmol), 3- (4- cyclopropyl -6- methoxy pyrimidin -5-yl) -1- methyl -4,5,6,7- tetrahydro -1H- pyrazolo [4,3-c] pyridine (80mg, 0.28mmol), t-BuONa (216mg, 2.24mmol), X-Phos (1069mg, 2.24mmol) and Pd (OAc) 2 (6mg, 0.03mmol) in toluene (5mL) is stirred at 100 DEG C for 16h.Then the mixture is cooled to room temperature, concentrated and water (10mL) is added.The mixture is extracted with EtOAc (10mL x 3).The combined organic eluent is washed with brine (20mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (PE / EA=1 / 3) to give the desired product (17.60 mg, 0.033 mmol, 11.8%).
[0550] LCMS: retention time: 1.780 min, (M+H) + =528.2, Method A.
[0551] 1HNMR (400MHz, DMSO-d6) δ = 8.61 (s, 1H), 7.90 (s, 1H), 7.50 (dd, J = 14, 2.0Hz, 1H), 7.42 (dd, J = 8.4, 2.0Hz, 1H), 7.17 (t, J = 8.8Hz, 1H), 4.00 (s,2H),3.90(s,3H),3.77(s,6H),3.56(t,J=5.6Hz,2H),2.86(t,J=5.2Hz,2H),2.19-2.15(m,1H),1.05-1.01(m,2H),0.95-0.90(m,2H).
[0552] Example B13: Synthesis of Compound 8
[0553]
[0554] 2-(4-Bromo-2-fluorophenyl)-4-(trifluoromethyl)-1H-imidazole
[0555] To a solution of 3,3-dibromo-1,1,1-trifluoropropane-2-one (6.65g, 24.63mmol) in H2O (60mL) was added NaOAc (4.04g, 49.26mmol). The mixture was stirred at 100°C for 1 hour and then cooled to room temperature. A mixture of 4-bromo-2-fluorobenzaldehyde (5g, 24.63mmol) and NH4OH (12.65mL, 98.52mmol) in MeOH (100mL) was added and the resulting mixture was stirred at room temperature for 16h. The mixture was then concentrated to remove methanol and extracted three times with ethyl acetate (30mL). The combined organic layer was washed with brine (80mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was recrystallized from (PE / EA=20 / 1, 100mL) to obtain the desired product (4.05g, 13.10mmol, 53% yield) as a yellow solid.
[0556] LCMS: retention time: 1.611 min, (M+H) + =309.0, Method A.
[0557] 2-(4-Bromo-2-fluorophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole
[0558] To a solution of 2-(4-bromo-2-fluorophenyl)-4-(trifluoromethyl)-1H-imidazole (2.00 g, 6.47 mmol) in DMF (30 mL) was added NaH (0.52 g, 12.94 mmol, 60% dispersion in mineral oil) at 0 ° C. After stirring for 0.5 hours, MeI (0.60 mL, 9.71 mmol) was added. The resulting mixture was stirred at room temperature for 16 h. The mixture was then quenched with saturated ammonium chloride solution (100 mL) and water (50 mL) at 0 ° C. The mixture was extracted three times with ethyl acetate (100 mL). The combined organic eluents were washed with brine (250 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (eluting with PE / EtOAc from 100 / 0 to 12 / 1) to give the desired product (1.75 g, 5.42 mmol, 84% yield) as a light yellow solid.
[0559] LCMS: retention time: 1.677 min, (M+H) + =323.0, Method A.
[0560] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-5-(3-fluoro-4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0561] To a solution of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (100 mg, 0.35 mmol), 2-(4-bromo-2-fluorophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole (226 mg, 0.70 mmol), X-Phos (334 mg, 0.70 mmol) and t-BuONa (334 mg, 0.70 mmol) in toluene (5 mL) was added Pd(OAc) (8 mg, 0.04 mmol). The mixture was degassed three times with N2 and stirred at 100 ° C for 16 h. The reaction mixture was cooled to room temperature and concentrated. The residue was then diluted with water (10 mL) and extracted with ethyl acetate (15 mL x 3). The combined organic layer was washed with brine (20 mL), filtered and concentrated to give a crude product. The crude product was purified by preparative TLC (PE / EA=1 / 1) to give the desired product (47.00 mg, 0.089 mmol, 25%).
[0562] LCMS: retention time: 1.577 min, (M+H) + =528.2, Method A.
[0563] 1 H NMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 7.91 (s, 1H), 7.35-7.31 (m, 1H), 6.98 -6.91(m,2H),4.18(s,2H),3.91(s,3H),3.81(t,J=5.4Hz,2H),3.75(s,3H),3.56(s ,3H),2.85(t,J=5.2Hz,2H),2.16-2.14(m,1H),1.04-1.02(m,2H),0.93-0.90(m,2H)
[0564] Example B14: Synthesis of Compound 9
[0565]
[0566] tert-Butyl 1-(difluoromethyl)-3-iodo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0567] To a mixture of tert-butyl 3-iodo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (2800 mg, 8.02 mmol) and potassium fluoride (932 mg, 16.04 mmol) in acetonitrile (50 mL) was added diethyl (bromodifluoromethyl)phosphonate (2141 mg, 8.02 mmol) at room temperature. The mixture was stirred at room temperature for 16 h. The mixture was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE / EtOAc=10 / 1) to give the desired product (1.565 g, 3.92 mmol, 48.9%) as a white solid.
[0568] LCMS: retention time: 1.526 min, (M+H) + =400.2, method B.
[0569] tert-Butyl 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(difluoromethyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0570] A mixture of tert-butyl 1-(difluoromethyl)-3-iodo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (1100 mg, 2.76 mmol), 4-cyclopropyl-6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1141 mg, 4.13 mmol), Pd(dppf)Cl2 (202 mg, 0.28 mmol) and K2CO3 (762 mg, 5.51 mmol) in dioxane (10 mL) and water (2 mL) was stirred at 100 ° C under Ar for 16 h. The mixture was then cooled to room temperature, diluted with water (15 mL) and extracted with EtOAc (15 mL x 3). The combined organic fractions were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE / EtOAc = 5 / 1) to give the desired product (700 mg, 1.66 mmol, 60.1%) as a white solid.
[0571] LCMS: retention time: 1.595 min, (M+H) + =422.2, Method B.
[0572] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(difluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0573] To a solution of tert-butyl 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(difluoromethyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (700 mg, 1.66 mmol) in DCM (6 mL) was added TFA (3 mL) at room temperature. The mixture was stirred at room temperature for 3 hours. The mixture was then concentrated and redissolved in DCM (15 mL). The pH of the solution was adjusted to 8.0 with 8N NH3 / MeOH and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=20 / 1) to give the desired product (500 mg, 1.56 mmol, 94%) as a white solid.
[0574] LCMS: retention time: 0.678 min, (M+H) + =322.1, Method B.
[0575] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(difluoromethyl)-5-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0576] A mixture of 3- (4- cyclopropyl -6- methoxypyrimidin -5- bases) -1- (difluoromethyl) -4,5,6,7- tetrahydro -1H- pyrazolo [4,3-c] pyridine (200 mg, 0.62 mmol), 2- (4- bromophenyl) -1- methyl -4- (trifluoromethyl) -1H- imidazole (190 mg, 0.62 mmol), Pd (OAc) 2 (14 mg, 0.06 mmol), X-Phos (593 mg, 1.25 mmol) and sodium tert-butoxide (120 mg, 1.25 mmol) in toluene (5 mL) was stirred at 100 ° C under Ar for 16 h. The mixture was then cooled to room temperature, diluted with water (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic phase was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EtOAc=1 / 1) to give the desired product (80 mg, 0.147 mmol, 23.7%).
[0577] LCMS: retention time: 1.531 min, (M+H) + =546.2, Method B.
[0578] 1 H NMR (400MHz, DMSO-d6) δ = 8.69 (s, 1H), 8.00-7.70 (m, 2H), 7.54 (d, J = 8.8Hz, 2H), 7.11 (d, J = 8.8Hz, 2H), 4.17 (s, 2H), 3. 94(s,3H),3.82-3.79(m,2H),3.74(s,3H),3.05-3.02(m,2H),2.03-1.99(m,1H),1.10-1.06(m,2H),0.98-0.94(m,2H).
[0579] Example B15: Synthesis of Compound 10
[0580]
[0581] 2-Fluoro-5-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine
[0582] To a solution of 3,3-dibromo-1,1,1-trifluoropropan-2-one (69.29 g, 256.78 mmol) in H o (150 mL) was added NaOAc (32.79 g, 399.73 mmol) at 0 ° C. The mixture was stirred at 0 ° C for 10 minutes and then heated at 100 ° C under Ar for another hour. After cooling to room temperature, 6-fluoronicotinaldehyde (25.00 g, 199.84 mmol), NH OH (93.39 g, 799.36 mmol, 30%) and MeOH (200 mL) were added. The mixture was stirred at room temperature under Ar for 16 hours. The mixture was then concentrated to remove MeOH. The resulting suspension was filtered. The solid was washed with water (100 mL) and Et o (100 mL) and dried to give the title compound (46.05 g, 199.22 mmol, 100% yield) as a yellow solid.
[0583] LC-MS (ESI+): m / z 232.1 (M+H) + .
[0584] 2-Fluoro-5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine
[0585] To a mixture of 2-fluoro-5-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine (10.00 g, 43.26 mmol) in DMF (200 mL) was added CsCO (35.24 g, 108.16 mmol) and 2-iodopropane (36.77 g, 216.31 mmol). The reaction mixture was stirred at 60 ° C under Ar for 16 hr. After cooling to room temperature, water (300 mL) was added to the mixture. After extraction with EtOAc (300 mL x 2), the combined organic layers were washed with brine (300 mL), dried over NaSO, filtered and concentrated under reduced pressure to give a residue, which was purified by silica gel column chromatography (eluted with ethyl acetate (0% to 8.5%) / petroleum ether) to give the title compound (4.24 g, 15.52 mmol, 36% yield) as a yellow solid.
[0586] LC-MS (ESI+): m / z 274.1 (M+H) + .
[0587] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-5-(5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0588] To a solution of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (100 mg, 0.35 mmol) in anhydrous DMF (3 mL) was added 2-fluoro-5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine (143 mg, 0.52 mmol) and Et3N (106 mg, 1.05 mmol) at room temperature. The reaction mixture was stirred at 100°C for 16 hours. After cooling to room temperature, water (30 mL) was added to the mixture. After extraction with EtOAc (20 mL x 2), the combined organic fractions were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EtOAc = 1 / 3) to give the title compound (10.52 mg, 0.02 mmol, 6% yield).
[0589] LC-MS (ESI+): m / z 539.3 (M+H) + .
[0590] 1 HNMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 8.25 (s, 1H), 8.12 (s, 1H), 7.74-7.64 (m, 1H), 7.04 (d, J = 8.8Hz, 1H), 4.46 (s, 2H), 4.45 -4.36(m,1H),4.08-4.00(m,2H),3.91(s,3H),3.76(s,3H),2.90-2.82(m,2H),2.22-2.13(m,1H),1.39(d,J=6.4Hz,6H),1.10 -1.01(m,2H),0.97-0.90(m,2H).
[0591] Example B16: Synthesis of Compound 11
[0592]
[0593] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-5-(5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-1-(methyl-d3)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0594] To a solution of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (400 mg, 1.39 mmol) (see Example B9 for its synthesis) in DMF (10 mL) was added TEA (0.193 mL, 1.39 mmol) and 2-fluoro-5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)pyridine (568 mg, 2.08 mmol). The reaction mixture was stirred at 100 ° C for 16 hr. After cooling to room temperature, water (15 mL) was added to the mixture. After extraction with EtOAc (15 mL x 3), the combined organic phases were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (DCM / MeOH=20 / 1) to give the title compound (46.95 mg, 0.087 mmol, 6% yield).
[0595] LC-MS (ESI+): m / z 542.3 (M+H) + .
[0596] 1 H NMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 8.25 (d, J = 2.4Hz, 1H), 8.12 (s, 1H), 7.70 (dd, J = 9.2, 2.8Hz, 1H), 7.03 (d, J = 9.2Hz, 1H), 4.50-4.36 (m, 3 H), 4.03 (t, J = 4.8Hz, 2H), 3.91 (s, 3H), 2.86 (t, J = 5.6Hz, 2H), 2.23-2.14 (m, 1H), 1.39 (d, J = 6.8Hz, 6H), 1.09-1.00 (m, 2H), 0.97-0.88 (m, 2H).
[0597] Example B17: Synthesis of Compound 13
[0598] 3-(4-cyclopropyl-6-methylpyrimidin-5-yl)-1-methyl-5-(5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0599]
[0600] Compound 13 was synthesized in a similar manner to the procedure according to compound 5 by replacing 4-chloro-6-methylpyrimidine with 4-chloro-6-methoxypyrimidine. The crude product was purified by preparative TLC (DCM / EtOAc=2 / 1) to give the title compound (3.54 mg, 1% yield).
[0601] LC-MS (ESI+): m / z 495.3 (M+H) + .
[0602] 1 H NMR (400MHz, MeOD-d4) δ = 8.83 (s, 1H), 8.39 (d, J = 2.0Hz, 1H), 7.84-7.81 (m, 1H), 7.67 (d, J = 1.2Hz, 1H), 7.02 (d, J = 9.2Hz, 1H), 4.65-4.41 (m, 2 H),4.22-4.04(m,2H),3.87(s,3H),3.78(s,3H),2.97(t,J=5.6Hz,2H) ,2.36(s,3H),1.94-1.88(m,1H),1.28-1.16(m,2H),1.13-0.95(m,2H).
[0603] Example B18: Synthesis of Compound 15
[0604]
[0605] 2-Fluoro-5-hydrazinopyridine
[0606] A suspension of 6-fluoropyridine-3-amine (5.00g, 44.60mmol) in water (50mL) and concentrated HCl (30mL) is cooled to -20 ° C. Then a solution of sodium nitrite (3.08g, 44.64mmol) in water (20mL) is added dropwise. The resulting mixture is stirred at -20 ° C for 45 minutes. Subsequently, SnCl (8.46g, 44.62mmol) is added in concentrated HCl (25mL). The mixture is stirred for another 1hr at 0 ° C. The pH of the mixture is adjusted to 10 with the 1N NaOH aqueous solution. After being extracted with ethyl acetate (80mL x 3), the combined organic layer is washed with brine (80mL), dried over Na SO dried, filtered and concentrated to give the title compound (7g, crude product), which is directly used in the next step.
[0607] LC-MS (ESI+): m / z 128.2 (M+H) + .
[0608] 2-Fluoro-5-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine
[0609] To a solution of 2-fluoro-5-hydrazinopyridine (7.00g, 11.01mmol, 20% purity) in HFIP (50mL) was added TEA (2.30mL, 16.62mmol) and 1,1,1-trifluoropentane-2,4-dione (0.85g, 5.52mmol) at 0°C. The reaction mixture was stirred at 0°C for 2hr. The mixture was then concentrated and diluted with water (15mL). After extraction with ethyl acetate (15mL x 3), the combined organic layers were washed with brine (20mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with 10% ethyl acetate / petroleum ether) to give the title compound (700mg, 2.86mmol, 52% yield) as a yellow solid.
[0610] LC-MS (ESI+): m / z 246.1 (M+H) + .
[0611] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-5-(5-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0612] To a solution of 2-fluoro-5-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine (120 mg, 0.49 mmol) and 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (70 mg, 0.245 mmol) in DMF (5 mL) was added TEA (0.10 mL, 0.72 mmol). The reaction mixture was stirred at 100 ° C for 16 hr. After cooling to room temperature, water (20 mL) was added to the mixture. After extraction with EtOAc (20 mL x 3), the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EA=2 / 1) to give the title product (18.65 mg, 15% yield).
[0613] LC-MS (ESI+): m / z 511.2 (M+H) + .
[0614] 1H NMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 8.25 (d, J = 2.8Hz, 1H), 7.71 (dd, J = 2.4Hz, J = 8.8Hz, 1H), 7.06 (d, J = 8.8Hz, 1H), 6.72 (s, 1H), 4.46 (s, 2H) ,4.03(t,J=6.0Hz,2H),3.90(s,3H),3.76(s,3H),2.87(t,J=5.2Hz,2H) ,2.27(s,3H),2.23-2.12(m,1H),1.07-1.00(m,2H),0.98-0.89(m,2H).
[0615] Example B19: Synthesis of Compound 16
[0616] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-ethyl-5-(5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0617]
[0618] Compound 16 was synthesized in a similar manner to the procedure according to compound 5 by replacing iodomethane with iodoethane. The crude product was purified by preparative TLC (PE / EA=1 / 3) to give the title compound (83.21 mg, 0.16 mmol, 32% yield).
[0619] LC-MS (ESI+): m / z 525.2 (M+H) + .
[0620] 1 HNMR (400MHz, DMSO-d) δ = 8.62 (s, 1H), 8.41 (d, J = 2.4Hz, 1H), 7.87 (s, 1H), 7.84 (dd, J = 2.0Hz, 8.8Hz, 1H), 7.02 (d, J = 9.2Hz, 1H), 4.46 (s, 2H), 4.1 4-4.00(m,4H),3.92(s,3H),3.74(s,3H),2.88(t,J=5.2Hz,2H),2.26-2 .16(m,1H),1.34(t,J=7.2Hz,3H),1.08-1.00(m,2H),0.97-0.87(m,2H).
[0621] Example B20: Synthesis of Compound 17
[0622]
[0623] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-5-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0624] To a mixture of 2-(4-bromophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole (254 mg, 0.83 mmol), 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (200 mg, 0.69 mmol) (synthesis, see Example B9), t-BuONa (533 mg, 5.55 mmol), and X-Phos (661.6 mg, 1.39 mmol) in toluene (5 mL) was added Pd(OAc)2 (15.58 mg, 0.07 mmol). The reaction mixture was stirred at 100° C. for 16 hr. After cooling to room temperature, water (30 mL) was added to the mixture. After extraction with EtOAc (30 mL x 2), the combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EtOAc=1 / 3) to give the title compound (117.08 mg, 0.23 mmol, 33% yield).
[0625] LC-MS (ESI+): m / z 513.2 (M+H) + .
[0626] 1 HNMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 7.83 (s, 1H), 7.52 (d, J = 8.8Hz, 2H), 7.08 (d, J = 8.8Hz, 2H), 4.14 (s, 2H), 3.91 (s, 3H), 3.77(t,J=5.6Hz,2H),3.73(s,3H),2.85(t,J=5.2Hz,2H),2.19-2.09(m,1H),1.09-1.00(m,2H),0.97-0.86(m,2H).
[0627] Example B21: Synthesis of Compound 18
[0628]
[0629] 2-Fluoro-5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine
[0630] To a solution of 2-fluoro-5-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine (5.00 g, 21.63 mmol) in DMF (50 mL) was added CsCO (14.10 g, 43.28 mmol) and iodomethane (4.61 g, 32.48 mmol). The reaction mixture was stirred at room temperature under Ar for 16 hr. Water (300 mL) was added to the mixture. After extraction with EtOAc (200 mL x 2), the combined organic layers were washed with brine (200 mL), dried over NaSO, filtered and concentrated under reduced pressure to give a residue, which was purified by silica gel column chromatography (eluted with ethyl acetate (0% to 11%) / petroleum ether) to give the title compound (4.09 g, 16.68 mmol, 77% yield) as a white solid.
[0631] LC-MS (ESI+): m / z 246.1 (M+H) + .
[0632] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-5-(5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0633] A mixture of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(methyl-d3)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (200 mg, 0.69 mmol) (synthesis, see Example B9), 2-fluoro-5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine (255 mg, 1.04 mmol) and TEA (0.29 mL, 2.10 mmol) in DMF (5 mL) was stirred at 100° C. for 16 hr. After cooling to room temperature, water (20 mL) was added to the mixture. After extraction with EtOAc (20 mL x 2), the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EA=1 / 3) to give the title compound (91.92 mg, 0.18 mmol, 26% yield).
[0634] LC-MS (ESI+): m / z 514.2 (M+H) + .
[0635] 1HNMR (400MHz, DMSO-d6) δ = 8.62 (s, 1H), 8.41 (d, J = 2.4Hz, 1H), 7.90-7.80 (m, 2H), 7.03 (d, J = 9.2Hz, 1H), 4. 46(s,2H),4.03(t,J=5.6Hz,2H),3.91(s,3H),3.74(s,3H),2.86(t,J=5.6Hz,2H),2.24-2.11(m,1H),1.09 -1.00(m,2H),0.98-0.87(m,2H).
[0636] Example B22: Synthesis of Compound 20
[0637]
[0638] 3-Iodo-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0639] To a solution of tert-butyl 3-iodo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (1.00 g, 2.86 mmol) in DCM (20 mL) was added TFA (2.13 mL, 28.58 mmol). The reaction mixture was stirred at room temperature for 2 hr. The mixture was then concentrated and dissolved in DCM (20 mL). NaHCO powder was added to adjust the pH to 7-8. The suspension was filtered. The filtrate was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (eluted with 2.5% to 10% MeOH / DCM) to give the title compound (1.10 g, crude material) as a brown oil, which was used directly in the next step.
[0640] LC-MS (ESI+): m / z 249.9 (M+H) + .
[0641] 3-iodo-5-(5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0642] To a solution of 3-iodo-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (715 mg, crude material, 1.86 mmol) in DMF (10 mL) was added 2-fluoro-5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine (658 mg, 2.41 mmol) and TEA (0.84 mL, 6.07 mmol). The reaction mixture was stirred at 100 ° C for 16 hr. After cooling to room temperature, water (30 mL) was added to the mixture. After extraction with EtOAc (200 mL × 2), the combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by silica gel column chromatography (eluted with 0-70% EtOAc / PE) to give the title compound (270 mg, 0.54 mmol, 29%) as a yellow solid.
[0643] LC-MS (ESI+): m / z 503.1 (M+H) + .
[0644] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-5-(5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0645] To a mixture of 3-iodo-5-(5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (230 mg, 0.46 mmol), 4-cyclopropyl-6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (164 mg, 0.59 mmol), and KCO (126 mg, 0.91 mmol) in dioxane (8 mL) and H0 (0.8 mL) was added Pd(PPh) (105 mg, 0.09 mmol). The reaction mixture was stirred at 100° C. for 16 hr. After cooling to room temperature, water (20 mL) was added to the mixture. After extraction with EtOAc (20 mL x 3), the combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EtOAc = 1 / 3) to give the title compound (43.30 mg, 0.08 mmol, 17%).
[0646] LC-MS (ESI+): m / z 525.3 (M+H) + .
[0647] 1 HNMR (400MHz, CDCl3) δ = 8.63 (s, 1H), 8.30 (s, 1H), 7.73 (d, J = 8.0Hz, 1H), 7.39 (s, 1H), 6.76 (d, J = 8.8Hz, 1H), 4.56 (s, 2H ),4.55-4.48(m,1H),4.14-4.06(m,2H),3.98(s,3H),3.03-2.94(m,2H),2.02-1.94(m,1H),1.45(d,J=6.4Hz,6H),1.28 -1.20(m,2H),1.04-0.96(m,2H).
[0648] Example B23: Synthesis of Compound 21
[0649]
[0650] 6-cyclopropyl-5-(5-(5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrimidin-4-ol
[0651] A solution of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-5-(5-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (70 mg, 0.13 mmol) in HCl (6 mL, 3 M in MeOH) was stirred at 100° C. for 16 hr. After cooling to room temperature, the mixture was concentrated under reduced pressure to give a residue, which was purified by preparative HPLC (column: Waters X bridge C18 10 um, OBD 19*250 mm; mobile phase: [0.1% NH 4 HCO 3 / water-MeCN]; B%: 30%-95%, 6.48 min) to give the title compound (24.00 mg, 0.05 mmol, 38% yield).
[0652] LC-MS (ESI+): m / z 525.2 (M+H) + .
[0653] 1HNMR(400MHz,DMSO-d6)δ=12.37(br s,1H),8.25(d,J=2.4Hz,1H),8.12(s,1H),8.08(s,1H),7.73-7.64(m,1H),7.01(d,J=8.8Hz,1H),4.46(s,2H),4.45- 4.35(m,1H),4.01(t,J=5.6Hz,2H),3.73(s,3H),2.83(t,J=5.6Hz,2H),2.28-2.16(m,1H),1.39(d,J=6.8Hz,6H),1.03 -0.94(m,2H),0.89-0.82(m,2H).
[0654] Example B24: Synthesis of Compound 24
[0655]
[0656] 3-Bromo-2-(difluoromethoxy)pyridine
[0657] 3-Bromopyridine-2-ol (10.00g, 57.47mmol) is dissolved in MeCN (100mL). Then 2,2-difluoro-2-(fluorosulfonyl)acetic acid (15.34g, 86.14mmol) and sodium sulfate (8.97g, 63.15mmol) are added at 0°C in 20 minutes. The reaction mixture is warmed to room temperature and stirred at room temperature for 16hr. The mixture is then filtered and concentrated. Water (50mL) is added to the residue. After extraction with ethyl acetate (70mL x 3), the combined organic layers are washed with saturated sodium bicarbonate aqueous solution (30mL), brine (80mL), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain residue, which is purified by silica gel column chromatography (eluted with 5% to 15% ethyl acetate / petroleum ether) to obtain the title product (9.96g, 44.46mmol, 77% yield) as a yellow oil.
[0658] 1 H NMR (400MHz, CDCl3) δ=8.13 (dd, J=1.6Hz, J=4.8Hz, 1H), 7.94 (dd, J=1.6Hz, J=7.6Hz, 1H), 7.65-7.27 (m, 1H), 7.01 (dd, J=4.8Hz, J=7.6Hz, 1H).
[0659] 2-(Difluoromethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
[0660] To a solution of 3-bromo-2-(difluoromethoxy)pyridine (100 mg, 0.45 mmol) in dioxane (10 mL) was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (168 mg, 0.66 mmol), KOAc (131.5 mg, 1.34 mmol), and Pd(dppf)Cl2 (32.67 mg, 0.04 mmol). The reaction mixture was stirred at 100°C for 16 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue was added water (10 mL). After extraction with ethyl acetate (10 mL x 3), the combined organic layers were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EA=3 / 1) to give the title compound (75 mg, 0.28 mmol, 62% yield) as a colorless oil.
[0661] LC-MS (ESI+): m / z 272.1 (M+H) + .
[0662] tert-Butyl 3-(2-(difluoromethoxy)pyridin-3-yl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate
[0663] To a mixture of tert-butyl 3-iodo-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (500 mg, 1.38 mmol), 2-(difluoromethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)pyridine (560 mg, 2.07 mmol) and Na2CO3 (146 mg, 1.38 mmol) in dioxane / water (5 mL / 1 mL) was added Pd(dppf)Cl2 (114 mg, 0.14 mmol). The reaction mixture was stirred at 100 ° C for 16 hr. After cooling to room temperature, the mixture was concentrated and diluted with water (20 mL). The resulting mixture was extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated to give a residue, which was purified by silica gel column chromatography (eluting with 5% to 20% ethyl acetate in petroleum ether) to give the title compound (330 mg, 0.87 mmol, 63% yield) as a white solid.
[0664] LC-MS (ESI+): m / z 381.1 (M+H) + .
[0665] 3-(2-(difluoromethoxy)pyridin-3-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0666] To a solution of tert-butyl 3-(2-(difluoromethoxy)pyridin-3-yl)-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (330 mg, 0.87 mmol) in DCM (10 mL) was added TFA (989 mg, 8.67 mmol). The reaction mixture was stirred at room temperature for 2 hr. The mixture was then concentrated and diluted with ethyl acetate (10 mL). The pH of the resulting mixture was adjusted to 8-9 with NaHCO powder. The mixture was then filtered. The filtrate was concentrated to give a residue, which was purified by preparative TLC (DCM / MeOH=10 / 1) to give the title product (160 mg, 0.57 mmol, 66% yield) as a white solid.
[0667] LC-MS (ESI+): m / z 281.2 (M+H) + .
[0668] 3-(2-(difluoromethoxy)pyridin-3-yl)-1-methyl-5-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0669] To a mixture of 3-(2-(difluoromethoxy)pyridin-3-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (160 mg, 0.57 mmol), 2-(4-bromophenyl)-1-methyl-4-(trifluoromethyl)-1H-imidazole (348 mg, 1.14 mmol), X-Phos (544 mg, 1.14 mmol) and sodium tert-butoxide (110 mg, 1.14 mmol) in toluene (10 mL) was added Pd(OAc)2 (12.82 mg, 0.06 mmol). The reaction mixture was stirred at 100 ° C for 16 hr. After cooling to room temperature, the mixture was concentrated and diluted with water (10 mL). The resulting mixture was extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EA=2 / 1) to give the title compound (106.00 mg, 0.21 mmol, 37% yield).
[0670] LC-MS (ESI+): m / z 505.1 (M+H) + .
[0671] 1 H NMR (400MHz, DMSO-d6) δ = 8.29 (dd, J = 2.0Hz, J = 4.8Hz, 1H), 8.08-7.67 (m, 3H), 7.51 (d, J = 8.8Hz, 2H), 7.35 (dd, J = 4.8Hz, J=7.2Hz, 1H), 7.08 (d, J=8.8Hz, 2H), 4.35 (s, 2H), 3.81-3.74 (m, 5H), 3.73 (s, 3H), 2.85 (t, J= 5.6Hz, 2H).
[0672] Example B25: Synthesis of Compound 25
[0673]
[0674] 5-(1-ethyl-4-(trifluoromethyl)-1H-imidazol-2-yl)-2-fluoropyridine
[0675] To a solution of 2-fluoro-5-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine (3.00 g, 12.98 mmol) in DMF (30 mL) was added NaH (0.78 g, 19.5 mmol, 60% dispersion in mineral oil) at 0 ° C. The mixture was stirred at 0 ° C for 30 minutes. Iodoethane (3.04 g, 19.49 mmol) was then added to the mixture at 0 ° C. The mixture was stirred at room temperature for 16 hours. Water (100 mL) was then added to the mixture. After extraction with EtOAc (100 mL x 2), the combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by silica gel column chromatography (eluted with ethyl acetate (0% to 11%) / petroleum ether) to give the title compound (1.64 g, 6.33 mmol, 49% yield) as a yellow solid.
[0676] LC-MS (ESI+): m / z 260.1 (M+H) + .
[0677] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-5-(5-(1-ethyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-2-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0678] A mixture of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (150 mg, 0.53 mmol), 5-(1-ethyl-4-(trifluoromethyl)-1H-imidazol-2-yl)-2-fluoropyridine (204 mg, 0.79 mmol) and TEA (160 mg, 1.58 mmol) in DMF (5 mL) was stirred at 100 ° C for 16 hr. After cooling to room temperature, water (20 mL) was added to the mixture. After extraction with EtOAc (20 mL x 2), the combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EA=1 / 3) to give the title compound (75.28 mg, 0.14 mmol, 26% yield).
[0679] LC-MS (ESI+): m / z 525.2 (M+H) + .
[0680] 1 HNMR (400MHz, DMSO-d6) δ = 8.63 (d, J = 4.0Hz, 1H), 8.32 (d, J = 2.4Hz, 1H), 7.97 (d, J = 1.2Hz, 1H), 7.77 (dd, J = 2.4Hz, 9.2Hz, 1H), 7.03 (d, J = 8 .8Hz,1H),4.46(s,2H),4.12-3.98(m,4H),3.91(s,3H),3.76(s,3H),2.86(t,J=5.2Hz,2H),2.24-2.11(m,1H),1.32(t,J=7.6Hz,3H),1.09 -1.00(m,2H),0.98-0.87(m,2H).
[0681] Synthetic intermediate 26.1
[0682]
[0683] 5-Bromopyrimidine-2-carbaldehyde
[0684] DIBAL-H (6.49mL, 6.49mmol, 1M in THF) is added dropwise to a cooling solution of 5-bromopyrimidine-2-ethyl formate (1.00g, 4.33mmol) in THF (10mL) at -75°C. The reaction mixture is stirred for 1hr at -75°C. The mixture is then quenched by adding saturated NH4Cl aqueous solution (20mL) and EtOAc (20mL). 2N HCl aqueous solution (4mL) is added to clarify the formed emulsion. The mixture is extracted with EtOAc (20mL x 3). The combined organic layer is washed with brine (30mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude product (450mg, 2.41mmol, 56% yield), which is directly used in the next step.
[0685] Example B26: Synthesis of Compound 26
[0686] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-5-(2-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyrimidin-5-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0687]
[0688] Compound 26 was synthesized in a manner analogous to the procedure according to compound 6 by replacing 5-bromopicolinaldehyde with (Intermediate 26.1) 5-bromopyrimidine-2-carbaldehyde. The crude product was purified by preparative TLC (DCM / MeOH=20 / 1) to give the title compound (27.47 mg, 19% yield).
[0689] LC-MS (ESI+): m / z 512.3 (M+H) + .
[0690] 1 H NMR (400MHz, DMSO-d6) δ = 8.67 (s, 2H), 8.63 (s, 1H), 7.93 (s, 1H), 4.27 (s, 2H), 3.97 (s, 3H) ,3.92(s,3H),3.91-3.83(m,2H),3.75(s,3H),2.94-2.86(m,2H),2.18-2.04(m,1H),1.08 -1.00(m,2H),0.96 -0.85(m,2H).
[0691] Example B27: Synthesis of Compound 27
[0692]
[0693] 2-Chloro-5-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyrimidine
[0694] A mixture of 3,3-dibromo-1,1,1-trifluoropropan-2-one (3.60g, 13.34mmol) and NaOAc (1094mg, 13.34mmol) in H2O (5mL) was stirred at 100°C for 1hr. After cooling to room temperature, a mixture of 2-chloropyrimidine-5-carboxaldehyde (950mg, 6.66mmol), MeOH (10mL) and NH4OH (10mL) was added. The resulting mixture was stirred at room temperature for 16hr. Water (50mL) was then added to the mixture. After extraction with EtOAc (50mL x 3), the combined organic layers were washed with brine (70mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by silica gel column chromatography (eluted with ethyl acetate (0% to 20%) / petroleum ether) to give the title compound (970mg, 3.90mmol, 59% yield).
[0695] LC-MS (ESI+): m / z 249.1 (M+H) + .
[0696] 2-Chloro-5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyrimidine
[0697] 2-Chloro-5-(4-(trifluoromethyl)-1H-imidazole-2-yl)pyrimidine (950mg, 3.82mmol) is dissolved in DMF (10mL). CsCO (1867mg, 5.73mmol) is added. The mixture is cooled to 0°C and stirred at 0°C for 30 minutes. Then CHI (813mg, 5.73mmol) is added. The reaction mixture is stirred at room temperature for 16hr. Water (30mL) is then added to the mixture. After extraction with EtOAc (20mL x 3), the combined organic layers are washed with brine (50mL), dried over NaSO, filtered and concentrated under reduced pressure to obtain a residue, which is purified by silica gel column chromatography (eluted with ethyl acetate (1% to 15%) / petroleum ether) to obtain the title compound (480mg, 1.83mmol, 48% yield).
[0698] LC-MS (ESI+): m / z 263.1 (M+H) + .
[0699] 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-5-(5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
[0700] To a solution of 3-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (245 mg, 0.86 mmol) and 2-chloro-5-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)pyrimidine (150 mg, 0.57 mmol) in i-PrOH (5 mL) was added DIPEA (0.28 mL, 1.61 mmol). The reaction mixture was stirred at 100 ° C for 16 hours. After cooling to room temperature, the mixture was concentrated. To the residue was added water (15 mL). After extraction with EtOAc (20 mL x 3), the combined organic layers were washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative TLC (PE / EA=1 / 3) to give the title compound (122.65 mg, 0.24 mmol, 42% yield). LC-MS (ESI+): m / z 512.1 (M+H) + .
[0701] 1 H NMR (400MHz, DMSO-d6) δ = 8.69 (s, 2H), 8.62 (s, 1H), 7.93 (s, 1H), 4.66 (s, 2H), 4.20 (t, J = 6.0Hz...
Claims
1. A compound having a structure of formula (IVa) or a salt thereof, in, Y 1 N or CR Y1 ; Y 2 N or CR Y2 ; Y 3 N or CR Y3 ; Y 4 N or CR Y4 ; R 1 is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 Heterocycloalkyl; R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 5 and R 5' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl; Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl or a bicyclic heterocycloalkyl; R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ); R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl; R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 Aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl; R Y1 , R Y2 , R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, and optionally substituted bicyclic heteroaryl; or R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl; or R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl; m is 0, 1, 2, 3 or 4; and p is 0 or 1.
2. The compound or salt thereof according to claim 1, wherein Y 1 N or CR Y1 ; Y 2 N or CR Y2 ; Y 3 N or CR Y3 ; Y 4 N or CR Y4 ; R 1 is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 Heterocycloalkyl, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, oxo, -OH, -NO2, -CN and C 1-3 Alkoxy; R 4 and R 4 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 4 and R 4 ' combine to form an oxo group, or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; R 5 and R 5 ' are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 5 and R 5 ' combine to form an oxo group, or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl, or R 6 and R 6 ' combine to form an oxo group, or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, or R 8 and R 9 together with the carbon to which it is attached, form an optionally substituted 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl or a bicyclic heterocycloalkyl; R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -NO2, oxo, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl, wherein the alkyl, alkenyl, alkynyl, heteroalkyl, alkylene, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 Haloalkyl; R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 Aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl or optionally substituted bicyclic heteroaryl, wherein the cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; R Y1 , R Y2 , R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, and optionally substituted bicyclic heteroaryl, wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 haloalkyl; or R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 haloalkyl; or R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 Haloalkyl; m is 0, 1, 2, 3 or 4; and p is 0 or 1.
3. The compound or salt thereof according to claim 1 or 2, wherein the compound has a structure of formula (IVa-1), 4. The compound or salt thereof according to claim 3, wherein the compound has a structure of formula (IVa-2), 5. The compound or salt thereof according to any one of claims 1 to 4, wherein R 1 C 1-3 alkyl.
6. The compound or salt thereof according to any one of claims 1 to 5, wherein R Y1 , R Y2 , R Y3 and R Y4 are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 ) 2. optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl.
7. The compound or salt thereof according to claim 6, wherein R Y1 , R Y2 , R Y3 and R Y4 Each is hydrogen.
8. The compound or salt thereof according to any one of claims 1 to 7, wherein Y 1 is N.
9. The compound or salt thereof according to any one of claims 1 to 7, wherein Y 1 CR Y1 .
10. The compound or salt thereof according to any one of claims 1 to 9, wherein Y 2 is N.
11. The compound or salt thereof according to any one of claims 1 to 9, wherein Y 2 CR Y2 .
12. The compound or salt thereof according to any one of claims 1 to 11, wherein Y 3 is N.
13. The compound or salt thereof according to any one of claims 1 to 11, wherein Y 3 CR Y3 .
14. The compound or salt thereof according to any one of claims 1 to 13, wherein Y 4 is N.
15. The compound or salt thereof according to any one of claims 1 to 13, wherein Y 4 CR Y4 .
16. The compound or salt thereof according to any one of claims 1 to 15, wherein ring A is a 3-6 membered monocyclic heterocycloalkyl group containing 1 to 4 hetero atoms selected from O, S, N, P and Si.
17. The compound or salt thereof according to any one of claims 1 to 15, wherein ring A is a fused, spiro or bridged bicyclic heterocycloalkyl group containing 1 to 4 heteroatoms selected from O, S, N, P and Si. 18 . The compound or salt thereof according to claim 1 , wherein ring A is a 5- or 6-membered monocyclic heteroaryl group.
19. The compound or a salt thereof according to claim 18, wherein Ring A is pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, oxazole, isoxazole or thiophene.
20. The compound or salt thereof according to claim 19, wherein for 21. The compound or salt thereof according to claim 19, wherein for 22. The compound or salt thereof according to any one of claims 1 to 15, wherein ring A is a bicyclic heteroaryl group.
23. The compound or a salt thereof according to claim 22, wherein Ring A is a fused 5-6, 6-6 or 6-5 bicyclic heteroaryl group.
24. A compound or salt thereof as claimed in any one of claims 1 to 23, wherein R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ).
25. The compound or salt thereof as claimed in claim 24, wherein at least one R A For-OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl or -S(O)2R 12 .
26. A compound or salt thereof as described in any one of claims 1 to 23, wherein each R A is independently substituted by one or more substituents independently selected from the following: halogen, -OH, -NO2, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl.
27. The compound or salt thereof as claimed in claim 26, wherein each R A is independently substituted by one or more substituents independently selected from the following: halogen, -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, oxo, amino and C 3-6 Cycloalkyl.
28. The compound or salt thereof as claimed in claim 26, wherein each R A is independently substituted with one or more substituents (e.g., 1, 2 or 3 substituents) independently selected from: -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 3-6 Cycloalkyl.
29. A compound or salt thereof according to any one of claims 1 to 15, wherein Selected from:
30. The compound or salt thereof as claimed in any one of claims 1, 2 or 5 to 29, wherein p is 1.
31. The compound or salt thereof as claimed in claim 30, wherein R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl.
32. The compound or salt thereof as claimed in claim 31, wherein R 8 and R 9 Each is hydrogen.
33. The compound or salt thereof as claimed in claim 30, wherein R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl.
34. A compound or salt thereof as described in any one of claims 1, 2 or 5 to 29, wherein p is 0.
35. A compound or salt thereof as described in any one of claims 1 to 34, wherein R B1 is optionally substituted C 3-8 Cycloalkyl or optionally substituted phenyl.
36. A compound or salt thereof as described in any one of claims 1 to 34, wherein R B1 is optionally substituted C 2-9 Heterocycloalkyl, optionally substituted monocyclic heteroaryl or optionally substituted bicyclic heteroaryl, each containing 1 to 4 heteroatoms selected from O, S, N, P and Si.
37. The compound or salt thereof as claimed in claim 36, wherein R B1 is an optionally substituted 5-membered monocyclic heteroaryl group having 1 to 4 heteroatoms selected from N, O, S and P.
38. The compound or salt thereof as claimed in claim 37, wherein R B1 is imidazole, pyrazole, triazole or tetrazole, each of which is optionally substituted.
39. The compound or salt thereof as claimed in claim 36, wherein R B1 is an optionally substituted fused 5-6, 6-6 or 6-5 heteroaryl.
40. A compound or salt thereof as described in any one of claims 1 to 39, wherein R B1 Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
41. The compound or salt thereof as claimed in claim 40, wherein R B1 Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 , -NO2, oxo, -CN, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 aminoalkyl, optionally substituted C 1-6 Hydroxyalkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl.
42. The compound or salt thereof as claimed in claim 40 or 41, wherein R B1 Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-NO2、oxyl、-CN、C 1-3 Haloalkyl, C 1-3 Alkyl, C 1-3 Aminoalkyl, C 1-3 Hydroxyalkyl, optionally substituted C 1-4 heteroalkyl (eg, -CH2C(=O)N(CH3)2), optionally substituted C 3-6 Cycloalkyl and optionally substituted C 2-5 Heterocycloalkyl.
43. A compound or salt thereof as described in any one of claims 36 to 38, wherein R B1 Selected from:
44. A compound or salt thereof as described in any one of claims 36 to 38, wherein R B1 for 45. The compound or salt thereof of claim 4, wherein Y 1 N or CR Y1 ; Y 2 N or CR Y2 ; Y 3 CR Y3 ; Y 4 CR Y4 ; R Y1 , R Y2 , R Y3 and R Y4 Each is independently hydrogen or C1-C6 alkyl; R 1 is hydrogen or C1-C6 alkyl; p is 0; for And each R A Independently OH, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 haloalkyl or C3-C6 cycloalkyl; and R B1 is optionally one or more selected from C 1-3 Haloalkyl and C 1-3 The substituent of the alkyl group is a 5-membered heteroaryl group substituted with a substituent.
46. The compound or salt thereof of claim 45, wherein R B1 for 47. A compound having a structure of formula (VI) or a salt thereof, in, Ring C is an optionally substituted 5-membered heteroaryl; Ring D is an aromatic, saturated or partially saturated 6-membered carbocyclic or heterocyclic ring, wherein each of the carbocyclic or heterocyclic ring is optionally substituted; R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 together to form an oxo group; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl; Ring A is phenyl, naphthyl, monocyclic heteroaryl, bicyclic heteroaryl, cycloalkyl or heterocycloalkyl; R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ); R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl; R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 Aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, and C 3-6 Carbocyclic ring, 3-membered to 6-membered heterocyclic ring, wherein the C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R B is hydrogen, halogen, -CN, -NO2, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl; m is 1, 2, 3 or 4; and p is 0 or 1.
48. The compound or salt thereof of claim 47, wherein Ring C is a 5-membered heteroaryl group, wherein the heteroaryl group is optionally substituted by 1, 2, 3 or 4 R 1C Replace, and Each R 1C are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Heteroalkyl, C 2-6 Alkenyl, C2-C6 alkynyl, C 3-8 Cycloalkyl, C 2-7 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 1Ca replace; Ring D is an aromatic, saturated or partially saturated 6-membered carbocyclic or heterocyclic ring, wherein each of the carbocyclic or heterocyclic rings is optionally substituted by 1, 2, 3, 4, 5 or 6 R 1D Replace, and Each R 1D are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Heteroalkyl, C 2-6 Alkenyl, C2-C6 alkynyl, C 3-8 Cycloalkyl, C 2-7 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 1Da replace; R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 together to form an oxo group; or R 8 and R 9 together with the carbon to which it is attached, forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; Ring A is phenyl, naphthyl, monocyclic heteroaryl, bicyclic heteroaryl, cycloalkyl or heterocycloalkyl; R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -NO2, oxo, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl, wherein the alkyl, alkenyl, alkynyl, heteroalkyl, alkylene, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 Haloalkyl; R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 Aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, and C 3-6 Carbocyclic ring, 3-membered to 6-membered heterocyclic ring, wherein the C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R B is hydrogen, halogen, -CN, -NO2, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl or optionally substituted bicyclic heteroaryl, wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; Each R a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-C6 alkylene-cycloalkyl, -C1-C6 alkylene-heterocycloalkyl, -C1-C6 alkylene-aryl or -C1-C6 alkylene-heteroaryl; wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted by one or more of the following groups: oxo, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S(= -S(═O)2NH2, -S(═O)2NHC1-C6 alkyl, -S(═O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(═O)OC1-C6 alkyl, -C(═O)C1-C6 alkyl, -C(═O)OH, -C(═O)OC1-C6 alkyl, -C(═O)NH2, -C(═O)N(C1-C6 alkyl)2, -C(═O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; Each R b wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-C6 alkylene-cycloalkyl, -C1-C6 alkylene-heterocycloalkyl, -C1-C6 alkylene-aryl, or -C1-C6 alkylene-heteroaryl is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-C6 alkylene-cycloalkyl, -C1-C6 alkylene-heterocycloalkyl, -C1-C6 alkylene-aryl, or -C1-C6 alkylene-heteroaryl; wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one or more of the following groups: oxo, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S( -C(=O)2C1-C6 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(=O)OC1-C6 alkyl, -C(=O)C1-C6 alkyl, -C(=O)OH, -C(=O)OC1-C6 alkyl, -C(=O)NH2, -C(=O)N(C1-C6 alkyl)2, -C(=O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; Each R c and R d wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-C6 alkylene-cycloalkyl, -C1-C6 alkylene-heterocycloalkyl, -C1-C6 alkylene-aryl, or -C1-C6 alkylene-heteroaryl is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-C6 alkylene-cycloalkyl, -C1-C6 alkylene-heterocycloalkyl, -C1-C6 alkylene-aryl, or -C1-C6 alkylene-heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one or more of the following groups: oxo, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S(=O) )2C1-C6 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(=O)OC1-C6 alkyl, -C(=O)C1-C6 alkyl, -C(=O)OH, -C(=O)OC1-C6 alkyl, -C(=O)NH2, -C(=O)N(C1-C6 alkyl)2, -C(=O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; or R c and R d The heterocycloalkyl group is optionally substituted with one or more of the following groups: oxo, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S(=O)2C1-C6 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C -C1-C6 alkyl)2, -NHC(═O)OC1-C6 alkyl, -C(═O)C1-C6 alkyl, -C(═O)OH, -C(═O)OC1-C6 alkyl, -C(═O)NH2, -C(═O)N(C1-C6 alkyl)2, -C(═O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; Each R 1Ca and R 1Da are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; m is 1, 2, 3 or 4; and p is 0 or 1.
49. The compound or salt thereof according to claim 47 or 48, wherein ring C is a 5-membered heteroaryl group and ring D is a 6-membered heteroaryl group.
50. The compound or salt thereof as claimed in claim 47 or 48, wherein ring C is a 5-membered heteroaryl group and ring D is a 6-membered heterocycloalkyl group.
51. The compound or salt thereof as described in any one of claims 47 to 50, wherein ring C and ring D are each independently optionally substituted by one or more substituents selected from the following: halogen, -CN, -OR a , -SH, -SR a 、-NR c R d , optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 wherein the alkyl, heteroalkyl, alkenyl or alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, oxo, -OH, -NO2, -CN and C 1-3 Alkoxy.
52. A compound or salt thereof as described in any one of claims 47 to 50, wherein for 53. The compound or salt thereof as claimed in any one of claims 47 to 52, wherein ring A is a 5- or 6-membered monocyclic heteroaryl group.
54. The compound or a salt thereof according to claim 53, wherein Ring A is pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, oxazole, isoxazole or thiophene.
55. The compound or salt thereof of claim 54, wherein for 56. The compound or salt thereof as claimed in any one of claims 47 to 52, wherein ring A is a bicyclic heteroaryl group.
57. The compound or salt thereof according to claim 56, wherein Ring A is a fused 5-6, 6-6 or 6-5 bicyclic heteroaryl.
58. A compound or salt thereof as described in any one of claims 47 to 57, wherein R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ).
59. The compound or salt thereof of claim 58, wherein at least one R A For-OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl or -S(O)2R 12 .
60. A compound or salt thereof as described in any one of claims 47 to 59, wherein each R A is independently substituted by one or more substituents independently selected from the following: halogen, -OH, -NO2, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl.
61. The compound or salt thereof of claim 60, wherein each R A is independently substituted by one or more substituents independently selected from the following: halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, oxo, C 3-6 Cycloalkyl and amino.
62. A compound or salt thereof as described in any one of claims 47 to 52, wherein Selected from:
63. A compound or salt thereof as described in any one of claims 47 to 62, wherein p is 1.
64. A compound or salt thereof as described in any one of claims 47 to 63, wherein R 8 and R 9 are each independently selected from hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl.
65. The compound or salt thereof of claim 64, wherein R 8 and R 9 Each is hydrogen.
66. A compound or salt thereof as described in any one of claims 47 to 63, wherein R 8 and R 9 Together they form an oxo group.
67. A compound or salt thereof as described in any one of claims 47 to 63, wherein R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or heterocycloalkyl.
68. A compound or salt thereof as described in any one of claims 47 to 62, wherein p is 0.
69. A compound or salt thereof as described in any one of claims 47 to 68, wherein R B is halogen, -CN, -NO2, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl.
70. The compound or salt thereof of claim 69, wherein R B is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl.
71. The compound or salt thereof of claim 70, wherein R B is an optionally substituted 5-membered monocyclic heteroaryl group having 1 to 4 heteroatoms selected from N, O, S and P.
72. The compound or salt thereof of claim 71, wherein R B is imidazole, pyrazole, triazole or tetrazole, each of which is optionally substituted.
73. The compound or salt thereof of claim 70, wherein R B is an optionally substituted fused 5-6, 6-6 or 6-5 heteroaryl.
74. A compound or salt thereof as described in any one of claims 47 to 73, wherein R B Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
75. The compound or salt thereof of claim 74, wherein R B Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 , -NO2, oxo, -CN, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 aminoalkyl, optionally substituted C 1-6 Hydroxyalkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl.
76. A compound or salt thereof as claimed in claim 74 or 75, wherein R B Optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-NO2、oxyl、-CN、C 1-3 Haloalkyl, C 1-3 Alkyl, C 1-3 Aminoalkyl, C 1-3 Hydroxyalkyl, optionally substituted C 1-4 heteroalkyl (eg, -CH2C(=O)N(CH3)2), optionally substituted C 3-6 Cycloalkyl and optionally substituted C 2-5 Heterocycloalkyl.
77. The compound or salt thereof of claim 69 or 70, wherein R B Selected from:
78. A compound or salt thereof as claimed in claim 69 or 70, wherein R B for 79. A compound having a structure of formula (IVa) or a salt or solvate thereof, in, Y 1 N or CR Y1 ; Y 2 N or CR Y2 ; Y 3 N or CR Y3 ; Y 4 N or CR Y4 ; R 1 is hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 Heterocycloalkyl; R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl; Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl or a bicyclic heterocycloalkyl; R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ); R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl; R 12 Each is independently selected from hydrogen, halogen, -OH, -NO2, -CN, C 1-6 Alkyl, C 1-6 Aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl; R Y1 , R Y2 , R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, and optionally substituted bicyclic heteroaryl; or R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl; or R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl; m is 0, 1, 2, 3 or 4; and p is 0 or 1.
80. The compound according to claim 1, or a salt or solvate thereof, wherein Y 1 N or CR Y1 ; Y 2 N or CR Y2 ; Y 3 N or CR Y3 ; Y 4 N or CR Y4 ; R 1 is hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 Heterocycloalkyl, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, oxo, -OH, -NO2, -CN and C 1-3 Alkoxy; R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 1-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 together with the carbon to which it is attached, form an optionally substituted 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, amino, -OH, -NO2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; Ring A is a monocyclic heteroaryl, a bicyclic heteroaryl, a monocyclic heterocycloalkyl or a bicyclic heterocycloalkyl; R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -NO2, oxo, amino, -CN, C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl, wherein the alkyl, alkenyl, alkynyl, heteroalkyl, alkylene, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 Haloalkyl; R 12 Each is independently selected from hydrogen, halogen, -OH, -NO2, -CN, C 1-6 Alkyl, C 1-6 Aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl or optionally substituted bicyclic heteroaryl, wherein the cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ), wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 Haloalkyl; R Y1 , R Y2 , R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, and optionally substituted bicyclic heteroaryl, wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, naphthyl, phenyl or heteroaryl are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NO2, amino, oxo, -CN, C 1-3 Alkoxy, C 1-3 Alkyl and C 1-3 haloalkyl; or R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 haloalkyl; or R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, amino, -NO2, oxo, C 1-6 Alkoxy, -CN, C 1-6 Alkyl and C 1-6 Haloalkyl; m is 0, 1, 2, 3 or 4; and p is 0 or 1.
81. A compound having a structure of formula (IVa) or a salt thereof, in, Y 1 N or CR Y1 ; Y 2 N or CR Y2 ; Y 3 N or CR Y3 ; Y 4 N or CR Y4 ; R 1 is hydrogen, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-7 Heterocycloalkyl; R 4 and R 4 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 4 and R 4 ' combine together to form an oxo group; or R 4 and R 4 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 5 and R 5 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 5 and R 5 ' combine together to form an oxo group; or R 5 and R 5 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 6 and R 6 ' are each independently selected from hydrogen, halogen, -CN, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl and optionally substituted C 2-7 Heterocycloalkyl; or R 6 and R 6 ' combine together to form an oxo group; or R 6 and R 6 'Together with the carbon to which it is attached, it forms a 3-6 membered cycloalkyl or a 3-6 membered heterocycloalkyl; R 8 and R 9 are each independently selected from hydrogen, halo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl; or R 8 and R 9 Together with the carbon to which it is attached, it forms an optionally substituted 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl; Ring A is aryl, monocyclic heteroaryl, bicyclic heteroaryl, monocyclic heterocycloalkyl or bicyclic heterocycloalkyl; R A are each independently selected from halogen, -NO2, oxo, -CN, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 Heterocycloalkyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )2S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 and -S(O)2N(R 12 )(R 11 ); R 11 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-7 heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted -C 1-4 Alkylene-C 3-8 Cycloalkyl, optionally substituted -C 1-4 Alkylene-C 2-7 Heterocycloalkyl, optionally substituted -C 1-4 Alkylene-phenyl or optionally substituted-C 1-4 Alkylene-heteroaryl; R 12 Each independently selected from hydrogen, -NO2, -CN, C 1-6 Alkyl, C 1-6 Aminoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, C 1-6 Heteroalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein the C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, oxo, amino, -NO2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Haloalkyl; R B1 is optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, or optionally substituted bicyclic heteroaryl; R Y1 , R Y2 , R Y3 and R Y4 Each independently selected from hydrogen, halogen, -CN, -NO2, -OR 11 、-SR 11 、-N(R 12 )(R 11 ), optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, -OR 11 、-SR 11 、-N(R 12 )(R 11 )、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )(R 11 )、-C(O)N(R 12 )(R 11 )、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )(R 11 )、-N(R 12 )S(O)2(R 12 )、-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )(R 11 ), optionally substituted C 3-8 Cycloalkyl, optionally substituted C 2-9 heterocycloalkyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted monocyclic heteroaryl, and optionally substituted bicyclic heteroaryl; or R Y1 and R Y2 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 heterocycloalkyl; or R Y3 and R Y4 Together with the carbon to which it is attached, it forms an optionally substituted C 3-8 Cycloalkyl or optionally substituted C 2-9 Heterocycloalkyl; m is 0, 1, 2, 3 or 4; and p is 0 or 1.
82. The compound or salt thereof as claimed in claim 81, wherein ring A is aryl, monocyclic heteroaryl, bicyclic heteroaryl, monocyclic heterocycloalkyl or bicyclic heterocycloalkyl, wherein when ring A is aryl, for Y 1 , Y 2 , Y 3 and Y 4 At least one of is N; and R B1 is an optionally substituted monocyclic heteroaryl group or an optionally substituted bicyclic heteroaryl group.
83. A compound or salt thereof as described in any one of claims 1 or 47, wherein the compound is a compound of Table 1.
84. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is 85. A pharmaceutical composition comprising a compound according to any one of claims 1 to 84 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
86. A method of modulating ubiquitin-specific protease 1 (USP1) in a subject, the method comprising administering to the subject a compound of any one of claims 1 to 84 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 85.
87. A method of inhibiting ubiquitin-specific protease 1 (USP1) in a subject, the method comprising administering to the subject a compound of any one of claims 1 to 84 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 85.
88. A method of inhibiting or reducing DNA repair activity regulated by ubiquitin-specific protease 1 (USP1) in a subject, the method comprising administering to the subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 84 or a pharmaceutical composition according to claim 85.
89. A method of treating a disease or condition associated with ubiquitin-specific protease 1 (USP1) in a subject, the method comprising administering to the subject a compound of any one of claims 1 to 84 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 85.
90. A method of treating a disease or condition associated with modulation of ubiquitin-specific protease 1 (USP1) in a subject, the method comprising administering to the subject a compound of any one of claims 1 to 84 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 85.
91. The method of claim 89 or 90, wherein the disease or condition is cancer.
92. A method of treating cancer in a subject, the method comprising administering to the subject in need thereof an effective amount of a compound of any one of claims 1 to 84 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 85.
93. The method of claim 91 or 92, wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, osteosarcoma, ovarian cancer, skin cancer, and breast cancer.
94. The method of claim 91 or 92, wherein the cancer is ovarian cancer.
95. The method of claim 91 or 92, wherein the cancer is breast cancer.
96. The method of claim 95, wherein the cancer is ovarian cancer or breast cancer.
97. The method of any one of claims 91 to 96, wherein the cancer comprises cancer cells having elevated levels of RAD 18.
98. The method of any one of claims 91 to 97, wherein the cancer is a DNA damage repair pathway defective cancer.
99. The method of any one of claims 91 to 98, wherein the cancer is a PARP inhibitor-resistant or recalcitrant cancer.
100. The method of any one of claims 91 to 99, wherein the cancer is a BRCA1 mutant cancer and / or a BRCA2 mutant cancer.
101. The method of claim 100, wherein the cancer is a BRAC1 -deficient cancer.
